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ABSTRACT
This work centers on the development of a novel passive transport system for two
tissue engineering applications – cell distribution and cell separation. This approach relies
on a wicking fiber-based system, derived from the textile field that functions by directing
and maintaining transport of cells as well as fluids and biomolecules. This system has the
ability to enhance cell movement for both the purpose of cell seeding distribution as well
as to isolate specific cell types from heterogeneous cell populations.
The success of spinal fusions and large bone defects is often limited by the
decreased surrounding vasculature and the ability of cells to penetrate and proliferate both
the surface and interior regions of large scaffolds. Therefore, the transport system was
tested for improved mass transport, distribution of bone-forming cells, and infiltration of
biomolecules in a commonly used spinal fusion scaffold. Heterogeneous cell solutions
containing cancerous and benign cell types were used as the proof-of-concept isolation
system, where the transport system rapidly and efficiently identifies and isolates cancer
cells. Methods to identify cancer cells rely considerably on biomarker detection and
analysis of gene expression, with biomarker detection often unreliable and limited. The
transport system distinguishes and isolates cancer cells of varying metastatic potential. An
integrated, interactive hands-on learning module was developed to introduce middle school
female students to transport and tissue engineering principles. The hands-on activity
introduces the engineering design process and promotes engineering problem solving.
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PREFACE
Wicking systems are commonly used in the textile industry. Wicking is a passive
mode of transport using capillary action to move fluids. The purpose of this work involves
the development and optimization of novel wicking fiber bundles to sustain transport of
nutrients and biomolecules, as well as direct and identify particular cell types. In one
application, wicking fiber bundles were applied to large tissue engineered scaffolds to
increase cellular distribution throughout the scaffold. Another application involved the
development of a wicking fiber system to separate and identify cell types. Different cells
move through the fiber bundles at varying rates and distances based on cell characteristics,
providing a means of isolating and analyzing pathological and multipotent cells.
The first application of the wicking fiber system involved improving the transport
limitations of bone grafts that are used for large bone defects, specifically in spinal fusions.
Spinal fusions are the standard treatment for lower back pain, as well as spinal deformities
and trauma. In the past 3 decades, there has been a significant increase in number and cost
of spinal fusions compared to other common surgical procedure[2]. Bone graft material is
an essential component used in spinal fusions and are also used in other large defect
fracture repair procedures. Successful bone formation can be controlled by the properties
of the bone graft. Alternate bone grafts such as allograft or synthetic substitutes lack the
bone-forming qualities of autologous bone graft. Due to availability limitations of
autologous grafts, there is a need and competitive market to improve bone substitutes that
augment bone formation in spinal fusion procedures[1]. The environment of the fusion site
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also greatly impacts the success of the fusion. The environment surrounding the implant
provides vasculature and the essential bone-forming factors. The success of bone formation
is highly dependent on the surrounding vasculature and is often overlooked when designing
tissue engineered constructs[4]. The current tissue engineering methods used to create
vascularity and improve transport of the bone construct have had very limited success.
Researchers have discovered non-homogeneous bone formation within the spinal fusion
site[5, 6]. Regions closer to the source of vasculature form bone more rapidly than regions
further away. The regions lacking vascular supply are more susceptible to pseudarthrosis,
which causes the fusion to fail. The first part of the work involved developing and testing
the novel non-biological wicking fiber approach to improve vascularity and direct transport
of essential bone-forming biomolecules and cells to all regions of the bone graft in the
implant site.
The second application of the wicking fiber bundles involved the development of a
wicking fiber system to separate and identify particular cell types, specifically cancer and
normal cells. The National Cancer Institute estimates 1 in 30 Americans have or have had
some form of cancer, with an annual cost of $126 billion[7]. This high incidence rate drives
the need for reliable and accurate testing. The occurrence of diagnostic error, including
failure to diagnose the existing cancer and delayed diagnosis, can be as frequent as 1 in 5
cancer cases[8]. A major contributing factor for this error is the extensive oncologic
pathology testing process. This extensive process provides frequent opportunities to switch
or contaminate samples, as well as to inadequately prepare, analyze, or interpret
specimens[9]. The gold standard for cancer detection involves histological analysis using
2

phenotypic and genotypic biomarkers. A major limitation of biomarkers in the
identification of cancer is the absence of a universal tumorigenic marker. The complexity
and heterogeneity of a tumor create a challenge for researchers to characterize the tumor
based on phenotypic and genotypic biomarkers alone. Tumors are reported to have
different subpopulations of cancer cells with varying phenotypes and degrees of tumorinitiating capabilities [12]. The transient phenotypes of these cells create complexities for
current detection methods and treatments[19]. For instance, cancer stem cells have the
potential to be dormant or aggressive[20]. This ability to phenotypically change may cause
resistance to treatment and recurrence[21].
An emerging field for oncology diagnostics involves the use of non-invasive liquid
biopsy tests. This involves testing blood, urine, or other bodily fluids for cancer cells or
oncologic related proteins and biomolecules. Again, these liquid biopsy samples are
typically analyzed using conventional methods for identifying progenitor or cancer cells,
which involve detecting phenotypic biomarkers and analyzing gene expression[13]. The
use of phenotypic and genotypic biomarkers to identify progenitors is unreliable, lacks
specificity, and provides limited information regarding the cancer cell potential. This work
involved the development of new physical biomarkers based on cell behavior through the
wicking fiber system. The goal of this application was to establish a method to better
capture and characterize cancer cells of different metastatic capabilities.
The goal of this work was to develop a novel approach using a wicking fiber system
that can achieve sufficient transport of biomolecules and cells throughout the entirety of
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the scaffold as well efficiently identify pathological cell types from heterogeneous samples
or tissues. To accomplish these overall goals the following specific aims were recognized:
Specific Aim 1 – Evaluate the effects of wicking fibers on the transport of biomolecules
and progenitor cells in tissue engineered scaffolds



Phase A – Characterize wicking fluid properties of wicking bundles
Phase B – Evaluate the effects of wicking fibers on recruitment of progenitor cells
and biomolecule transport in 3-dimensional scaffolds

Specific Aim 2 – Investigate the use of a wicking fiber system to improve the success
rates of bone graft used for spinal fusion



Phase A– Determine if wicking fibers improve cellular viability, proliferation, and
distribution of large bone scaffolds
Phase B – Evaluate if incorporating wicking fibers in large bone scaffolds
improve cellular differentiation and bone formation

Specific Aim 3 – Develop and assess a passive transport system to improve large tissue
engineered constructs



Phase A - Develop and assess the capabilities of the passive transport system to
sustain movement and direct cell and biomolecule movement
Phase B - Investigate the effectiveness of the passive transport system as an
antibiotic eluting system and assess the release of antibiotic

Specific Aim 4 – Assess the ability of the wicking fibers to identify and isolate
subpopulations of cancer cell with different metastatic capabilities




Phase A – Optimize the wicking fiber approach to identify cancerous cells from a
mixture of benign and more aggressive cancer cells
Phase B – Investigate the distribution of cancer cells of varying metastatic
potential and changes in cells mechanical properties
Phase C – Assess the efficiency of the wicking fiber and absorbent construct to
rapidly collect cancer cells of high metastatic potential

Specific Aim 5 – Develop and assess an interactive learning module that introduces
middle school female students to tissue engineering and related transport phenomena
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Chapter 1 provides an overall literature review of the topic; various sections
published in Critical Reviews in Biomedical Engineering, 2014. Studies supporting the
first aim, described in chapter 2, investigated fluid transport properties of various
configurations of wicking fibers, and the ability of wicking fibers to transport biomolecules
and progenitor cells; work published in the Journal of Tissue Engineering & Regenerative
Medicine, 2014. Studies supporting the second aim, presented in chapter 3, explored the
effects of wicking fiber bundles on cell viability, proliferation, and distribution in all
regions of the scaffold, predominately in regions in the center of the scaffold or furthest
from the vascular source. The final study in chapter 3 determined the effect of wicking
fiber on osteoblastic differentiation. Studies building toward the third aim (Chapter 4)
involved the development of a passive transport system using the wicking fiber bundles
and evaluation of whether the system can sustain transport longer and more efficiently
direct the movement of progenitor cells and biomolecules to the center of the scaffold
where necrosis or delayed bone formation occurs. In Chapter 5, the cross-sectional effects
of the fiber bundles on antibiotic elution were explored, as well as, various mechanisms to
load the antibiotic into the system. Experiments supporting the final technical aim,
presented in chapters 6, investigated the ability of the wicking fiber transport system to
identify and isolate cancer cells of different stages of aggressiveness. This chapter further
explores the use of the wicking system to separate progenitor cells of varying
differentiation potential. The factors affecting cell of cell type separation were investigated
in Chapter 7. The final chapter reviews the development of an educational module designed
to effectively introduce young middle school students to tissue engineering and the impacts
5

of tissue engineering on advancing the medical field; the module impact was evaluated
using pre- and post- quizzes to assess if there is an improvement in the understanding of
tissue engineering. Survey assessments were implemented to evaluate if the module
influenced a change in interest in the field of science and engineering. The following flow
chart illustrates the specific aims of this work.

6

7

CHAPTER ONE
LITERATURE REVIEW
Introduction
Bone grafting is required in sites where bone formation will not spontaneously
occur, to bridge a large bone defect or fusion site. These grafts are used to improve the
formation of bone in critical defect sites that can result from trauma, complex non-unions,
fusions, or resections from pathologies1,2. In the United States, 1.5 million bone grafting
procedures are conducted annually and are increasing at an annual growth rate of 13%3,4.
Spinal fusions are the most common grafting procedure, constituting half of all bone graft
orthopaedic procedures5. Even with the use of bone grafts to augment bone regeneration,
non-unions or impaired bone formation occur in both critical bone defects and fusions.
Delayed bone formation or non-union occurs in 5-10% of all fracture cases and in 20% of
high-energy trauma fractures1,6. Non-union rates in spinal fusions are reported at a relative
frequency of 5-40% based on the location, surgical technique, type of graft used, and
patient indications7.
The cause of pseudoarthrosis, or non-unions, can be related to both patient and
surgical factors, including metabolic abnormalities, smoking, infection, fracture location
and pattern, soft tissue damage, and excessive motion at the fusion or defect site8,9.
Regardless of which surgical approach is used to treat a patient with a large critical bone
defect, there are necessary contributing factors that result in successful bone formation.
These contributing factors include the use and choice of instrumentation, the amount and
type of graft material, the surgical technique, and the surrounding environment7,10–13.
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Successful bone formation in spinal fusion and fracture repair procedures can, in
part, be controlled by the properties of the bone graft. Even with advancements in tissue
engineering and the development of composite grafts, autologous bone grafts remain the
gold standard for bone grafting procedures14,15. Due to availability and limited amounts of
autologous bone graft, there is a need and competitive market to develop bone substitutes
that enhance bone formation in fusion procedures and critical size bone defects16.
Currently, no alternative bone grafts, including allograft, synthetic, and composite
substitutes, have stimulated comparable bone forming qualities to autologous bone graft.
In fact, only 10% of the bone grafting procedures globally are performed with synthetic
bone graft17. Vast research has been conducted to identify the critical cellular and
molecular events during the well-orchestrated bone formation process18,19. By
understanding the local and systemic molecular and cellular factors, synthetic bone grafts
can be improved.
The local surrounding environment of the implant site influences the bone healing
process and plays a critical role in the success of the graft. The implant environment varies
based on location, fracture pattern, patient indication, quality and loss of bone, as well as
surgical technique. Therefore, it is critical to understand the interactions and effects of the
surrounding tissue environment with bone grafts to improve success rates. Critically
important to this implant environment is the presence of vasculature. The success of bone
formation is highly dependent on the surrounding vasculature and is often overlooked when
designing tissue engineered constructs20. Many tissue engineering methods fail to account
for the contribution of the surrounding environment. By understanding the interaction
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between the surrounding tissue of the fusion or defect site and the bone graft, tissue
engineered constructs can be better tailored to lower rates of non-unions.
Critical defects and fusions require large amounts of bone formation to successfully
repair or fuse the bone. Hence, a large bone graft is desired to fill the region and stimulate
bone formation. The intrinsic limitation of large bone scaffolds is their inability to promote
mass transport and encourage penetration of bone-forming cells and biomolecules into the
scaffold’s interior21. Bone formation is directly impacted by the vascularity of the scaffold
and the surrounding implant site. Researchers have shown that lack of vasculature in the
central region results in high risk for pseudoarthrosis and failure of complete fusion 22–25.
Likewise, avascular regions in critical fracture defects have led to necrosis of cells in the
interior of large scaffolds, as well as heterogeneous formation of bone26.
This first section of this chapter will provide background information on the
anatomy and physiology of the spine as well as clinical information regarding the types of
spinal fusion procedures and their limitations. The second section of this chapter will assess
the importance of vasculature and related environmental factors during the bone healing
process both for spinal fusions and for large fracture defects. This next section will focus
on the vascular, cellular, and biomolecular contribution of local surrounding tissue,
including the adjacent muscle and periosteum, to bone formation. The final sections will
evaluate currently available bone substitutes and bone tissue engineering approaches to
improve transport and vascularity within large bone scaffolds for critical defects.

10

Market for Spinal Fusion Surgeries
Spinal fusion procedures are standard treatments for lower back pain caused by
disc degeneration, spinal deformities, or trauma27. The worldwide market for spinal
devices totals 3-5 billion in revenue and is growing approximately 25% each year28. A
recent article in Spine analyzed the frequency and trends of spinal fusions in the United
States from 1998 to 200827. Figure 1.1 shows the frequency of spinal fusion surgeries in
this decade compared to other common surgical techniques, which include: total knee
replacement (TKR), total hip replacement (THR), laminectomy, coronary artery bypass
graft (CABG), and percutaneous transluminal coronary angioplasty (PTCA)27. In the
past three decades, there has been a significant increase in the number and cost of spinal
fusion surgeries in contrast with other surgical procedures with lumbar fusions
experiencing the largest increase in number of procedures performed this decade.27
Fusion procedures require the use of a bone graft. Over 500,000 orthopedic
procedures are conducted with the use of bone grafts in the United States. Spinal fusions
make up roughly 50% of these procedures28. The increase in prevalence of lower back
pain and, subsequently, the increase in spinal fusion procedures show there is a need and
competitive market to improve bone substitutes that augment bone formation in spinal
fusion procedures16.
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Figure 1.1: Graph depicts the rate of common surgical procedures in past decade
(Adapted from Rajaee et al. (2012) Spine)27.

Problems with Spinal Fusion Procedures
Spinal fusion treats lower back pain and other spinal deformities by restoring
stability29. A non-successful spinal fusion indicates pseudoarthrosis, or the formation of a
“false joint” caused from failure of bone formation, union, or remodeling. Pseudoarthrosis
can result in pain, instability, and disability. A 2013 review article from Journal of the
American Academy of Orthopaedic Surgeons have reported non-unions to occur at a
relative frequency between 5-40% based on the location, surgical technique, type of graft
used, and patient indications. Posterolateral spine fusion (PLS) is the most common spinal
fusion procedure and involves placing the bone graft in the posterolateral portion of the
spine, where fusion occurs. The incidence rate of pseudoarthrosis for this procedure has a
similar relative frequency between 5-44%7. The cause of pseudoarthrosis, or non-unions,
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in spinal fusion surgeries can be related to a number of factors, including metabolic
abnormalities, smoking, infection, and excessive motion at the fusion site. Regardless of
which surgical treatment is used to treat a patient with a degenerative spinal disorder, there
are necessary contributing factors that result in a successful spinal fusion. These
contributing factors include the use and choice of instrumentation, the amount and type of
graft material, and the surgical technique7,10–12. Like most implanted tissue engineered
constructs, the surrounding environment and its interaction with the construct plays a
critical role in the success of the graft. The environment of the fusion site is unique in that
bone forms where it normally does not. Therefore, understanding the contributing factors
from surrounding tissue and interaction with the bone graft is essential for improving fusion
rates. The surrounding environment of the implant provides vasculature. The success of
bone formation is highly dependent on the surrounding vasculature and is often overlooked
when designing tissue engineered constructs20. Although tissue engineering advancements
have resulted in synthetic bone substitutes with attributes that contribute to bone formation,
autologous bone graft is still the gold standard. Many of the tissue engineering methods
fail to emphasize the contribution of the surrounding environment. By understanding the
interaction between the surrounding tissue of the fusion site and effect on the bone graft,
and using this knowledge for tissue engineering constructs, the success of bone grafts will
increase, ultimately resulting in lower rates of pseudoarthrosis.
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Anatomical Background
Bone
Bone regeneration is a multifaceted intrinsic process involved predominately in
bone healing and skeletal remodeling30.

This process can be compromised in bone

conditions such as large bone defect, tumor resection, or skeletal abnormalities. Often in
orthopaedic surgeries, such as oral and maxillofacial surgery or spinal fusions, bone
regeneration and formation is required in large quantities that the body cannot generate
normally. When bone regeneration is compromised, bone substitutes and other bone tissue
engineering solutions are critical for improving bone repair and bone formation30.
Understanding the components of bone, the dynamic processes, and the factors that
maintain bone, will greatly contribute to developing a bone tissue engineering solution
when bone regeneration and formation is compromised.
Bone is a dynamic, specialized connective tissue with the inherent ability to
remodel and renew itself. The dynamic processes of bone are controlled by physiological
stimuli, such as hormones, external mechanical loads, and pathological conditions31. Bone
contains both mineralized and nonmineralized content. The mineralized content comprises
mostly hydroxyapatite. This component of bone provides support and a storage site for
calcium and phosphate. The organic component, or nonmineralized content, of bone is
produced by osteoblasts and consists of collagen type 1 and ground substance of
proteoglycans and noncollagenous glycoproteins31,32.
Bone tissue can be characterized by the porosity or volume fraction of soft tissue.
There are two types of bone tissue: cortical or trabecular (cancellous). Cortical bone
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comprises dense and compact bone, with 5%-10% porosity. Cortical bone is formed from
densely packed osteons, or Haversian systems, the functional unit of bone33. Cortical bone
is found primarily on the diaphysis of long bones, such as the femur31. This type of bone
forms a rather thick cortex, which provides essential strength for the mechanical loading
conditions of the femur. Low vasculature found in cortical bone is a result of the dense
packing, and is supplied by the Haversian canal system31. Trabecular, or cancellous, bone
is less dense than cortical bone and is most abundant in cuboidal bone, such as vertebrae.
Trabecular bone has a much higher porosity, 75%-95%, than cortical bone. The bone
matrix of trabecular bone is formed by trabeculae, which are plates or struts. The porous
interlocking structure of trabeculae provides compressive strength for the tissue33. In
comparison to cortical bone, trabecular bone is greatly vascularized as a result of its highly
porous structure and abundant vascular complexes between trabeculae31. Trabecular bone
responds quicker to metabolic alterations due to the high vascularity. As a result, bone
tissue composed of trabecular bone, such as vertebral bodies, is more susceptible to
processes, such as osteoporosis, that can increase bone resorption31.
The four types of bone cells include osteoclasts, osteoblasts, osteocytes, and bonelining cells. The primary functions of these bone cells are to form and maintain bone
matrix. These cells either form or resorb bone in response to mechanical or physiological
stimuli. Osteoclasts are multinuclear cells related to macrophages that resorb bone. In
contrast, osteoblasts are mononuclear cells that differentiate from mesenchymal cells.
These cells are involved in bone formation by producing osteoid. Osteoblasts that are
surrounded by bone matrix are considered osteocytes, and housed in cavities called
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lacunae. However, osteoblasts that remain quiescent on the surface are bone-lining cells.
These cells function to transfer mineral, sense mechanical strain, and initiate bone
remodeling33. Bone cells play an essential role in physiological remodeling, which occurs
throughout life and consists of bone resorption and bone formation. Adaptive remodeling
will occur in response to alterations in physiological and mechanical conditions, also
described in Wolff’s Law34.
Understanding the processes associated with maintaining and forming bone tissue
provides a foundation for solutions when bone regeneration and formation is compromised.
Spinal fusion surgeries require the formation of a large quantity of bone between vertebrae.
Bone substitutes are necessary to augment and accelerate the bone forming process
required for fusion. Understanding the biology of spinal fusions and the bone forming
process can help improve the bone substitutes needed for spinal fusions.
Anatomy and Physiology of the Spine
Vertebrae are classified as irregular bones due to the complexity of their shape.
Vertebrae contain both cortical and cancellous bone tissue. The micro-architecture of the
bone tissue dictates the strength and functionality of the vertebrae. The vertebral column
consists of thirty-three vertebrae connected by intervertebral discs. The three distinct
regions of vertebrae include: the cervical spine, the thoracic spine, and the lumbar spine35–
37

. There are typically seven cervical vertebrae, twelve thoracic vertebrae, five lumbar

vertebrae, five fused vertebrae to form the sacrum, and four fused vertebrae to form the
coccyx36,37. Lower back pain targets the lumbar region of the spine and, consequently, most
spinal fusion surgeries are performed in this region. The lumbar vertebrae are the largest
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moveable vertebrae in the spine, supporting more weight than any other region of the
spine36.
Structure of Vertebrae
As shown in Figure 1.2, the lumbar vertebrae contain a large vertebral body, which
forms the anterior element of the vertebrae. The vertebral body comprises primarily
trabecular bone. The micro-architecture of the trabecular bone dictates the strength and
mechanical properties of the vertebral body. The trabecular bone is highly dense and
organized along the peripheral and the posterior region. The center and anterior regions of
the vertebral body contain smaller, irregular, and less dense trabeculae, which contribute
to the reduced compressive strength of these regions38.
The posterior arch is composed of two pedicles and laminae, which join to form the
spinous process31,36. Superior and inferior articulating processes form the bilateral facet
joints. Transverse processes attach on both lateral sides of the arch. The vertebral body and
posterior arch form the vertebral foramen as a triangular opening. The cauda equine, a
system of spinal nerves, transverse this opening. Compression of these nerves by spinal
abnormalities or disc herniation can result in lower back pain35. Muscle tissue attaches to
the transverse and spinous processes31,39. The lumbar ligaments function to prevent anterior
separation of vertebral bodies and provide stability35. The transverse processes, which are
located on either side of the arch, play a role in supplying vasculature for posterolateral
spinal fusion surgeries.
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Intervertebral Disc Anatomy and Function
The intervertebral disc is a complex fibrocartilaginous tissue located between the
vertebral bodies of the spine and plays a significant role in spinal support, flexibility, and
durability40,41. The intervertebral disc is the largest avascular tissue in the human body,
with essentially no repair capabilities. Furthermore, there is a sensitive and multifaceted
interaction between the small local cell population within the discs and the surrounding
matrix40,42. The normal highly heterogeneous tissue micro-architecture of the intervertebral
disc is intricately and precisely constructed to provide the spine optimal support and
stability. These factors contribute to the challenges and difficulties for tissue engineering
solutions.
The intervertebral discs are defined by three structures: the nucleus pulposus (NP),
the annulus fibrosus (AF), and the vertebral end-plates42. The nucleus pulposus, located
in the central region of the intervertebral disc, contains collagenous and noncollagenous
proteins, which include: collagen types III, V, IV, IX, elastin, fibronectin, and laminin40.
This region is highly mechanically loaded in compression. The high density of
proteoglycans located in this region maintains a large amount of water content in the
intervertebral disc to resist the compressive loads. Proteoglycans are core proteins, with at
least one hydrophilic, negatively charged glycosaminoglycan (GAG) attached. This
hydrophilic component causes osmotic pressure or interstitial swelling pressure, which
maintains the hydration of the disc37.
The concentration of proteoglycans and water content decreases toward the
periphery of the disc. The inhomogeneous radial distribution of proteoglycans contributes
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to even distribution of forces within the spine, resulting in spine stability. The low cell
density of chondrocytes in the NP primarily functions to maintain synthesis of the
surrounding extracellular matrix40,42. The balance of matrix synthesis and degradation is
controlled by cytokines and growth factors released from surrounding cells and matrix43.
This balance maintains the normal function and structure of the disc. Alterations of growth
factor and cytokine concentrations can lead to structural changes that will potentially
disrupt normal function. In comparison to the NP, the annulus fibrosus is composed
primarily of collagen with much less proteoglycan content. The outer region of the AF is
formed by densely packed collagen oriented in concentric arrays. Toward the central region
of the AF, the collagen is less dense and organized. In contrast to the cellular components
of the NP, the AF contains fibroblast-like cells that are thin and elongated. The concentric
arrangement of collagen fibers and radial composition changes contribute to anisotropic
mechanical properties to resist complex mechanical loads37.
Vertebral Endplates
The vertebral end plates are located between the vertebral bodies and intervertebral
disc. The endplates consist of a uniform layer of hyaline cartilage and cortical bone, which
provide even distribution of loads. The blood supply for the end plates and vertebral bodies
is the segmental artery41. The end plates are semipermeable and facilitate diffusion of
water, solute, and wastes, through marrow channels, to the intervertebral disc44. The red
arrows in Figure 3 indicate the supply of nutrients from the vertebral endplates to the
nucleus pulposus and annulus fibrosus. The mechanical properties of the end plates vary
radially as well37. The thickness is largest in the periphery and smallest in the center.
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Understanding the biomechanics of normal vertebral components and how they are altered
with age and other abnormal spinal conditions is essential for developing tissue engineering
solutions38.

Figure 1.2: Indicates three components of intervertebral discs. Red arrows indicate
vascular channels in endplates supplying the disc (Adapted from Ullrich et al. (2004)
Spine-Health)45.

Most of the vertebral components are innervated. The dorsal root ganglion and
branches innervate most of the lumbar region. The nerve endings and mechanoreceptors
located in these components can contribute to lower back pain. The annulus fibrosus and
posterior longitudinal ligament contain nociceptive fibers, which are branches from the
sino-vertebral nerve. In addition, facet joints contain sensory autonomic nerve fibers in the
capsule. Abnormal spinal conditions, aging, and disc degeneration can influence the
innervated components of the lumbar region, triggering pain.
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Spinal Fusion Procedures
Causes of Spine Instability and Altered Environment
The spinal segments of intervertebral disc and vertebral components influence each
other. The mechanical stability of the intervertebral disc is dependent on the integrity of
the nucleus pulposus and annulus fibrosus. The normal intervertebral disc main function is
to create stability in the spine by redistributing compressive stresses. Degeneration to the
disc will alter the ability of the disc to distribute stresses46–48. Load alterations of the disc
will also affect bone density distribution in the vertebral body and load alterations in the
vertebral component, especially the facet joints46. These spinal abnormalities can lead to
altered spinal motion and cancellous bone architecture, which have adverse consequences,
including back pain and segmental instability.
The natural aging process alters the vertebral micro-architecture, cell interplay, and
overall function of essentially every anatomical structure in the spine. Intervertebral disc
degeneration and lower back pain is linked with age. The frequency of lower back pain and
disc alterations increases with age. Miller and coworkers used data from published reports
regarding cadavers and disc degeneration incidence. They found that 97% of the
individuals had developed some level of disc degeneration by age 4942,49. The natural aging
process of the spine includes bone mass reduction and degenerative changes. The effects
of normal aging and degenerative disc disease are difficult to differentiate 50. It has been
suggested that disc degeneration disease is a result of accelerating this aging process,
however, the exact causes are unknown50,51. The aging process will result in a continuous
loss of bone mass, alterations in architecture of the spine components, and degeneration of
21

the disc33,38. Disc degeneration results when the intervertebral disc goes through
degenerative changes that cause a loss or destruction of tissue, ultimately altering the load
transfer which affects the mechanical properties and tissue composition of the vertebral
components42,50. Disc degeneration can result due to abnormal components of the matrix
or abnormal concentrations of growth factors that promote matrix degradation; for
example, IL-1 or TNF-α will lead to structural changes and impaired function of the disc43.
Understanding the effects of age and disc degeneration on the mechanical properties of the
vertebral endplates and vertebrae is imperative for developing spinal treatments that
include instrumentation and tissue engineered bone scaffolds.
Aging and disc degeneration alter the environment and vasculature of the spine and
surrounding tissue. Age and other conditions, such as atherosclerosis, reduce the blood
supply by altering vertebral capillaries that supply the lumbar vertebrae components. As a
result, there is a significant decrease in blood perfusion of the vertebral bone marrow,
which supplies nutrients to the intervertebral disc. In one particular study, dynamic
contrast-enhanced MRI was used to evaluate two vertebral bodies from 25 patients. The
vertebral bodies evaluated were either between two adjacent normal discs or between two
adjacent degenerated discs. This study found a 14% decrease in blood perfusion between
two degenerated intervertebral discs compared to the perfusion between two normal discs,
suggesting there is a relationship between insufficient vertebral marrow perfusion and
degenerative disc disease41,52.
Aging affects the composition of the vertebral endplates and causes both
calcification of the cartilage and vertebral bone sclerosis. The architecture and alterations
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in calcification of the vertebral end plates will affect transport of nutrients into the nucleus
pulposus. Consequently, there is a reduction in blood flow and transport into the disc53,54.
In another study, the diffusion and temporal pattern of paramagnetic contrast medium in
regions of vertebral bone and intervertebral disc were evaluated in 96 normal discs and 54
degenerative discs using magnetic resonance. The temporal pattern of enhancement
between the vertebral bone and intervertebral disc was evaluated throughout both regions.
This study determined the diffusion into the nucleus pulposus is related to the amount of
perfusion in the bone and endplate. Furthermore, endplate changes due to age or
degenerative disc resulted in altered diffusion patterns. Vertebrae with intact cartilage
showed no changes in response to the diffusion pattern, while vertebral endplates
containing damaged tissue or alterations changed the diffusion pattern53.
Cell function in the intervertebral disc is altered due to the reduction in blood flow
from vertebral end plate alterations and from local vasculature changes. This reduction will
initiate or enhance degeneration55. Other factors shown to influence degeneration include
nerve and vessel ingrowth into the nucleus pulposus as well as cytokine alterations55. An
increased level of inflammatory mediators and cytokines has been shown to affect disc
degeneration and cause lower back pain. Understanding the environmental changes due to
these factors will affect the design of tissue engineering solutions and therapeutics. The
environment and surrounding vasculature plays an essential role in bone formation. The
degenerative environment of the vertebrae and interaction with native cell populations must
be taken into account when developing tissue engineering solutions, such as scaffolds, to
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promote bone formation. The complexity of the intervertebral disc and the environment
provide major challenges for developing tissue engineering solutions for the spine56.
Spinal Indications for Lumbar Fusion Treatment
Spinal fusion surgery was originally used to treat infectious conditions. In later
years, these surgeries were used to treat deformities and traumatic injuries. With better
surgical techniques, instrumentations, and understanding of the pathology, these treatments
are frequently used and are currently standard treatment for degenerative spinal
conditions11.
Spinal fusion treatment is a procedure performed to generate stability in painful
spinal segments by immobilizing the region. Panjabi describes the stability of the spine as
a system consisting of three subsystems: the spinal column, the spinal muscles surrounding
the column, and the neural control unit coordinating and evaluating responses. Panjabi
developed a mathematical model evaluating the contribution of each of these components
to the biomechanical stability of the spine. This model evaluated changes in these
components due to degenerative disorders or spinal abnormalities. It also provides a basis
for spinal treatment and the rationale to recreate biomechanical stability by limiting
mobility. Instability defined by Panjabi is the loss of the ability of the spine to maintain
normal patterns and distributions of physiological loads11. Degenerative disorders and
spinal deformities alter intervertebral motion, which can lead to lower back pain.
Therefore, treatments such as spinal fusions decrease intervertebral motion to treat the pain.
The intervertebral disc and components of vertebral bone, if causing pain, can be removed.
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There are various types of spinal fusion procedures; however, in general a fusion
procedure immobilizes painful segments of vertebral bone by generating new bone
between the segments57. Spinal fusion can be performed in combination with other
procedures such as discectomy, decompression, and laminectomy. The type of spinal
fusion and treatment is governed by a number of indications presented by the patient. These
factors include the spinal disorder or disease, the quality of bone, and the patient’s age. The
most common spinal conditions treated with fusions include scoliosis, spondylolisthesis,
disc degeneration, spinal stenosis, spinal instability due to trauma, or adverse changes to
vertebrae due to infection or malignancy. Spondylolysis is a defect such as a fracture in the
pars interarticularis, which is a vertebral structure between the inferior and superior
articular processes. Spondylolisthesis is the forward displacement of one vertebra over the
other. In some spondylolysis cases, a slip may occur and the situation progresses to
spondylolisthesis; this is also known as isthmic or spondylolytic spondylolisthesis 58. In
fact, 50-81% of individuals with spondylolysis also have spondylolisthesis59. Patients can
be affected by multiple conditions or the development of one condition can initiate and
progress to another. For example, a patient with degenerative disease can subsequently
have narrowing of the spinal canal or spinal stenosis. Spinal stenosis can also develop with
degenerative

spondylolisthesis

and

degenerative

scoliosis.

The

alterations

in

biomechanical loading due to one spinal abnormality can alter the structure of the vertebrae
leading to progressive degeneration.
Degenerative disc disease in the lumbar region is the most common indication of
spinal fusion treatment. From the years 1998 to 2008, it is important to note the significant
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increase in degenerative disc disease and spinal stenosis of the lumbar region correlates
with the increase in average age of patients receiving spinal fusions. In 1998, the average
age of patients was 48.8 years and increased to 54.2 years in 2008. Due to the increasing
average age of our population, degenerative spinal disorders are more frequently
diagnosed60–62. A study evaluated a Medicare population of patients 65 years of age and
older who had surgical procedures for lumbar stenosis. From 2002 to 2007, the analysis of
Medicare recipients showed a decrease in treatments that include only decompression or
simple fusion. However, the surgical rate employing complex fusion procedures increased
approximately 15-fold. Complex fusion involves both anterior fusion with posterior or
transverse fusion33.
Spondylolisthesis is the most recognized indication for spinal fusion in the lumbar
spine. This condition is defined by the forward translation of the superior vertebrae on the
inferior vertebrae. There are five different types of spondylolisthesis. However, type III or
degenerative spondylolisthesis is most often treated with spinal fusion surgeries. This type
of spondylolisthesis occurs due to chronic disc degeneration with vertebral segment
instability from facet joint arthritis. Disc degeneration causes the narrowing of the disc
space and instability in the ligamentum flavum, which leads to instability in the sagittal
plane, which can progress to spondylolisthesis11. Degenerative scoliosis is another
indication for fusion, primarily in the lumbar spine. Scoliosis is a structural disorder to the
spine that results in a lateral curvature. This spinal abnormality is caused by disc
degeneration that results in instability in the frontal plane. There are various types and
degrees of scoliosis63; however, degenerative scoliosis is directly related to disc
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degeneration. Spinal fusion can also be employed to treat instability caused by other spinal
treatments. This includes patients who had an extensive laminectomy, which is the removal
of vertebrae on the posterior arch to alleviate pain by reducing pressure on the nerve roots.
Types of Spinal Fusions
One of the first types of fusions in the early 20th century was a posterior fusion
performed by placing bone graft on lamina. Major complications resulted due to placement
of bone graft. These included pseudoarthrosis and overgrowth of bone into the spinal canal,
a condition called stenosis57. This posterior fusion surgery was improved by placing bone
graft on the side of the vertebrae between the transverse processes, a procedure known as
posterolateral fusion. This technique remains is still the gold standard of posterior fusion57.
Spinal fusion can augment other procedures such as decompression, which can
involve laminectomy and or discectomy procedures. A laminectomy involves the removal
of lamina, ligamentum flavum, and portions of the facet joints that are causing pressure on
nerve roots, resulting in pain. This procedure and foraminectomies, which are frequently
performed with laminectomies, typically approach the spine posteriorly64. Similarly, a
discectomy is a removal of disc material adversely affecting nerve roots, or the removal of
the annulus if the patient indicates discogenic pain, or stimulated nociceptors in the outer
annulus. Discectomies are typically performed to treat herniated discs. Decompression is
somewhat controversial. Studies suggest this treatment to cause instability and contribute
disc degeneration. However, there is evidence in literature supporting treatments of
decompression and fusion for certain indications, such as degenerative spondylolisthesis.
Instrumentation is typically recommended with fusion surgeries; however, depending on
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the diagnosis of the patient before fusion, this may not always be the case65. Spinal
instrumentation augments the spinal fusion by straightening and stabilizing the spine.
Typically, hooks, rods and wires are used to redistribute stresses and align the bones66.
One of the first methods of using instrumentation, developed by Dr. Harrington, used hooks
placed the under lamina and connected by rods. This led to further advances using bone
screws attached through facet joints and then to screw plate fixation. Screw-plate fixation
remains an important method for augmenting a fusion. This technique involves the
placement of screws through the pedicle and the screws are connected with rods57–65,67.
Numerous spinal fusion procedures implemented are based on the spinal condition.
Each surgery incorporates the use of a bone graft to promote bone growth between the
vertebral bodies and generate fusion45. The most common lumbar spinal fusion surgeries
include posterolateral fusions and lumbar interbody fusions68. These procedures are
typically approached from the posterior or anterior. The standard method for approach is
posterior, which allows direct decompression of neural structures. However, an advantage
to the anterior approach is better restoration of the disc height and ability to prepare the site
for graft material.
Posterolateral spine fusion is the most common procedure and involves placing the
bone graft, usually autologous bone graft from the iliac crest, in the posterolateral portion
of the spine. This procedure does not always remove the intervertebral disc, as shown in
Figure 1.3a. Furthermore, instrumentation such as pedicle screws and rods are used for
greater stability69,70. One study found the addition of instrumentation to posterolateral
spine fusion has improved spinal fusion rates from roughly 60% to 90%45. However, the
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use of this instrumentation is still controversial due to the increased complication rates and
inconsistent clinical outcomes71. Posterolateral spinal fusions are frequently used to treat
degenerative conditions such as degenerative spondylolisthesis and spinal stenosis. This
surgery has high clinical success rates with degenerative spondylolisthesis patients 50,72. A
study involving a long-term follow up of patients of various spinal degenerative conditions
and abnormalities that were treated with posterolateral fusion with instrumentation found
that patients with degenerative spondylolisthesis had the greatest improvement overall with
the treatment.
Interbody fusions each involve the removal of the intervertebral disc, which is replaced
by bone graft and stabilized with hardware68.

Four types of interbody fusion surgeries

include posterior lumbar interbody fusion (PLIF), anterior lumbar interbody fusion (ALIF),
transforminal lumbar interbody fusion (TLIF), and circumferential interbody fusion.
Posterior lumbar interbody fusion is also used to treat degenerative disc disease and chronic
back pain. This treatment first involves a laminectomy, which is the removal of bone and
disc to relieve the pressure from a pinched nerve. A spinal cage containing a bone graft can
be incorporated into the empty disc space. The addition of the bone graft will promote a
bone bridge, or fusion, between the vertebral bodies45. Anterior lumbar interbody fusion
parallels the PLIF technique but is approached from the anterior region of the spine, as
shown in Figure 1.3b. This approach is less frequently used to treat degenerative conditions
because of the difficulty in performing decompression73. Transforminal lumbar interbody
fusion surgery, shown in Figure 1.3c, is similar to the posterior lumbar interbody fusion,
but only requires one insertion site from the side to perform the procedure, which enhances
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recovery time. Laminectomy and implantation of bone graft in the empty disc space still
occurs. Additional instrumentation, such as pedicle screws and rods are often used for more
stability45. Anterior/posterior or circumferential lumbar fusion is a type of spinal fusion
surgery that fuses the vertebral bodies from both the anterior and posterior. Circumferential
fusion typically involves anterior lumber interbody fusion and posterolateral fusion with
instrumentation74.

Several clinical studies showed better clinical results and

pseudoarthrosis rates with circumferential fusion in comparison to posterolateral fusion
with instrumentation74,75.

Although the additional fusion technique results in better

outcomes, there are supplementary complications. These include operation time, cost, and
neurological issues75.

Figure 1.3: Spinal fusion surgeries. A: posterolateral spinal fusion. B: Anterior lumbar
interbody spinal fusion. C: Transforminal lumbar interbody fusion (Adapted from Ullrich
et al. (2004) Spine-Health)45
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Vascularity and Bone Regeneration
The amount of bone formation is directly related to the amount of vasculature, which
provides the mass transport of oxygen and nutrients, and a mode of delivery for cells and
growth factors that contribute to bone formation21,76,77. In general, large-area bone defects
require large scaffolds that promote the transport of oxygen and nutrients through
vascularization77.

This transport is essential for bone tissue constructs that include

mesenchymal stem cells or other osteogenic cell types. Oxygen diffusion is limited to
200μm from the blood vessel. Mesenchymal cells in a large tissue construct will not
proliferate, differentiate, and ultimately lead to ontogenesis without a transport of oxygen,
nutrients, and essential growth factors that promote bone formation24. Non-unions and
pseudoarthrosis may occur due to poor blood supply, which is essential for the bone healing
process12.

Spinal fusions require large bone grafts. For successful fusions, sufficient

vascular supply must be incorporated and maintained. For example, cervical fusions have
a higher success rate compared to fusions of the lumbar region due to increased vascularity
to the cervical region12,67. The cervical region of the spine, the abundance of vertical source
arteries, anastomoses, and segmental branches provides considerably more blood flow,
resulting in bone fusion even when the site is not sufficiently prepared67. In posterolateral
lumbar spinal fusion, bone formation is needed in a space greater than the critical size
defect. As shown in Figure 1.4, this treatment requires large amounts of bone regeneration
and therefore a large quantity of bone graft that promotes transport of nutrients and oxygen.
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Figure 1.4: Schematic A shows the furthest cell supported by a capillary vessel is 0.1 mm.
Red arrows in Image B depict the flow of nutrients from a vascular network on the
transverse processes. This supply must span the entire length of fusion (30 mm)78.

Vascular supply and types of tissue surrounding a defect will vary based on
anatomical location and impact bone formation accordingly. Spinal fusions of the
cervical region have a higher success rate compared to fusions of the lumbar region, due
to increased vascularity to the cervical region12,79. In the cervical region of the spine, the
abundance of vertical source arteries, anastomoses, and segmental branches provides
considerably more blood flow, resulting in bone fusion even when the site is not
sufficiently prepared79. In posterolateral fusion of the lumbar spine, bone formation is
needed in a region comparable to a critical size defect. The lumbar spine does not have

32

the vascular supply of the cervical region, increasing the susceptibility for non-unions.

Figure 1.5A indicates the transverse processes as the major blood supply of
posterolateral fusion80. This type of spinal fusion involves high surrounding muscle tissue
coverage, as compared to interbody fusion which involve the formation of bone in the
intervertebral disc space between adjacent vertebral bodies80. In contrast, interbody
fusion has a greater supply of blood and osteoprogenitor cells from the high surface area
of the perforated inferior and superior vertebral endplates81, seen in Figure 1.5.
Generally interbody fusion procedures have successful fusion rates due to the
enhanced vascularity and access to bone marrow80. The design of a large bone graft for
fusion procedures should not only consider the amount and orientation of vascular supply
but the contribution of biomolecules and osteoprogenitor cells from the surrounding
tissues.
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Figure 1.5. Diffusion distances of vasculature; (A) depicts the flow of nutrients from a
vascular network on the transverse processes, this supply must span the entire length of
fusion, 30mm78; (B) major vascular supply for interbody fusions, must span the
intervertebral distance of 10mm. (Also published in Tabbaa et al. (2014) Critical Reviews
in Biomedical Engineering82)

Similarly, in long bone defects the vascular supply and soft tissue coverage of the
bone segment will contribute to the success of the fracture repair. Figure 1.6 indicates the
major blood supplies to long bone, including blood vessels, periosteum, bone marrow, and
other surrounding soft tissues. Fractures in the tibia, especially in the distal shaft, have the
highest rate of non-unions compared to other long bone fractures. The limited vascular
supply to the tibia is a significant factor for the high rates of non-unions83. The tibia is
supplied by nutrient, periosteal, and epiphyseal-metaphyseal vascular systems. The
periosteal blood supply can support the entire tibia. A traumatic fracture to the tibia will
typically result in stripping of the periosteum, resulting in loss of major vasculature supply
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and high risk for non-union84. Long bone defects like femoral diaphyseal fractures have
much lower rates of non-unions. In contrast to tibia fracture sites, diaphyseal fracture sites
have increased vascular supply and significantly greater soft tissue coverage83.

Figure 1.6. Surrounding vascular supply of tibia. Contributing factors are the
surrounding musculature as well as the highly vascularized periosteum, the anterior
tibial artery, and the bone marrow. (Also published in Tabbaa et al. (2014) Critical
Reviews in Biomedical Engineering82)

Vascularity and Tissue Contribution in Posterolateral Spinal Fusions
Bone formation in spinal fusion occurs through two different mechanisms based on
the region in the spine. Intramembranous formation is one mechanism, where bone forms
by direct ossification of fibrous tissue. Endochondral formation is the other mechanism,
where bone replaces a cartilaginous intermediate85. The process of bone formation in
posterolateral spinal fusion begins with the migration of osteoprogenitor cells from
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decorticated transverse processes and marrow cavity of autologous bone graft.
Osteoinductive factors and osteoclast resorption promote the differentiation of
osteoprogenitor cells into osteoblasts. These bone-forming cells deposit bone matrix,
which is remodeled. The bone forming process begins at the decorticated surfaces86.
Boden and coworkers developed an intertransverse process arthrodesis model using
New Zealand white rabbits to simulate the human environment better than previous
models—demonstrating a nonunion rate similar to that in humans. This model provides
insight into the biology of the bone-forming process in posterolateral fusion17,24,80,87–89. The
technique included an intermuscular posterolateral approach, decortication of transverse
processes, and the use of autologous bone graft to augment bone formation. The bone
healing process was analyzed through various methods, including manual palpation, x-ray,
light microscopy, quantitative histology, and molecular biology.
The manual palpation and macroscopic imaging revealed a nonunion rate
comparable to that in humans. The results of quantitative histology demonstrated three
temporal phases of spine fusion healing in posterolateral fusion, which occur at different
times in the different regions of the fusion. These phases include inflammatory, reparative,
and remodeling. In regions near the decorticated transverse processes, also called the “outer
zones”, bone formation was most advanced. Quantitative histology in these regions
demonstrated bone was formed through intramembranous formation. Conversely, in the
“central zone”, or region furthest away from the transverse processes, bone formed via an
endochondral bone-forming mechanism. Figure 1.7 indicates the location of outer and
central zones in relation to adjacent vertebrae (V) and fusion mass (FM)88.
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Figure 1.7: Depicts the central and outer regions. The central region forms bone later
than outer regions and is often a cause for fusion failure. (Adapted from Boden et al.
(2000) Tissue Engineering89)

This central region experienced a lag effect, where the formation of bone was
delayed with a cartilage intermediate. The lag effect, shown in Figure 1.8 below, correlates
to non-unions occurring in the central zone. The lack of inadequate blood supply and
increased mechanical motion resulted in lack of remodeling and ossification in this region
and rendered it susceptible to nonunions24,80,88–90.

Figure 1.8: Faster cancellous bone formation in the outer zones compared to the central
zone. (Adapted from Boden et al. (2000) Tissue Engineering89)
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Bone formation in this posterolateral fusion model was further characterized by
gene expression, which was analyzed by real-time polymerase chain reaction from
ribonucleic acid (RNA) in both the central and outer zones. Osteoblast-related gene
expression demonstrated a temporal and spatial pattern. Osteocalcin peak expression in the
central zone occurred 2 weeks later than in the outer zone, which agrees with the delayed
bone formation depicted via histology. The temporal patterns of mRNA expression of bone
morphogenetic proteins were analyzed in the outer and central zones. BMP-2, BMP-4, and
BMP-6 depicted different levels of expression at various time points. BMP-6 was
expressed in the outer zones the earliest and had the greatest increase over time. The
expression of BMP-6 in the central zone showed a different temporal pattern, with delayed
expression, which corresponds to the smaller bone formation and susceptibility of
nonunion in this region22,24,26,80,88,90,91.
The delayed bone formation in the central zone of posterolateral fusion is a result
of less vascularization. In another study, Giannicola and coworkers showed that
neovasculature is essential to support osteogenic potential cells and bone formation92. In
this study, the rabbit posterolateral fusion model was employed. The neovasculature in the
interapophyseal zone (central zone) and periapophyseal zone (outer zone) were evaluated
using immunostained histology sections with α-smooth muscle actin antiserum. The
number of blood vessels per surface area (VD) was calculated in both regions. Giannicola
and coworkers found a significant difference in VD between central and outer zones of
posterolateral fusion. VD was significantly higher in the periapophyseal region than in the
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interapophyseal region, reflecting a gradient of VD across the regions. The most significant
source of blood supply is from the transverse processes. As a result, the central or
interapophyseal region is furthest from the blood supply and contains the least amount of
new blood vessel formation. Similar to critical bone defects, the area of bone formation in
the central region is a critical size92. In a similar study, Toribatake and coworkers evaluated
the extent of vascularization using microangiograms in solid fusions, cartilaginous cleft
type fusions, and nonunion type fusions in New Zealand white rabbits26. This study related
the success of posterolateral fusion to the amount of area vascularized on the transverse
processes. Area of vasculature on transverse processes and fusion mass were greatest for
solid fusion. The cartilaginous cleft area of vascularization was greatest along the edges
but did not penetrate the fusion mass. Nonunion type fusions had no vessels along the
transverse processes. This study confirmed that adequate decortication is necessary for
branches of the transverse process blood vessels to penetrate the fusion mass. These studies
are consistent with trends shown by Boden and coworkers22–24,80,88,91. Both bone formation
and BMP temporal expression lagged in the central region because this region is the
furthest from the decorticated transverse processes, the major source of vasculature and
osteogenic potential factors and cells.
In addition to adequate decortication, the integrity and quality of the surrounding soft
tissue also plays an important role in bone formation. In posterolateral fusion, the
paraspinal muscles comprise most of the surrounding soft tissue. Part of the surgical
procedure involves placement of the muscles to secure the graft material as shown in Figure
1.9 below. The surrounding soft tissue, including the paraspinal muscles, must support
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osteogenic potential cells in the graft, as well as the migration of bone-forming cells and
inflammatory cells into the fusion mass. The effect of the surrounding soft tissue on bone
formation was evaluated using a dog posterior spinal fusion model. In one group, a plastic
porous membrane permeable to tissue fluids but not to cells was placed between the site of
the fusion mass and the surrounding muscle tissue. Another group contained a membrane
between the fusion site and muscle tissue that was impermeable to tissue fluids and cells.
The latter of the two groups resulted in nonunions. This study suggests the surrounding
soft tissue provides nutrition and osteogenic factors and cells necessary for fusion93–95.

Figure 1.9. Location of posterolateral placement of bone graft and paraspinal muscle
tissue. (Figure was also published in Tabbaa et al. Critical Reviews in Biomedical
Engineering, 201482)

Bawa and coworkers evaluated whether the paraspinal muscles have any adverse
effects on the fusion mass. Muscle tissue becomes incorporated into the bone graft,
resulting in formation of fibrous tissue and inhibits bone formation. To further evaluate the
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role of paraspinal muscles on posterolateral fusion, Bawa and coworkers used a rabbit
posterolateral fusion model, where the animal was treated with iliac crest autologous bone
graft with and without a porous or nonporous barrier sheet. The computed tomography
(CT) scans and histological results demonstrated the group with a porous polymer barrier
sheet between the fusion site and paraspinal muscles had the highest rate of fusion (90%).
The nonporous barrier group and control group had fusion rates of 40% and 55%,
respectively. This study suggests the porous barrier improves the fusion rate by preventing
interposition of the muscle tissue and providing local growth factors and cells that result in
bone formation and vessel ingrowth. Histology samples of the bone-muscle interaction
revealed vascular ingrowth into the fusion mass in the group with the porous barrier sheets.
The nonporous group contained no neovessel formation from the muscle tissue to the
fusion mass. The control group had vascular ingrowth from both muscle and transverse
processes. However, the increased numbers of cases of pseudarthrosis are thought to be a
result of muscle interposition or migration of bone graft from the fusion site. Although the
mechanism and specific factors regarding the contribution of surrounding muscle to spinal
fusion is unknown, the surrounding soft tissue significantly contributes to the spinal
fusion96,97. Tissue engineering should evaluate the mechanism soft tissue contributes to
spinal fusions to develop new tissue engineering solutions to improve the success rates of
fusions93.
Tissue Contribution to Fracture Repair
Similar to fusions, the composition of tissues surrounding the defect site will
influence healing and susceptibility for nonunion. The loss of tissue and soft tissue damage
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of a fracture plays a critical role in the successful bone repair. The tissue surrounding a
fracture will vary depending on the type of fracture and anatomical location. For example,
high-energy fractures typically lose bone marrow and periosteum and are supported by the
vasculature of the local muscle and soft tissues. In closed fracture cases, the main sources
of tissue that promote healing include bone marrow and periosteum—experimentally
shown to enhance fracture healing. Both sources are accepted as the major contributors of
osteoprogenitor cells, vasculature, and bone forming biomolecules. The role of
surrounding soft tissue, including muscle and fat, is less established. Muscle tissue
coverage has been shown to increase vasculature and bone formation in both fusion and
long bone defect animal models98. Non-unions are more prevalent in defects or fusions
lacking muscle tissue and an intact periosteum. The degree of soft tissue damage will
influence the activity of the periosteum, blood flow, and rate of bone formation99,100.
Landry and coworkers showed that moderate soft-tissue damage of the muscle tissue will
actually enhance the periosteum, suggesting that injury to the muscle will not impair
fracture healing. However, muscle resection has been shown to adversely affect bone
healing of a trauma defect100.
The fracture healing process is generally described with cellular and vascular
contribution from the periosteum and bone marrow. Also of importance are the cellular,
biomolecular, and vascular contributions from surrounding soft tissues including muscle
and fasciocutaneous tissue. Harry and coworkers investigated the role of muscle or
fasciocutaneous tissue in a murine mouse open tibia fracture model with stripped
periosteum and soft tissue disruption. The outcomes indicated the group with muscle tissue
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coverage had faster bone formation, 50% higher bone mineral content, and three-fold
stronger union101. Harris and colleagues suggested the rich vascular supply from the muscle
tissue enhanced the bone formation in the tibia defect101. In a follow-up study, Harry and
coworkers investigated the amount of vasculature in muscle and fasciocutaneous tissue
when in contact with the open tibia fracture site102. The vascular density was determined
using immunohistochemistry post fracture at various time points throughout the fracture
healing process. The outcomes showed the fasciocutaneous tissue coverage of the tibia
fracture contained higher vascular density at each time point throughout the fracture
healing process.102 However, the muscle tissue coverage indicated accelerated bone
formation. This study suggests other factors from the muscle tissue are enhancing the bone
healing process.102
To investigate potential contributing factors from muscle tissue, other researchers
have explored the osteogenic potential of myogenic cells103,104. Studies have demonstrated
the ability of isolated muscle-derived progenitor cells to differentiate towards osteoblast
lineages, both in vitro and in vivo105. Liu and colleagues investigated the contribution of
muscle progenitor cells (MyoD- lineage cells) in vivo using a MyoD-Cre+: Z/AP+
conditional reporter mouse with MyoD-lineage cells labeled with a human alkaline
phosphatase (hAP) reporter106. The contribution of the MyoD-lineage cells were assessed
in both open and closed mouse tibia fracture models. The closed fracture model consisted
of an intact periosteum, whereas the open fracture model simulated a high-energy fracture
with tissue trauma and a stripped periosteum. Although the outcomes from the closed
fracture group showed no significant contribution of the MyoD-lineage cells to the fracture
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callus, the open fracture group contained approximately 50% of the MyoD-lineage cells.
The outcomes suggest the muscle acts a “secondary periosteum”, as described by Liu and
coworkers. In cases such as closed fractures where the periosteum is intact, the muscle
demonstrated limited contribution. The periosteum can directly supply the fracture with
vasculature and mesenchymal progenitor cells as well as other bone forming growth
factors. In fracture cases where the periosteum is stripped or damaged the muscle will
directly impact the fracture healing contribute significant amounts of progenitor cells 107.
This work suggests that muscle supplies vasculature as well as muscle-derived progenitors,
which play a critical role in the bone repair process in addition to the conventional
contributors, periosteum and bone marrow.
Table 1.1: Soft tissue contribution to fracture repair and spinal fusion (Table was also
published in Tabbaa et al. Critical Reviews in Biomedical Engineering82)
Soft tissue
evaluation

Animal
model

Experimental
groups

Outcomes

Comments

Rabbit
posterolatera
l fusion
model

Control - autograft
in one side of rabbit;
Group 1 - autograft
contained in porous
barrier sheet; Group
2 - autograft
contained in
nonporous barrier

Control - graft in
contact with muscle,
55% fusion; Group
1 - porous sheet
allows blood vessel
and cell penetration,
90% fusion; Group
2 - nonporous sheet
prevented muscle
contact, 40% fusion

The porous sheet
allowed
vasculature and cell
penetration,
creating fusion
rates. The porous
barrier prevents
muscle
interposition that
can lead to
pseudoarthrosis

Canine
posterior
fusion model

Group 1 posterolateral fusion
with autograft;
Group 2 - posterior
fusion with
paraspinal muscle
flap

Group 1 – 50%
fusion rate after 16
weeks; Group 2 –
87.5% fusion rate
after 16 weeks

Outcomes suggest
the blood supply
and muscle derived
factors contribute
to the enhanced
fusion rates

Auth
ors

Posterolateral fusion

Paraspina
l muscle

Paraspina
l muscle

Tibial
fracture
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Baw
a et
al.
2006
93

Xi et
al.
2010
94

Fasciocuta
neous and
muscle
tissue
coverage

Fasciocuta
neous and
muscle
tissue
contact

Myogenic
progenitor
cells

Injured
muscle on
periosteu
m

Murine open
tibial
fracture
model with
stripped
periosteum
and soft
tissue
disruption

Group 1 - tibial
fracture covered
with muscle tissue;
Group 2 - tibial
fracture covered
with
fasciocutaneous
tissue

Muscle coverage
group: faster bone
formation, higher
bone mineral
content, stronger
union
Fasciocutaneous
coverage: Greater
vascular density

The
fasciocutaneous
revealed slower
bone formation
than muscle tissue
coverage group,
however, the tissue
did not impair
callus formation

Harr
y et
al.
2008

Murine open
tibial
fracture
model

Control - no fracture
with soft tissue and
periosteum
dissected; Group 1 fracture covered
with muscle; Group
2 - fracture covered
with
fasciocutaneous
tissue

Fasciocutaneous
tissue resulted in
higher vascular
density than muscle
throughout the
fracture healing,
muscle showed
accelerated bone
formation

Outcomes imply
factors other than
vascularity are
contributing to the
accelerated bone
formation with
muscle tissue
coverage

Harr
y et
al.
2009

Murine tibial
fracture
model

Group 1 - closed
fracture; Group 2 open fracture

Rat tibial
bone defect

Group 1 - Bone
defect with muscle
injury
Group 2 - Bone
defect without
injury

Group 1 - musclederived progenitor
cells had no
significant
contribution
Group 2 - 50% of
muscle-derived
progenitor cells
contributed to
fracture callus
The bone defect
with muscle injury
resulted in increased
proliferation of the
periosteum and
increased osteoblast
activity
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Suggests muscle
directly affects
repair in fractures
with damaged
periosteum; intact
periosteum is the
major contributor
in cases such as
closed fractures
Moderate soft
tissue damage to
the muscle initiates
the inflammatory
response and
increases
periosteum activity

Liu
et al.
2011
106

Land
ry et
al.
2000
99

Cellular Contribution in Fracture Site from Surrounding Tissues
In addition to vascular contribution, the surrounding connective tissues may also
supply osteogenic progenitor cells and bone initiating biomolecules critical for bone
formation. Researchers have investigated the osteogenic cellular contribution from
surrounding tissues, including the periosteum, local bone, bone marrow, muscle, fat, soft
tissues, as well as homing through the systemic circulation108.
Vascular pericytes are considered multipotent osteoprogenitor cells that penetrate
the fusion or defect site through invading capillaries and other microvessels109,110. Several
research groups have investigated the osteogenic potential of vascular pericytes isolated
from aortic intima. The studies found, both in vitro and in vivo, that vascular pericytes are
osteogenic and capable of differentiation into functional osteoblasts111.
Muschler and coworkers investigated the osteoprogenitor cells in the systemic
circulation and their ability to migrate through the systemic circulation to contribute to
bone formation of the defect112. This study used a mouse parabiotic murine model with
transgenic green fluorescent mice (GFP+) and wild type mice (GFP-). The outcomes
indicated the GFP+ cells from the donor mouse home through the peripheral blood and
contribute to the fracture. Furthermore, the results showed an increase in GFP+ cells
between 7-14 days post fracture, suggesting the osteoprogenitor circulating cells coincide
with revascularization and hard callus formation112. The outcomes of this study support
the outcomes of earlier investigations, finding the fracture site may provide a homing single
for circulating progenitor cells112,113.
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Shirley and coworkers used New Zealand rabbits to study the systemic transport of
bone marrow-derived stem cells in an osteotomy model113. Bone marrow mesenchymal
stem cells were isolated and fluorescently tagged to allow image analysis. After osteotomy,
cells were transplanted into the fracture site intravenously, or into a remote tibial bone
marrow cavity. Interestingly, general systemic MSCs implanted intravenously did not
relocate to the site of the osteotomy, while both the directly implanted MSCs and remotely
located MSCs within the tibial remained and migrated to the site, respectively. Not only
are stem cells recruited from the adjacent tissue during fracture repair, but also they are
recruited systemically from locations of higher mesenchymal stem cell reservoirs.
Table 1.2: Osteogenic Cell Contributions. (Also published in Tabbaa et al. (2014)
Critical Reviews in Biomedical Engineering82)
Stem cell

Mesench
ymal

Muscle

Muscle

Pericyte

Source

Plastic
potential

Procedural notes
Hind limb ischemic
model of nude mice
using human adiposederived stem cells
(ADSC); isolated by
collagenase-I
Rat muscle; cell isolation
by collagenase-XI
digestion and plating
onto collagen-coated
flasks

Outcomes

Human
adipose
tissue

Proangio
genic

Rat
hindlimb
muscle

Osteogen
ic

Human
skeletal
muscle

Myogeni
c,
adipogeni
c,
osteogeni
c,
chondrog
enic

Cells isolated by
modified pre-plate
technique and subjected
to immunomagnetic
separation

Demonstrates muscle stem
cells as a potential multipotent
stem cell, needs further testing
to demonstrate osteogenic
potential

Bovine
retina

Chondro
genic,
adipogeni
c

Pericytes identified by
morphology, expression
of α-smooth muscle
actin, and cell-surface
ganglioside

Preliminary evaluation
demonstrating the potential for
these two lineage cell
maturation; further studies
needed to confirm
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Increased blood perfusion in
the injury model; potential for
improved neovascular support

Potential for highly osteogenic
source of stem cells for tissue
engineering applications

Autho
r
Kim et
al.
200711
4

Kim et
al.
200810
5

Lu et
al.
201011
5

Farrin
gtonRock
et al.

200410
9

Pericyte

Periostea
l

Human
gracilis
and
semite
ndinos
us
muscle
Mouse
hindlimb
periost
eum

Adipogen
ic,
osteogeni
c

Rat
bone
marro
w

Mesench
ymal

Rat
periost
eum

Rat
adipose
tissue

Osteogen
ic

Isolation by collagenase-I
and plating onto
collagen-coated flasks

Adult skeletal muscle could be
an important source of
multipotent stem cells;
isolated cells do not express
endothelial cell surface
markers

Tissue explants cultured
on fibronectin-coated
flasks

MC3T3-E1 preosteoblast cells
exhibited higher levels of
ALP activity; fibroblasts
demonstrated higher levels of
Oil Red O over periosteal
cells; periosteal stem cells
have potential but potentially
limited

Bone marrow of femora,
centrifuged through cell
strainer and adherent
cells used
Diaphyseal areas of
femora and tibiae;
collagenase and
centrifuged through cell
strainer, adherent cells
used

Inguinal adipose tissue;
collagenase

Levy
et al.
200111
6

Arnsd
orf et
al.
200911
7

Had lower colony forming
units but demonstrated highest
levels of osteogenic potential
Periosteal cells demonstrated
osteogenic potential, only
slightly lower than MSC;
differs from other literature
potentially due to passage
levels of cells evaluated
Demonstrated lower
osteogenic potential than bone
marrow and periosteal stem
cells; should be considered
when investigating sources for
bone tissue engineering

Hayas
hi et
al.
200811
8

Review of Bone Tissue Engineering and Bone Substitutes
Bone Tissue Engineered Scaffolds
The field of tissue engineering is based on understanding normal tissue formation
and regeneration and applying this knowledge to produce new functional tissue when
normal repair process is impaired and there is a need for new tissue formation. The design
of tissue engineered constructs incorporates skills from the fields of cell biology, medicine,
and engineering. The goal of tissue engineering is to generate functional tissue; one
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approach encompasses incorporating progenitor cells and growth factors on a scaffold (also
termed “matrix” or “construct”) designed for a specific anatomical region or purpose. One
typical approach for developing a tissue engineering construct involves isolating cells from
the patient, differentiating cells on a 3-dimensional matrix with growth factors, and
culturing the composite to form an in vitro tissue construct that can be implanted into the
patient15. When designing constructs for tissue engineering it is essential to understand the
pathological environment and anatomical location of the defect or area where bone
regeneration is required. The location for bone regeneration will vary in terms of
mechanical load, type of bone, and degree of vascularity. Furthermore, the altered
environment due to the patient’s condition will affect the fixation, vascularization, and
integration of the construct30,34,76,119–122.

In comparison to organ transplants, tissue

engineered bone grafts lack pre-existing vascular networks. This avascularity is a
considerable problem for spinal fusion, where a large amount of bone formation is needed.
The tissue engineered construct depends on diffusion from surrounding tissue for nutrient
supply and waste removal as well as essential growth factors and osteoprogenitor
cells21,123,124. Designing tissue-engineered scaffolds that promote transport or stimulate
vasculature is essential for the success of bone grafts in areas requiring large amounts of
bone formation.
Bone tissue engineered scaffolds or bone grafts are defined by three main attributes:
osteogenic, osteoinductive, and osteoconductive. Osteogenic is defined as the ability of the
construct to form bone tissue by containing and supporting cells that can differentiate into
functional osteoblasts. Osteoinduction is defined as the recruitment and stimulation of local
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bone-forming cells, typically through growth factor signaling, such as bone morphogenic
proteins (BMPs). Osteoconduction describes the ability of the bone graft to act as a scaffold
and generate new bone by allowing infiltration of osteogenic cells and neovasculature. The
diamond concept of bone tissue engineering describes four essential factors for bone
formation. These factors necessary for optimal bone formation include the biological
attributes of osteoinduction, osteoconduction, and osteogenesis as well as the mechanical
environment

77,125,126

.

In spinal fusion treatments, mechanical stability is a significant

factor in contributing to successful fusion. Mechanical stability can be achieved using
instrumentation, which has increased the fusion rates. The significant impact of mechanical
stability in the success of spinal fusion is reflected by fusions in the lumbosacral junction.
This region is disposed to instability due to excessive motion. As a result, this region of the
spine in particular has elevated rates of spinal failure124,127,128.
The diamond concept of bone tissue engineering describes four essential factors for
bone formation, including the biological attributes of osteoinduction, osteoconduction, and
osteogenesis as well as a proper mechanical environment77,126,129. Although these four
factors are critical for bone formation, a fifth element of sufficient vascularization is critical
for optimizing bone formation.
depicts an additional apex to the diamond shaped model, thus establishing the star concept
for bone healing. That is, successful tissue engineering bone grafts should not only
incorporate the diamond concept attributes, but should also factor in principles of
vascularization76,120. For successful bone formation, the principles of vascularization
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include preparation of the recipient site, the vascular supply from surrounding tissue, and
vascularization of the bone graft.

Vascularity
Osteogenic
cells

Osteoconductive
scaffold
Diamond
Concept

Mechanical
environment

Osteoinductive
molecules

Osteogenic
cells

Mechanical
environment

Star
Concept

Osteoconductive
scaffold

Osteoinductive
molecules

Figure 1.10. Bone fracture healing concepts. Schematic shows an additional apex for
vascularity, revealing the star concept model (Also published in Tabbaa et al. (2014)
Critical Reviews in Biomedical Engineering82)

Types of Bone Grafts for Spinal Fusion
Autologous Grafts
Autologous bone, or autograft, is the clinical gold standard for bone repair and
spinal fusions. Autografts contain the necessary attributes for promoting bone formation,
including osteoinduction, osteoconduction, osteogenesis, and vascular elements.
Autografts are obtained by a secondary surgical procedure, commonly derived from the
iliac crest or intramedullary canal. The most common and successful autograft in spinal
fusion surgery is corticocancellous bone harvested from the iliac crest. Cancellous bone
contains marrow that the cortical bone lacks, and provides osteogenic cells and inductive
proteins. Furthermore, the porosity of the cancellous bone promotes neovasculature at the
fusion site and an influx of osteogenic cells91. Disadvantages of autografts include tissue
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morbidity at the bone graft harvest site, lack of structural integrity, increased operative
time, and increased blood loss. Most importantly, autografts are limited by the total amount
available. This drawback is especially an issue in spinal fusion surgeries, where large
amounts of bone grafts are needed for fusion, or patients require multiple levels of
fusion6,17,85,129,130.
Allografts
Allografts incorporate the necessary attributes to some degree but do not
revascularize or remodel as well as autografts15,30,34,120,123. Allografts are mostly
osteoconductive, somewhat osteoinductive, and are not osteogenic. In comparison to
autografts, allografts are more available but have a higher failure rate in spinal fusion
surgeries. Slower fusion rate and higher graft resorption were also observed with
allografts130.

Other associated problems include the risk of disease transmission.

Demineralized bone matrix (DBM) can be allografts or xenografts. DBM contains growth
factors, proteins, and a portion of the mineral phase; the major disadvantage of DBM is
variability between grafts. The macrostructure and mechanical properties significantly vary
and are challenging to control.
Synthetic Grafts
The shortcomings of allografts and autografts led to the use of synthetic materials
and composites of materials from natural and synthetic origin. Synthetic bone substitutes
include the use of ceramics, polymers, metals, and cements8,131,132. Polymer materials used
as osteoconductive scaffolds include polyglycolide, poly-L-lactide, and polylactide-co52

glycolide. Ceramics are the most commonly used synthetic material in surgery. Ceramics
include calcium phosphates that incorporate hydroxyapatite (HA) and tricalcium phosphate
(TCP). Various ratios of HA and TCP are used to obtain optimal bone fusions. HA
biodegrades slowly, which increases the mechanical strength but hinders remodeling. On
the other hand, TCP biodegrades too fast to support bone fusion130.
Ceramics are strongly osteoconductive but lack the osteoinductive and osteogenic
capabilities of autologous bone. This has led to the use of composite bone substitutes,
which include osteoinductive factors coupled with osteogenic potential cells to augment an
osteoconductive material17. Bone morphogenetic proteins, in native (BMP) and
recombinant forms (rhBMP), are the most effective inductive agents for bone-forming
applications. BMP, in combination with a biodegradable osteoconductive polymer or
ceramic, has been reported to increase union rate and has been shown to be effective in
spinal fusion treatment. However, more recent literature shows BMP use in the clinic to
have adverse effects on patients and complications133. The addition of osteogenic
progenitor cells, ranging from sources such as bone marrow aspirate to a synthetic
osteoconductive material that contains osteoinductive agents, creates a composite that
encompasses all of the bone-forming properties similar to autologous bone grafts.
Composite synthetic bone grafts, as an alternative to autologous bone grafts, have huge
potential since these grafts incorporate the bone-forming attributes but do not have the
limitations of autologous grafts22,91,134. Other inductive growth factors, including
transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), and growth
differentiation factor 5 (GDF-5), augment the bone forming process91. Autologous bone
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marrow aspirate is used to augment synthetic bone grafts. The marrow is typically obtained
from the posterior iliac crest and contains progenitor cells that can be isolated and
expanded17,89,127. Tissue engineering techniques are employed to produce composites that
are effective and assist the natural bone-forming process.
The ideal bone graft should incorporate all the bone-forming attributes of the star
concept to some degree. Most bone grafts used in the clinic lack one or multiple properties
essential for promoting spinal fusions. Figure 1.11 depicts the attributes various bone grafts
possess and quantifies the strength of each attribute. Most bone grafts contain some degree
of osteoconductive and osteoinductive properties while very few bone grafts incorporate
vascularity via factors that promote angiogenesis or neovessel formation. Vascularized
autografts and cancellous autografts are the only bone grafts that incorporate all five
attributes to some degree. The inclusion and strength of each bone-forming property is
directly related to the functionality of the bone graft. Autografts are the only type
containing each of the five attributes to some degree and, as a result, have the most success
in spinal fusions and remain the gold standard. This further illustrates the need for a bone
graft to promote vascularity for bone regeneration.
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Functionality of Various Bone Grafts
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Figure 1.11. Functionality of various bone grafts based on the strength of the start
concept attributes. (Also published in Tabbaa et al. (2014) Critical Reviews in
Biomedical Engineering82)

Bone Substitutes in the Clinic
Autologous iliac crest bone graft is the most commonly used bone substitute and is
still today the gold standard for lumbar fusion. The complications involved with using this
bone substitute are still present135. Graft alternatives, in addition to bone substitutes,
include graft enhancers and graft extenders. Graft extenders are used in combination with
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autologous bone graft and provide a comparable fusion rate to autologous bone alone. Graft
extenders are employed when there is a limited supply of autologous bone graft,
predominantly for patients who require multiple levels of fusion136. Graft enhancers
function to improve the fusion rates of autologous bone used in adequate amounts. Graft
extenders and enhancers are both used in the clinics.
Animal Studies to Test the Efficacy of Bone Substitutes
Relevant animal studies must allow simulation of the surgical procedure of
posterolateral fusion and replication of similar bone formation as in humans. During the
surgical technique of posterolateral fusion, the surgeon must extensively prepare the site
for fusion by decortication; instrumentation is frequently employed. The animal models
used to study posterolateral fusion do not accurately replicate all the aspects of this surgical
technique nor the pathology and spinal abnormalities the patient indicates. An animal
model must not only simulate fusion from the surgical technique but must also create a
pathological environment that demonstrates the instability of spinal conditions134.
In the rabbit model, no instrumentation is used and decortication is limited to the
transverse processes. Dog and sheep models are anatomically better in size. A sheep model
allows decortication and use of instrumentation; however, the model does not replicate the
human environment better than rabbits127. The canine models use posterior thoracic
fusions, which do not correlate well to lumbar posterolateral intertransverse fusions.
Another issue with the canine model is the 100% autologous bone graft fusion rate, which
is not analogous to humans91. The evolutionary complexity of the species will affect the
biological factors affecting spinal fusions. Animals with lower complexity, such as rats,
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used in studies exhibits a much higher spinal fusion rate compared to other, more complex,
species. Furthermore, the chronology of fusion will differ between species. For example,
rabbit lumbar intertransverse spinal fusion develops after 4-6 weeks, whereas this process
in humans and primates take months. Several animal studies are used to demonstrate the
efficacy of a bone substitute for posterolateral fusion. The athymic nude rat muscle pouch
assay can demonstrate the concept. The rabbit posterolateral fusion model can demonstrate
the feasibility. The nonhuman primate spinal fusion model is used as an efficacy study.
However, due to the cost and ethical issues associated with experimenting with primates,
this type of study is only performed when the feasibility models are highly successful134.
Clinical Studies and the Efficacy of Bone Substitutes in Posterolateral Spinal Fusion
The effectiveness of ceramics in posterolateral spinal fusions has been studied in
animals and in clinical trials. In some studies, the ceramic bone substitutes showed
comparable fusion rates to autologous bone. Other researchers have demonstrated that
ceramics are a successful graft extender for autologous bone130,135,137.
The clinical use of ceramics in spinal fusion procedures involves the use of bone
marrow aspirate (BMA), which contains osteoprogenitor cells and osteoinductive
factors138. The success rate of ceramics and BMA in the clinic for spinal fusions has had
varied results. Several researchers have claimed ceramic and BMA composites have
comparable results to autologous bone graft, whereas other studies have shown less
successful fusions. The contribution of BMA in improving fusion is not well understood.
BMA is highly cellular, containing hematopoietic and mesenchymal cells that both
contribute to bone formation. However, only the mesenchymal-derived cells can lead to
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bone forming cells. The osteoprogenitor cells within the BMA are a very small sub-fraction
of the cellular component. In fact, one mesenchymal cell is present in 100,000 cells of the
BMA. The lack of mesenchymal or osteoprogenitor cells in the BMA is a major
limitation139,140.

Other limitations include variability between patients and loss of

osteoinductive cells and factors from the site through migration or diffusion135,137. The
cellular composition of the bone marrow aspirate will affect its success in spinal fusion and
contribution to bone formation. This is reflected in the variability of BMA in efficacy trials
for spinal fusion procedures.
Researchers have proven platelets to provide an ample amount of growth factors.
Activated growth factor (AGF) platelet gel consists of ultraconcentrated growth factors.
AGF platelet gel is suggested to improve fusions by stimulating pathways that promote
osteogenesis, reducing postoperative blood loss by initiating clot formation, and stabilizing
the site141,142. Multiple clinical studies have demonstrated the addition of platelet gel to
autologous bone graft to decrease the fusion rate has no benefit as a graft extender in
posterolateral spinal fusions. Rihn and coworkers suggests the platelet gel may dissolve
via fibrinolysis, reducing the amount of growth factors in the site and reducing the fusion
rate. This article suggests platelet gel is inadequate as a bone graft enhancer due to the
potential reduction in concentration of growth factors and because the specific types of
growth factors in the platelet gel may inhibit osteogenesis143.
Demineralized bone matrix (DBM) contains osteoinductive glycoproteins that
contribute to bone formation. Similar to BMPs, several animal studies have evaluated if
DBM increases the success rate for spinal fusions when combined with autologous bone
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graft. Boden and coworkers suggested the use of DBM as an extender for autologous bone
graft. The researchers performed bilateral posterolateral lumbar spinal fusion on 47 New
Zealand white rabbits. Groups were evaluated based on the ratio of autograft to DB with
which they were treated. The results of this study suggest that DB combined with
autologous bone graft is comparable to using only autologous bone graft. The fusion rates
were similar for each group and were determined by manual palpation22. The results of this
study are comparable to a study evaluating DBM in dogs, which had similar findings.
A review of DBM to augment spinal fusion treatments found significant
inconsistencies between animal studies and efficacy in spinal treatments. A major
contributing factor to these inconsistencies is the variability in DBM. The osteogenic
potential of this bone substitute is dependent on the type, the donor, and how the DBM is
prepared. These factors in DBM contribute to the inconsistencies of the results in animal
studies and clinical trials22,144. Wang and coworkers evaluated the osteoinductive potential
of three commercially available DBM bone grafts. This study found each product contained
various amounts of DBM, with different osteoinductive potential between products,
altering the efficacy of the products. The author suggests the processing procedures, the
donor quality, and the sterilizing techniques alter the quality of DBM products. Bae and
coworkers evaluated the amount of BMP in commercially available DBM products using
enzyme-linked immunosorbent assay. Interestingly, this study determined there were
varying amounts of BMPs in DBM from different lots of the same manufacturer. DBM
quality and osteopotential is inconsistent between DBM products and between lots within
the commercial products145,146.
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Molecular biology analysis of posterolateral spinal fusion shows bone morphogenic
proteins (BMP-2, BMP-4, BMP-6) play a critical role in formation of bone. In a review by
Boden and coworkers, the effect of recombinant human morphogenetic protein-2 (rhBMP2) combined with autologous bone used in posterolateral fusions in rabbits was analyzed.
Histology and CT scans showed the fusion mass formed from the composite had greater
volume and more contact with host bone than that formed with just autograft. Histology,
and analysis of gene expression of rhBMP-2 and other bone related genes, showed rhBMP2 recruited bone-forming cells and expressed bone forming genes more homogeneously in
both zones, indicating no delay in bone formation of the central zone. The use of rhBMP2 with autologous bone graft in rabbits resulted in 100% success rate of fusion. In general,
bone formation in lower vertebrae is much faster and requires less of a dose compared to
nonhuman primates. This success rate was further replicated in a primate model, however,
at a significantly higher dose and after a much longer fusion time. The incorporation of this
osteoinductive factor with autologous bone resulted in local production of BMPs,
migration of osteoprogenitor cells from surrounding muscle, and similar rates of bone
formation in the central and outer zones. Human clinical trials of rhBMP-2 combined with
HA and tricalcium phosphate granules showed the ability of rhBMP-2 to induce bone on
an appropriate carrier. Generating large doses of recombinant and extracted BMP is not
feasible or cost-effective. Furthermore, a delivery system is required to maintain levels of
BMP expression corresponding to the unimpaired natural bone healing process24,88,91.
The US Food and Drug Administration (FDA) approved two recombinant human
bone morphogenetic proteins (rhBMP-2 and rhBMP-7) for specific spinal fusion
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procedures. Infuse, a bone substitute containing rhBMP-2 (Medtronic; Memphis,
Tennessee), is a commercially available product approved for 1-level anterior lumbar
interbody fusion. Osteogenic protein-1 (OP-1), BMP-7 (Stryker Biotech; Hopkinton,
Massachusetts), is also a commercially available product approved for revision
posterolateral fusion. All other uses are off-label and not approved135. Numerous clinical
studies were conducted to evaluate the efficacy of BMPs. Based on these studies, the
efficacy of BMPs is difficult to define. The indications of the patients, the surgical
techniques, the outcome measures, and varying types of bone grafts used with BMPs were
all varying factors between studies. Major disadvantages of BMPs are the possible
complications, which include: heterotopic bone formation, resorption or osteolysis,
seromas or hematomas, antibody formation, inflammatory reaction, and adverse effect on
neural elements135,140.

Table 2 provides a list of various commercially available bone

grafts and evaluates the use of various commercially available products.
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Table 1.3: A summary of bone grafts used in posterolateral fusions provides examples of
commercially available bone grafts and their potential use as a bone substitute or bone
graft extender. (Also published in Tabbaa et al. (2014) Critical Reviews in Biomedical
Engineering82)
Graft
Commercial
Efficacy of graft
References
Discrepancies
Material
name
material
Radiographically
Studies have
cannot determine
suggested both
Bonograft
Bansal et
Ceramic +
quality of fusion,
comparable and
(India)
al.
BMA
cannot be assessed
poorer fusion rates
with histology
with the use BMA
Range of patients
osteoset,
degenerative or
TCP and HA
Wright
spondylolytic
ceramic can be used
Ceramic +
Medical
Niu et al.
spondylolisthesis,
as an effective graft
BMA
Technologies,
smokers and
extender
Arlington, TN
nonsmokers
DBM can be used as
graft extender.
Grafton, DBM
Several studies have
(Osteotech
Variability between
Vaccaro et
shown comparable
DBM
Eatontown,
DBM products
al.
fusion rates to
NJ)
autologous bone
graft
Acela
Connexus
Results suggest can
(IsoTis
Low patient
be used as extender Schizas et
DBM
OrthoBiologics
number
with comparable
al.
Inc., Irvine,
fusion rates
CA)
Activating
Activated growth
Interpore Cross
growth
Controversial use in factor platelet gel is
International
Rihn et al.
factor
spinal fusions
not an effective graft
(Irvine, CA)
(AGF)
extender
platelet gel
BMP use is effective
Infuse
Off-label use,
in spinal fusions
(Medtronic,
uncertain dosages,
however adequate
Taghavi et
rhBMP-2
Memphis,
and possible
dosages and
al.
Tennessee)
complications
complications are
unclear
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In summary, autografts are the most effective bone substitute for posterolateral
surgery. However, the amount available is limited and donor site morbidity may result as
a complication. Allografts are more available and cost effective than autografts but are not
effective bone substitutes in posterolateral fusion due to their variability and loss of
osteoinductive factors and cells. DBM, however, demonstrate comparable fusion rates to
autografts when used as a graft extender. BMPs are also effective graft extenders.
However, the cost is high and there are complications such as adverse effects to neural
elements. Ceramics, similar to DBM, have proven to be effective graft extenders when
combined with BMA or BMPs. Currently, there is no effective replacement for autologous
bone grafts.
Table 1.4: Characteristics of bone grafts used for posterolateral fusion.
Efficacy
as
extender
High

Donor
site
morbidity
High

Cost

Disease
Availabilit
transmission y

Limita
tions

Autograft

Efficacy
as
substitute
High

Low

None

Low

Yes

Allograft

Low

Moderate

None

Moderate

Low

High

None

rhBMPs

Moderate

Moderate

None

High

None

Moderate

Yes

BMA

Low

Moderate

None

Low

Low

Low

None

Ceramic

Low

Moderate

None

Moderate

None

Moderate

None

Bone Tissue Engineering Strategies to Improve Vascularity
The design of tissue-engineered constructs incorporates skills from the fields of cell
biology, medicine, and engineering. The goal of tissue engineering is to generate functional
tissue, specifically in an environment that is indicated for poor healing. Conceptually,
tissue engineering has focused on the potential of using a patient’s progenitor cells and a
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biologically indicative scaffold to develop an active and healthy tissue construct through
in vitro culture techniques that could then be implanted into a patient15. When designing
constructs for tissue engineering it is essential to understand the pathological environment
and anatomical location of the defect or area where bone regeneration is required. The
location for bone regeneration will vary in terms of mechanical load, type of bone, and
degree of vascularity. Furthermore, the altered environment due to the patient’s condition
will affect the fixation, vascularization, and integration of the construct30,34,76,119,120,122. In
comparison to organ transplants, tissue engineered bone grafts currently lack pre-existing
vascular networks. This avascularity is a considerable problem for spinal fusions and
critical bone defects, where a large amount of bone formation is needed. Tissue-engineered
constructs depend on diffusion from surrounding tissue for nutrient supply and waste
removal as well as essential growth factors and osteoprogenitor cells21,123,124. Designing
tissue-engineered scaffolds that promote transport or stimulate vasculature is essential for
the success of bone grafts in areas requiring large amounts of bone formation.
Tissue engineering provides tools to develop vascularity in bone grafts to improve
the overall functionality and success of critical defects. Table 1.5 summarizes various
tissue engineering methods to improve vasculature and the complexities that parallel the
benefits. A major limitation is often the slow rate of vasculature formation. This rate
hinders cellular proliferation, recruitment, and osteoblastic differentiation. Other
limitations of current tissue engineering techniques to improve vasculature are
predominately seen in large or thick tissue constructs. Tissue engineering methods, where
progenitor cells such as endothelial progenitor cells are seeded to promote and develop
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vasculature or new vessels prior to implantation, often fail because the cells and
neovasculature are not supported from surrounding vasculature and compete for limited
supplies of nutrients and oxygen.
Current tissue engineering methods to develop or accelerate vasculature formation
in bone grafts overlook the support of the surrounding vasculature. The anatomical location
of the defect, composition of surrounding soft tissues, and degree of tissue damage will
influence the bone formation process. Tissue engineered bone grafts should be designed
specifically to the intended application area. The design of a tissue engineered scaffold
should consider optimization of the transport of osteogenic factors, nutrients, and cells
from surrounding tissue. Current bone substitutes on the market are comparable or less
efficient than autologous bone graft. However, without a mode of transport, such as
vascularization, the transplanted or recruited osteogenic cells will not be supported and
osteoinductive factors will not be spatially or temporally present to contribute to cell
recruitment and differentiation. Due to the environment of many spinal fusions and trauma
fractures, the damage to or lack of surrounding vascular supply requires development of
tissue engineered constructs to specifically address transport characteristics to improve
bone regeneration.
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Table 1.5: Comparison of current tissue engineering methods to improve vasculature.
(Also published in Tabbaa et al. (2014) Critical Reviews in Biomedical Engineering82)
Tissue engineering
method to improve
vasculature

Potential Benefits

Modify scaffold
architecture

Improve mass transport by
adjusting porosity, pore size,
and scaffold filaments

Use angiogenic factors

Enhance and accelerate
vascularization

Transplant
vasculogenic cells such
as endothelial
progenitor cells
Genetically modify
cells to secrete factors
that promote
vasculature

Shortcomings

Form new vessels within the
scaffold

Provides limited mass
transport in large scaffolds
and may decrease
mechanical strength
Causes slow rate of
vascularization, can cause
necrosis
Creates competition of
oxygen and nutrients inside
the scaffold, limiting cell
proliferation and viability

References

Liu et al.
2012
Muschler et
al. 2004
Tsigokou et
al. 2009

Produce proteins that
promote vasculature

Creates biological risk with
genetic manipulation

Shen et al.
2005

Generate in vitro
vasculature prior to
implantation

Develop new vessels within
the scaffold that can be
anastomosed with host
vasculature

Forms vessels requiring
vasculature from
surrounding tissue

Johnson et
al. 2011

Implant construct into
subcutaneous region
prior to implanting in
implantation site

Minimize cost using existing
vasculature to form new
vasculature networks in the
scaffold

Forms random blood vessels
in the bone, limiting
vasculature; injury may
result in surrounding
vascular network and new
network

Safak et al.
2000 Kneser
et al. 2006

Stimulate electrically

Upregulate osteoinductive
factors necessary for vascular
formation, improves
vascularity

Generates expense and lack
of evidence for efficacy in
spinal fusion surgeries

Gan et al.
2006

Summary
Bone grafts should be designed specifically to the area they are implemented. The
design of the tissue engineered scaffold should ideally consider how to optimize the
transport of osteogenic potential factors and cells from surrounding tissue. Current bone
substitutes on the market are comparable or less efficient than autologous bone graft. The
substitutes are designed to incorporate attributes of osteoconduction, osteoinduction, and
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osteogenesis. However, without a mode of transport, such as vascularization, the
transplanted or recruited osteogenic cells will not be supported and osteoinductive factors
will not be spatially or temporally present to contribute to cell recruitment and
differentiation. Due to the environment of posterolateral fusion and lack of vascular supply,
the improvement of transport characteristics of the bone graft is essential for improving
fusion rates.
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CHAPTER TWO
EFFECT OF WICKING FIBERS IN TISSUE ENGINEERED SCAFFOLDS
Introduction
Large fracture defect sites and spinal fusions require large amounts of additional
bone tissue; therefore, bone substitutes (commonly referred to as scaffolds) are used to
augment bone tissue reformation1–4. These large tissue-engineered scaffolds are limited
by a diminished capacity to transport nutrients, oxygen, large biomolecules, and
osteoprogenitor cells 5,6. Conventional approaches to improve the transport properties in
large bone tissue-engineered scaffolds involve the inclusion of biomolecules that promote
angiogenesis and of co-cultured endothelial progenitor cells and other vasculogenic cells
that stimulate neovasculature7–9. These approaches have shown limited success due to the
slow rate of angiogenesis and the formation of nonfunctional vessels; requiring
substantial improvement before consideration for clinical trials10.
A novel approach to improve transport involves incorporating polymeric wicking
fibers into a tissue-engineered construct. A wicking fiber has a grooved cross-section and
parallel continuous channels that run the length of the fiber. The fiber configuration,
shown in Figure 2.1, has been geometrically optimized by Eastman Chemical Company
to enhance capillary action along the channels, resulting in enhanced transport properties.
It is well established that the proprietary wicking fiber shape provides highly efficient
transport in textile and chromatographic separations11–16. The fibers were later introduced
by our research team, to the field of tissue engineering17.
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Figure 2.1: Scanning electron microscope (SEM) image of a wicking fiber. Adapted with
permission from Elsevier (Marcus RK et al. 2005). Image shows non-circular grooved
cross-section and parallel channels of the wicking fiber, which facilitate strong wicking
action and greatly increase surface area.

The increased transport properties of the wicking fiber is achieved through
geometrically optimized intra-fiber spaces or grooves that combine capillary pressure to
enhance fluid transport along a single wicking fiber as opposed to a single capillary
channel14. The cross-sectional geometry increases the shape factor of the wicking fiber so
the surface area is 2.5-3.2 times a conventional circular cross-sectional fiber or macro
channel of nominal diameter, resulting in significantly greater wicking capabilities18,19.
The objective of these studies was to investigate the capabilities of wicking fibers
to enhance the transport of not only fluid, but transport of biomolecules and progenitor
cells. The first phase of this study assessed the transport efficacy of round and wicking
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polylactide fibers of various bundled configuration. The second phase of this aim
investigated the movement of fluorescently labeled biomolecules in a 3-dimensional (3D)
collagen-agarose hydrogel 3-dimensional (3D) constructs containing round or wicking
fibers. The final phase investigated the ability of wicking fibers to transport and distribute
osteoprogenitor cells both along the fiber and through a 3D construct.

Fluid Transport of Fibers
Methods and Materials
Polymer Extrusion
Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm and poly-L-lactide round
fibers were extruded with cross-sectional diameter of 0.5 mm. Wicking and round fibers
were sliced with razor blade into individual fibers of 2, 3, and 6 cm lengths. Both fiber
types were cleaned in three changes of ethanol, for 1 hour each, and placed under
ultraviolet light for 6 hours. Samples were then soaked in a phosphate-buffered saline
(PBS, Invitrogen) solution for 2 hours and air-dried overnight in a sterile hood.
Fluid Transport Tests of Round and Wicking Fibers
The transport phenomena through fibers includes diffusion and wicking--the
spontaneous flow of liquid driven by capillary action. The wicking behavior of the fibers
can be assessed using a vertical wicking test, commonly performed in the textile industry
to characterize transport phenomena in fabrics20–22. The wicking tests were performed
using two methods. The first method assessed wicking capabilities of the fibers by
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recording the height of the fluid front moving vertically along the fiber at various time
points, shown in image A of Figure 2.2. The second method assessed the wicking rate of
the fibers by evaluating the change in mass of the fluid reservoir over regular time
intervals presented in image B.

Figure 2.2: (A) Vertical test apparatus to evaluate the rate of the fluid front in various
fiber configurations. (B) Vertical test set-up to assess the amount of fluid wicked through
the fiber over a time interval

Both test methods were used to evaluate the wicking capabilities of round and the
wicking properties were characterized in conformations of single fibers and of bundled
fibers in a braided or twisted configuration (Table 2.1: Experimental groups of fiber
configuration for vertical test investigating wicking height).
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Table 2.1: Experimental groups of fiber configuration for vertical test investigating
wicking height
Experimental

Number of fibers in
Fiber Type

Configuration

Group

bundle

1

Round

Single

1

2

Wicking

Single

1

3

Round

Twisted bundle

3

4

Wicking

Twisted bundle

3

5

Round

Braided bundle

3

6

Wicking

Braided bundle

3

One end of the 6 cm fiber configuration was attached to the clamp shown in the
Figure 2.2A. The bottom end was weighed down by a clip and lowered into a reservoir of
dye solution to create contact of only 10 mm of fiber. The dye solution was comprised of
phosphate buffered saline (PBS, Invitrogen) and 10% blue assorted food coloring
(McCormick). The vertical displacement of the fluid front was measured after 30, 60, 90,
120, 150, 300 seconds for each sample configuration, with each having a sample size of
n=4. The fluid front rate was determined for each sample.
Vertical Test - Wicking Rate Assessment
To determine the mass of liquid removed by the fibers from the reservoir over
time, the balance was set up to collect mass data measurements. The balance was
connected to the computer using a USB to RS232 cable. PuTTY software was used to
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transfer information from the balance to the computer. The balance was programmed to
continuously measure the weight of the reservoir at a rate of two measurements per
second. Fiber samples were then vertically dipped into the liquid reservoir using a clip
and string to lower the samples through the top window of the balance. The fibers were
suspended so only the tip was interfacing the fluid. Measurements were taken from the
time of contact with the fiber to the fluid reservoir over 10 minutes. After ten minutes the
continuous function was stopped and the recorded data was saved as a text file for further
analysis in Excel. The wicking rate for each sample was calculated using a mass (mg)
versus time (minutes) plot. The plots for each experimental group were normalized by an
experimentally determined equation for the rate of evaporation of liquid from the
reservoir, found in a similar method to sample evaluation.
Statistical Analysis
JMP software was used to conduct an unpaired two-sample t-test to compare the
change in wicking rate of single wicking and round fibers using a significance level of
p<0.05. The average wicking rate of twisted wicking bundles was compared to the
average wicking rate of twisted round bundles using an unpaired two-sample t-test. The
final statistical assessment used an unpaired two-sample t-test to compare the mean
wicking rate of braided wicking fibers and braided round fibers.
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Results
Fluid Transport Tests
To characterize the round and wicking polylactide fibers the vertical test was used
to evaluate the height of the fluid front over a 10 minute time interval. The qualitative
results are shown in Figure 2.3. The blue dye-solution in the images corresponds to the
height the fluid front traveled through the fiber.

Figure 2.3: Results from vertical wicking test. Left image shows the vertical test
apparatus. (A) Bundled and (C) single wicking fiber samples depict greater vertical
movement of the dye-solution than (B) bundled and (D) single round fiber samples

The wicking rate was calculated for each experimental group by plotting the
height of the fluid front by the time in seconds, as shown in image A of Figure 2.4. The
wicking rate was determined by calculating the change in height of the liquid front over
the time interval. The results (image B) show the single and bundled wicking fibers
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wicking rate is significantly higher than samples of round fiber configurations. The
height of the fluid front (image C) in both single and bundled wicking fiber samples is
significantly greater than the round fiber samples. The twisted bundle round fibers depict
greater vertical wicking height than the single round fibers. Additionally, the height and
rate of the fluid front was assessed for wicking fibers of braided and twisted
configurations. The twisted configurations showed higher wicking heights and increased
wicking rate than braided wicking fiber configurations. The wicking rate was also
assessed by measuring the change in mass continuously over a 10 minute time interval.
The loss of water from the fluid reservoir on the balance correlates to the water gain from
the fiber bundles. The results were normalized to the rate of evaporation from the fluid
reservoir. The results show the wicking fiber samples have a significantly greater wicking
rate than the twisted round fiber samples (Imaged D). Consequently, the wicking fibers
also absorb greater amounts of water than round fiber samples.
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Figure 2.4: Wicking behavior of round and wicking fibers (A) Plot of wicking height vs
time for round and wicking fibers (B) The wicking rate (cm/min) of single, bundle, and
braided round and wicking fibers (C) The maximum height reached for each fiber type
(D) Wicking rate (mg/min) of round and wicking twisted bundles (*) signifies significant
difference between round and wicking fiber types, p<0.05.

Effect of Wicking Fibers on Biomolecule Transport
Materials and Methods
Unimolecular Diffusion of FITC-Conjugated Bovine Serum Albumin in a Hydrogel
The effect of fibers on protein movement in a 3D system was evaluated by
analyzing the unimolecular diffusion of FITC-conjugated bovine albumin (Sigma; St.
Louis, MO, USA) in a 50:50 collagen-agarose composite hydrogel containing individual
round or wicking fibers.
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A 50:50 collagen-agarose hydrogel was formed creating a solution consisting
45% (by volume) of 2% (w/v) agarose (Sigma, St. Louis, MO, USA) in 1x phosphatebuffered saline (PBS, Invitrogen), 45% (by volume) of 3.2 mg/mL PurCol, Bovine
Collagen Solution Type 1 (Advance Biomatrix; San Diego, CA, USA), and 10% (by
volume) of collagen reconstitution buffer. The collagen reconstitution buffer was
comprised of 4.8% HEPES buffer (Fisher Scientific; Waltham, MA USA), and 2.2%
NaHCO3 (Fisher Scientific) in deionized water. To make 2% agarose solution agarose
powder was autoclaved at 124°C for 45 min and added to PBS solution. To dissolve the
agarose the solution was stirred at low heat using a magnetic stirrer and hot plate. After
agarose is completely dissolved the solution is cooled and stored at 4°C until further use.
The agarose solidifies at room temperature and is melted in the microwave prior to use.
The collagen gel is formed by change in pH using collagen reconstitution buffer and
incubating at 37°C. The 50:50 collagen-agarose hydrogel was formed by first adding the
collagen solution to the reconstitution buffer. After thorough mixing using the pipette, the
melted 2% agarose solution was quickly added at the appropriate dilution. The agarose
component was solidified by cooling the hydrogel at room temperature for 10 minutes
followed by incubation at 4°C for 5 minutes. The samples were placed in a 37°C
incubator overnight to allow the collagen to solidify.
The 50:50 collagen-agarose hydrogel was formed in half of an individual well on
a 2-well chamber slide by turning the chamber slide on its side and loading it with 1 mL
of collagen-agarose solution, as seen in image A of Figure 2.5. Three fibers with lengths
of 2 cm were placed vertically, with forceps, in the center of the hydrogel while the
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chamber slide was on its side and before the hydrogel was gelled as shown in figure
below. Two samples with each fiber type were formed. After the hydrogel gelled, 1 mL
of 100 μg/mL solution of FITC-conjugated bovine albumin and serum free medium was
pipetted into the section of the chamber well without the hydrogel, as shown in image B
of Figure 2.5.

Figure 2.5: Schematics of experimental set-up of collage-agarose gel containing fibers.
(A) Digital image of the rotated chamber well to create a hydrogel in half the well and
with inserted fibers. (B) The sample was then laid back on its side and tested and then
imaged using fluorescent confocal imaging of the FITC albumin along the horizontal axis
with laser confocal microscopy

The rate of FITC-albumin diffusing horizontally through the different fiberhydrogel systems was evaluated using fluorescent laser confocal microscopy (Nikon
Eclipse TI); NIS-Elements imaging software was used to obtain 3D time-lapse images.
The intensity was measured in 7-second intervals for 15 minutes along the center image
frame containing the fiber. The rate of FITC-albumin movement was determined in
regions of interest (ROI) along the fibers at various distances from the interface of the
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collagen-agarose gel and FITC-albumin solution. As shown in Figure 2.6, ROI at various
distances from the interface were used to calculate the average rate of albumin
movement.

Figure 2.6: (A) Schematic of an individual well in a 2-well chamber slide filled partially
containing with collagen-agarose gel containing either round or wicking fibers. The
other portion of the well is filled with medium containing the BSA-FITC solution. (B)
Image frame from confocal real-time video of the BSA-FITC diffusion diffusing into the
collagen-agarose gel.

Statistical Analysis
JMP 10 statistical software was used to perform a repeated measures analysis with
(p<0.05) was performed to compare the rate of FITC-albumin movement in hydrogels
containing wicking or round fibers for each distance from the interface.

91

Figure 2.7: (A) Schematic indicates interface between hydrogel and FITC-albumin
solution and the region of interest locations. (B) The rate of BSA-FITC in the collagenagarose gel at various distances into the hydrogel. The hydrogel samples containing
wicking fibers have a significantly greater rate than the samples with round fibers;
*p<0.001. The rate of BSA-FITC is consistent for various distances from the interface for
both fiber types into the sample. (also published in Tabbaa et al. 2014 JTERM23)

Results
The diffusion of FITC-albumin was analyzed in collagen-agarose hydrogels
containing wicking or round fibers. The results showed the rate of the FITC-albumin
movement in hydrogels with wicking fibers was significantly (p<0.001) greater than in
the gels containing round fibers for each ROI as presented in Error! Reference source
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not found.. Statistical analysis also showed the distance from the interface did not
significantly affect the rate of protein movement (p=0.9342), suggesting the wicking
fibers increase the rate of movement homogeneously through the gel.

Enhanced Cell Transport Using Wicking Fibers
Materials and Methods
Progenitor Cell Transport through Wicking Fibers
The effect of fiber type on the transport of progenitor cells was evaluated using
D1 mouse mesenchymal stromal cells (ATCC; Manassas, VA, USA). The cells were
cultured in Dulbecco’s Modified Eagle’s medium (DMEM; Invitrogen; Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco; Grand Island, NY,
USA), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma; St. Louis, MO, USA).
D1 cells were labeled with CellTrackerTM Green CMFDA probe (Invitrogen; Grand
Island, NY, USA), following the manufacturer’s protocol using a long term labeling
concentration of 25μM, to evaluate the movement of cells along wicking and round
fibers. Twelve poly-L-lactide wicking and twelve round fibers were cut into 3-cm length
samples. The fibers were cleaned by extensive washes with 70% ethanol. After ethanol
washes, the samples were soaked in 1x-phosphate buffered saline (PBS, Invitrogen;
Grand Island, NY, USA) for 3 hours, washed three times with PBS, and air dried before
use. Lids, with fitted holes and plastic tubes, were custom-made for the 12-well plate to
securely hold the 3 cm wicking or round fibers vertical. After lids were prepared, 1 mL of
D1 cell solution, containing 1 million cells in growth media, was pipetted into each well
93

of a low attachment 12-well, the fibers were individually and vertically placed into each
well and secured by the custom-made lid.

Figure 2.8: Schematic depicts experimental set-up to assess progenitor cells wicking in
round or wicking fibers. The purple cylinders depict the holding mechanism of the fibers

The fluorescently tracked cells are carried in the media solution and wick with the
media along the conduits of the fiber. The cells penetrating the fibers present the same
spherical morphology as when the cells are suspended in solution. The vertical
displacement of the cells along the fibers was determined at time points of 0.5, 6, and 24
hours with the initial time point being fiber placement into the cell solution. To assess the
cell vertical displacement, the fibers were transferred to microscope slides and evaluated
using fluorescent microscopy and imaging software.
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Statistical Analysis
JMP 10 statistical software was used to perform statistical analysis for vertical
cell movement. A block design of time was conducted to compare the vertical
displacement of D1 cells on wicking fibers or round fibers with (p<0.05).
Transport of Progenitor Cells through Fibers in Hydrogel
This study has adapted a 3-D in vitro system established by Takata et al. to
evaluate the effects of progenitor cell movement in a collagen gel24. This assay involves a
simple system to assess cellular movement by preparing a double-layered collagen gel
hemisphere with the first layer containing the cells and the second layer containing a
growth factor molecule that has shown to be a chemotactic molecule that stimulates and
encourages cell migration as shown in Figure 2.9. The distribution of progenitor cells
within hemispheres containing round fibers, wicking fibers, or no fibers was assessed
after 24 hours.
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Figure 2.9: Schematic illustrates the arrangement for double-layered collagen
hemispheres (A) without fibers and (B) with round or wicking fibers. The pink sphere
corresponds to the first hemisphere layer containing fluorescently tracked D1 mouse
progenitor cells. The blue sphere depicts the second larger collagen hemisphere
containing a chemotactic growth factor encapsulating the first hemisphere with or
without fibers.

Forming First and Second Layer of Collagen Gel Hemispheres
D1, mouse mesenchymal stromal (ATCC), cells were cultured in Dulbecco’s
Modified Eagle’s medium (Invitrogen; Grand Island, NY, USA) supplemented with 10%
fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U penicillin, and 10 mg
streptomycin/mL (Sigma; St. Louis, MO, USA). D1 cells were labeled with
CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA), following the
manufacturer’s protocol using a long term labeling concentration of 25μM. The first layer
of the 1.0mg/mL collagen gel hemisphere was formed by mixing 3.2mg/mL PurCol,
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Bovine Collagen Solution Type 1 (Advance Biomatrix; San Diego, CA, USA), D1 mouse
mesenchymal DMEM growth media, and 1 N NaOH. Immediately following mixing, D1
cells labeled with red tracker at a cell density of (2x106 cells/mL) were added to the
collagen gel prior to gelation. The second layer was formed without cells using the same
collagen gel composition and methods with the addition of 1% recombinant human
vascular endothelial growth factor (rhVEGF, R&D Systems, Minneapolis, MN).
Fiber Preparation
To prepare the fibers, poly-L-lactide wicking and round fibers were cut into 5-mm
length samples. The fibers were cleaned by extensive washes with 70% ethanol. After
ethanol washes, the samples were soaked in phosphate buffered saline (Invitrogen; Grand
Island, NY, USA) for 3 hours, washed three times with phosphate buffered saline, and air
dried before use.
Forming Collagen Hemisphere Composite
Three different groups of collagen hemisphere composite samples were formed.
The groups included hemispheres with round, wicking, or no fibers; each with a sample
size of four and set up as shown in Figure 2.10.
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Figure 2.10: Two 8-well chamber slides were used to make two-layered collagen
hemispheres samples (n=4) with and without fibers.

To form the first layer, 5 μL of 1 mg/mL collagen gel solution containing 2x104
D1 cells was dropped directly onto the glass bottom in each well of an 8-well glass
chamber slide system (Fisher Scientific, Pittsburgh, PA). Single 5 mm round or wicking
fibers were centered and placed directly on top of the first layer. Samples were incubated
at 37°C and 5% CO2 for 1 hour. After the first layer gelled, the second layer of 1mg/mL
collagen gel containing 1% VEGF was directly dropped on the fiber encapsulating both
fiber and first layer forming a double-layered collagen gel hemisphere. In samples
without fibers the second layer was directly added to the first layer. After incubating the
samples at 37°C and 5% CO2 for 1 hour 250 μL of growth media was added to each
sample incubated again for 24 hours. Following incubation the collagen hemispheres
were imaged with an inverted fluorescence microscope and camera using 50x total
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magnification. A tetramethyl rhodamine iso-thiocyanate (TRITC) filter was used to
image the distribution of the red-labeled D1 cells. Image J software was used to
quantitatively determine the extent of D1 cell expansion in the collagen hydrogel
composite for each experimental group. To do this each image was converted to
greyscale and split into each specific color channel: red, blue, or green. The cellular
information from red-labeled D1 cells was solely on the red channel. Blue and green
channel images were removed. Using the red channel the image was converted to a
binary image. Figure 2.11 illustrates the conversion of a captured image through this
imaging J processing method.

Figure 2.11: Depicts images after image J processing methods. (A) The initial fluorescent
image captured, (B) the split red channel image, and (C) the converted binary image.

An elliptical region of interest was used to measure the distance of cell expansion
from the center. The perimeter (in number of pixels) of cell expansion was calculated for
each sample based on the elliptical region. The number of pixels was converted to
micrometers using the length of the scale bar. The perimeter of expansion was
determined for each experimental group using the same image processing method.
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Statistical Analysis for Transport of Cells through a Fiber in a Hydrogel
Statistical analysis was assessed using JMP 10 software. The perimeter of
expansion of cells was compared in double layer hemisphere samples with round and
wicking fibers as well as samples without fibers.
Results
Progenitor Cell Transport through Wicking Fibers
The vertical displacement of fluorescently green-labeled D1 cells was assessed along
wicking and round fibers. The results show a significantly (p<0.001) greater vertical cell
displacement along the wicking fiber than on the round fiber. Figure 2.12 illustrates a
much higher density of cells along the wicking fiber compared to the round fibers
suggesting the wicking fibers can significantly augment cell recruitment.
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Figure 2.12: (A) Schematic illustrating the location of the captured fluorescent images
shown in (B) along wicking or round fibers. Measurements of progenitor cell movement
quantified through imaging software and shown in the chart (C). The vertical
displacement and cell density along the wicking fibers is significantly greater than the
round fibers; *p<0.001.

Effect of Fibers on Transport of Progenitor Cell through a Hydrogel with and without
Fibers
The expansion and distribution of progenitor cells was assessed in a doublelayered collagen hydrogel in samples with and without round or wicking fibers after 24
hours of incubation. The fluorescent and binary images shown in Figure 2.13 depict
greater progenitor cell expansion in collagen hemisphere hydrogels containing wicking
fibers than hydrogel samples with round fibers or without fibers. The images further
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illustrate greater progenitor cell expansion in collagen hemisphere samples with round
fibers than hemispheres containing no fibers.

Figure 2.13: Qualitative fluorescent and binary images of collagen hydrogel hemisphere
samples containing no fibers and samples with round or wicking fibers. Images show
greatest cell expansion with wicking fibers compared to samples with round fibers or no
fibers

The data was semi-quantitatively analyzed using image J processing. The
perimeter of expansion of each hydrogel sample was determined in number of pixels and
converted into units of micrometers using the scale bar. The chart below shows the
results perimeter of cell expansion for each sample types. Expansion for hydrogel
samples containing wicking fibers is significantly greater (p<0.05) than all other
treatment groups. Hydrogels with round fibers are also significantly greater than just the
control group without fibers.
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Figure 2.14: Results of progenitor cell expansion in double-layered collagen hydrogels.
Samples with wicking fibers showed greatest cell distribution compared to all other
experimental groups. (* represents significantly different groups with p<0.05)

Discussion
It is well established that the proprietary wicking fiber shape provides highly
efficient fluid transport in textile and chromatographic separation applications11–13,15,25.
The increased transport properties of the wicking fiber is achieved through geometrically
optimized intra-fiber spaces or grooves that combine capillary pressure to enhance the
fluid transport or wicking along a single wicking fiber11,14. The unique architecture of a
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single fiber greatly enhances the capillary action as opposed to a single channel. This is
confirmed by the fluid transport studies conducted in this chapter.
Wicking occurs when fluid initially contacts the inter- or intra- fiber space and
travels due to capillary pressure. The enhanced transport shown by the wicking fibers is a
result of the shape factor19,20,26.
Brojeswari Das and coworkers showed a linear relationship between shape factor
and water uptake. As the shape factor of the fiber increases the water uptake and fluid
transport increases linearly. The wicking fibers contain 2.5-3.2 times the surface area of
conventional circular cross-sectional fibers with nominal diameter18. The increase in
shape factor significantly increases the capillary pressure of the fiber, which improves the
wicking properties of the fiber. This phenomena is described by Young-Dupre’s equation
shown below. Chung and coworkers showed that Polylactide wicking fibers have a much
lower contact angle and superior wetting behavior than round PLA fibers27. The capillary
pressure is also directly related to the contact angle as described in Young-Dupre’s
equation. The low contact angle and high shape factor contribute to the superior capillary
pressure and wicking behavior of the wicking fibers.19,20,27
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Equation 2.1: Young-Dupre’s Equation
𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 = 𝛾𝐿𝑉 𝑐𝑜𝑠𝜃𝑋
𝑤ℎ𝑒𝑟𝑒,
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑋 = 𝑆ℎ𝑎𝑝𝑒 𝑓𝑎𝑐𝑡𝑜𝑟
𝑋𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 = 3
𝑋𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟 = 1
𝜃𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 = 67°
𝜃𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟 = 121°
𝑃𝑤𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟 ≫ 𝑃𝑟𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟

The equation below shows the relationship between spontaneous wicking and
contact angle and shape factor. Spontaneous wicking will occur with a wicking fiber due
to the high shape factor and low contact angle. This relationship is not satisfied for round
fibers.
𝑺𝒑𝒐𝒏𝒕𝒂𝒏𝒆𝒐𝒖𝒔 𝒘𝒊𝒄𝒌𝒊𝒏𝒈 𝒐𝒄𝒄𝒖𝒓𝒔 𝒊𝒇 𝒕𝒉𝒆 𝒇𝒐𝒍𝒍𝒐𝒘𝒊𝒏𝒈 𝒆𝒒𝒖𝒂𝒕𝒊𝒐𝒏 𝒊𝒔 𝒔𝒂𝒕𝒊𝒔𝒇𝒊𝒆𝒅:
(1 − 𝑋𝑐𝑜𝑠𝜃) < 0
𝑤ℎ𝑒𝑟𝑒,
𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑋 = 𝑆ℎ𝑎𝑝𝑒 𝑓𝑎𝑐𝑡𝑜𝑟
(1 − 𝑋𝑐𝑜𝑠𝜃) < 0 (𝑊𝑖𝑐𝑘𝑖𝑛𝑔 𝑓𝑖𝑏𝑒𝑟)
(1 − 𝑋𝑐𝑜𝑠𝜃) > 0 (𝑅𝑜𝑢𝑛𝑑 𝑓𝑖𝑏𝑒𝑟)

Fewer studies have assessed the effects of various bundling configurations on the
diffusive and wicking properties of the fibers. Multiple groups have investigated the
parallel packing of the wicking fibers for chromatography applications. Wicking occurs
when fluid initially contacts the inter- or intra- fiber space and travels due to capillary
pressure 19,20,26. By bundling the wicking fibers more intra- and inter- fiber spaces are
105

created. The increased spaces within the fiber bundles generates more capillary pressure
and consequently leads to enhanced wicking rates. The studies assessing wicking
properties of various bundled fibers showed a significant difference in wicking potential
between braided and twisted fibers. The braided configuration creates discontinuities
within the conduits of the bundle impeding the fluid flow. The braided configuration also
shows larger pore sizes between fibers reducing the capillary pressure resulting in a lower
maximum height of the fluid. Twisted fibers showed both higher fluid front heights and
greater wicking rates. The twisted configuration shows less inter-fiber space with greater
contact between individual fibers. The smaller inter-fiber spaces generate smaller pore
sizes that will increase the capillary pressure of the bundle and result in higher maximum
heights. The twisted bundles increase the continuity of the channels, which will improve
the wicking rate of the sample.
The individual cross-sectional size of the wicking fibers comprising a fiber bundle
and the number of individual fibers in a bundle will greatly influence the wicking
properties. The tension of the twisted fiber bundles also plays a major role in the fluid
properties. Fiber bundles of high tension may distort the grooves of the individual fibers
blocking fluid flow. On the other hand, bundles with less tension lack the formation of
inter-fiber spaces that create an increased number of capillary channels along the bundle.
Future work will investigate the effect of various tensions and of cross-sectional sizes of
the wicking fibers.
The wicking fibers were also able to significantly enhance the movement of
biomolecules into a 3D collagen-agarose hydrogel. It has been well demonstrated that
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wicking fibers can transport and separate compounds such as proteins, triglycerides, and
inorganic and organic lead compounds for chromatographic separation by providing
increased surface area and fluid transport 12,28,29. Similarly, the wicking fibers facilitate
the transport of the FITC-albumin protein into the hydrogel. The parallel channels along
the wicking fiber provide high surface area and increased capillary pressure that greatly
increases the fluid transport and subsequently the rate of protein movement
These wicking fibers have previously been considered for tissue engineering
constructs but investigation into the cellular movement was never evaluated12,29,30. The
final studies in this chapter investigated the potential of wicking fibers to transport
progenitor cells to assess if these fibers can be used in tissue engineered constructs to
improve progenitor cell recruitment. The results demonstrated the wicking fibers have
capabilities to promote both cellular infiltration and distribution. The large surface area
and superior capillary action and wettability properties promote cellular infiltration along
the grooves of the wicking fibers. Cell transport was demonstrated by the vertical
movement of green-labeled D1 cells along the wicking round fiber samples. Significantly
more cells penetrated the wicking fibers and traveled higher than the round fibers. This
influx of cells into the wicking fibers is enhanced by the increased surface area and
wicking properties of the fibers. The intrinsic fluid properties of the fiber were shown to
enhance the transport of cells, which can provide a unique approach to improving cellular
seeding in scaffolds. Future work involves tailoring the fibers to recruit and transport
specific cell types along the conduits.
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In the last analysis collagen hemisphere hydrogels were used to investigate cell
distribution and expansion in hydrogel samples containing round or wicking fibers. Prior
to adapting and developing the collagen hemisphere hydrogel earlier systems using
collagen-agarose hydrogels were used to optimize a system to assess cell movement in
the gels with and without fibers. Optimization involved developing a system to observe
cell mobility. Mobility of cells is dictated by matrix microarchitecture. Factors of the
matrix that influence cell movement includes fiber density, pore size, stiffness, and bulk
modulus.
Prior systems involved embedding round or wicking fibers in a collagen-agarose
gel comprised of various ratios and assessing movement of fluorescently labeled cells
into the hydrogel. The addition of agarose to the hydrogel greatly increases stiffness of
the gel and reduces pore size. Cells show increased mobility in substrates with greater
stiffness but lose mobility in substrates with reduced pore size. The addition of agarose
increases stiffness, however, the reduction in pore size greatly inhibits cell movement.
One mechanism to simulate cell movement is through gradients of stiffness. Cells interact
with the matrix through mechanosensory molecules and will migrate to regions of higher
stiffness. Mesenchymal progenitor cells move by binding to collagen fibers through their
actin cytoskeleton. These cells move through contractility and relaxation of the matrix by
their actin skeleton1.
To stimulate progenitor cell movement, the hydrogels were formed to generate a
gradient of stiffness. One mechanism for changing stiffness of the substrate is by
adjusting the concentration of the hydrogel. In this case, varying amounts of agarose were
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added to create a gradient of stiffness. This was reflected by the preliminary studies
assessing cell movement in collagen-agarose hydrogels. To drive cell migration the
hydrogels were formed with a gradient of stiffness. The hydrogels were comprised of
various ratios of collagen-agarose (50:50, 65:35, and 80:20) to stimulate cell migration.
The preliminary studies showed minimal cell migration in all ratios of collagen-agarose
hydrogel illustrating the inhibitory effects of agarose on cell movement.
Building from the preliminary work, other systems were developed to assess the
use of VEGF to drive cell migration in a collagen hydrogel. VEGF is a growth factor that
can function and a mitogen and chemoattractant for mesenchymal stem cells. Preliminary
systems showed both VEGF and changes in collagen concentration can be utilized in this
to assess cell movement.
The collagen hemisphere hydrogel study described in this chapter used VEGF as
the stimulant for the D1 cells to migrate into the second layer of the hemisphere. The
results from this study showed the wicking fiber greatly increased the distribution and
expansion of progenitor cells in the double-layered hemisphere compared to hemispheres
without fibers and with round fibers. The increased surface area of the wicking fiber
provided conduits within the collagen gel to augment the movement and dispersal of cells
within the collagen hemisphere. The enhanced surface area and unique cross-section of
the wicking fibers can be used to improve large tissue engineered scaffolds with limited
transport capabilities. The fibers can be applied to these large scaffolds to provide
conduits and capillary forces necessary to recruit and distribute cells.
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Conclusion
The results indicate wicking fibers not only play a major role enhancing the
movement of biomolecules into a 3-dimensional system, but also recruiting and
transporting cells. This work suggests the intrinsic fluid properties of the wicking fibers
have potential to greatly improve large bone tissue engineered constructs by providing
conduits and enhanced capillary forces necessary for enhancing the transport of nutrients
and movement of biomolecules and cells essential for bone formation.
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CHAPTER THREE
IMPROVING TRANSPORT LIMITATIONS OF LARGE SCAFFOLDS
Introduction
Spinal fusions are considered large volume bone defects and require large area
bone grafts to augment repair similar to traumatic fractures. Like most implanted large
tissue-engineered scaffolds, the surrounding environment and its interaction with the
scaffold plays a critical role in the success of the graft. When the bone graft is first
implanted in the fusion site the cellular component of the graft is supported by diffusion
from the vascular sources of the surrounding site until new vessels are formed during the
healing process. Therefore, understanding the vascular contribution of the bone graft and
the surrounding tissue is essential for improving fusion rates1.
Even with advancements in tissue engineering, the transport properties and
vascularity of large bone scaffolds are very limited. In most cases, the furthest distance
oxygen can reach from a capillary vessel via diffusion is roughly 100 μm through tissue.
Most clinically available synthetic bone grafts exhibit structures that, while are not as
densely packed as native tissue and may allow for better diffusion ability, are still ten
times the maximum diffusive distance to the center of the bone graft2 creating oxygen
limitations. Typically, bone marrow aspirate (BMA) containing osteoprogenitor cells is
seeded on the bone graft prior to implanting in the fusion site. Due to the increased
diffusion distance in these scaffolds progenitor cells seeded on the grafts compete for
oxygen and nutrients. The diffusion distance in large scaffolds limits the amount of viable
cells that can be supported and proliferate. Muschler and coworkers describes a simple
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engineering model that relates the size of the bone graft, the seeded cell density, oxygen
levels, and cell viability2. Necrosis within a bone graft can be theoretically modeled
based on the oxygen levels at the surface, the cell density within the scaffold, the
metabolic activity of the cells, and the diffusivity properties of the scaffold. The graph in
the figure below illustrates the decreased ability of oxygen to reach the central region of
the scaffold.

Figure 3.1: (A) The model developed by Muschler and coworkers shows the highest
concentration of oxygen is at the surface of the graft and decreases towards the center of
the graft2. (B) The minimum oxygen concentration occurs at the center of the graft.
Depending on the number of cells seeded and their metabolic activity necrosis can occur.
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Equation 3.1: Muschler’s Model Describing of Oxygen Consumption and Diffusion2
𝑑 (𝐶⁄𝐶 )
[𝐶𝑒𝑙𝑙]𝒬𝑐𝑒𝑙𝑙 𝐿2
𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
𝑜
2
=
𝜙
=
→
<2
𝑥
𝐶𝑜 𝐷𝑜𝑥𝑦𝑔𝑒𝑛
𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝑟𝑎𝑡𝑒
𝑑( ⁄𝐿)
𝐶 = 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑜𝑥𝑦𝑔𝑒𝑛 𝑖𝑛 𝑖𝑚𝑝𝑙𝑎𝑛𝑡 𝑠𝑖𝑡𝑒
[𝐶𝑒𝑙𝑙] = 𝐶𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑
𝑥 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑠𝑢𝑟𝑓𝑎𝑐𝑒 𝑖𝑛𝑡𝑜 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑
𝑄𝑐𝑒𝑙𝑙 = 𝑂𝑥𝑦𝑔𝑒𝑛 𝑐𝑜𝑛𝑠𝑢𝑚𝑝𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 𝑝𝑒𝑟 𝑐𝑒𝑙𝑙
𝐿 = 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑠𝑢𝑓𝑎𝑐𝑒 𝑡𝑜 𝑡ℎ𝑒 𝑐𝑒𝑛𝑡𝑒𝑟 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑
𝐷𝑜𝑥𝑦𝑔𝑒𝑛 = 𝐷𝑖𝑓𝑓𝑢𝑠𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡

The solution to the theoretical equations described by this model provides the
oxygen concentration profile with the lowest oxygen concentration occurring at the
center of the device. This is determined by the cellular consumption of oxygen and
diffusion of oxygen. The parameter, Φ2, represents the relative ratio of consumption to
diffusion. When the ratio of consumption to diffusion of this parameter is equal to two
the oxygen concentration at the center is zero. This model can be useful to predict
necrosis in large bone scaffolds and determine the optimal number of cells to seed the
grafts to prevent necrosis. This model can also be used to predict the mass transport of
small biomolecules such as glucose, fatty acids, amino acids, and other small
biomolecules transport into and out of scaffolds2. Larger molecules, such as growth
factors are transported by convection caused from the surrounding vasculature. The
convection generates pressure gradients to transport the larger biomolecules2. The lack of
transport of biomolecules will also contribute to necrosis or inadequate tissue formation
in the central region.
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In this chapter, the transport limitations of a commercially available bone graft,
chronOS strip, and potential modifications to improve this were investigated. The
chronOS strip is a commercially available synthetic bone graft manufactured by Synthes
and FDA approved for use in posterolateral fusion shown in image A of Figure 3.2
below. This graft is a composite osteoconductive bone graft comprised from beta
tricalcium phosphate granules and poly(lactide-co-ε-caprolactone) resorbable polymer.
Similar to most bone grafts used in large defects, the chronOS strip has a
thickness of 6 mm as shown in Image B below. The oxygen diffusion distance to the
center of the graft is 3mm, which is 30 times the normal diffusion distance resulting in
inadequate sustainable oxygen levels or essential bone forming biomolecules2. It is
important to note, the main vascular supplies of the posterolateral fusion site are the
transverse processes, positioned at the outer region of the fusion site, and surrounding
tissue muscle shown in images C and D. Decortication of the transverse processes allows
them to contribute as a source of vasculature to the fusion site. Image D depicts the 30
mm fusion site to which the transverse processes must provide vasculature. This gap
places the central region of the bone graft 15 mm from the vasculature source; more than
100 times the normal diffusion distance. Other research groups have shown the
surrounding muscle, depicted in image C, also plays a major role in contributing
nutrients, biomolecules, and progenitor cells to the fusion site3. However, the extent of
contribution from the muscle tissue as well as the mechanism and factors contributed
from muscle are less established.
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Figure 3.2: (A) Illustrates placement of chronOS strip during posterolateral fusion (B)
Dimensions of chronOS strip (C) and (D) depict the two major sources of vasculature to
the fusion site, transverse processes and paraspinal muscles, respectively. (Also published
in Tabbaa et al. 20144)

The limited transport to the central region of the fusion site is mirrored in the
research conducted by multiple groups, most notably Boden and coworkers, who
discovered a discrepancy between bone formation in the outer regions of the fusion site
near the transverse processes and in the central region of posterolateral fusion using a
New Zealand rabbit model. The outer regions experienced significantly faster cancellous
bone formation compared to the central region, which experience a lag effect or delayed
bone formation5–9. The delayed bone formation or fibrous formation in the central region
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greatly increases the susceptibility of pseudarthrosis9–13. Cinotti et al. confirmed the
vascular density in the outer regions is significantly higher than the central region
indicating the transverse processes are the main source of vascular supply12–14. The
delayed bone formation in the central zone is a result of both a lack of neovascularization
within the region as well as a limited surrounding vascular supply.
Tissue engineering approaches for improving mass transport in large bone grafts
involve modifying scaffold architecture. Scaffold porosity, shape, interconnectivity,
permeability along with other parameters can affect mass transport properties. Optimal
pore size has been extensively studied and defined typically between 150μm to 500μm to
improve mass transport and promote bone in growth15,16. Researchers have also
extensively studied the ideal porosity for effective diffusion and cell penetration for bone
regeneration. Typically, researchers have shown a higher porosity of around 90% and a
greater surface area improves mass transport and overall bone regeneration17–19.
However, other studies have shown porosity and permeability to have limited effects on
cell penetration and proliferation, and found the macrostructure including pore shape,
distribution, and alignment to have a greater influence on the success of the scaffold20,21.
In this chapter wicking fiber bundles were incorporated into the chronOS scrip
scaffolds to improve the transport properties by increasing porosity and providing
conduits that enhance transport and diffusion. The goals of this study were to first test if
the intrinsic transport properties and architecture of the wicking fibers will improve fluid
transport. The porosity, as well as the fluid retention and distribution of the chronOS strip
scaffolds were investigated with and without wicking fibers. The second goal of this
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chapter was to analyze the effects of the fiber bundles on cell viability, distribution, and
proliferation in the chronOS strip. The last goal was to investigate if the wicking fibers
would improve bone formation by evaluating the differentiation of bone progenitor cells
into an osteoblast phenotype within the chronOS strips.

Scaffold Characterization with Fibers
Materials and Methods
ChronOS Strip Preparation
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA)
with length of 2.0 cm, width of 2.0 cm, and thickness of 0.60 cm; or length of 4.0 cm,
width of 2.0 cm and thickness of 0.60 cm were modified with wicking fibers. Poly-Llactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular crosssectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten wicking
fibers, 2.0 cm in length, were securely fit through three separately drilled tunnels with
diameter and length, 1.04 mm and 2.0 cm, respectively that parallel the long axis of
chronOS strip. Two bundles of ten wicking fibers, 2.0 cm in length, were securely fit
through two separately drilled holes in the chronOS strips with smaller dimensions.
Porosity Measurements
A liquid displacement method established by Ramay and coworkers was used to
determine the porosity of the chronOS strip samples, 2.0 cm x 2.0 cm x 0.60 cm, with and
without wicking fiber bundles22. To determine the porosity, the chronOS strip scaffold
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with or without fibers was submerged in a graduated cylinder containing a known volume
of 100% ethanol (Vo). The graduated cylinder containing the scaffold was placed under
vacuum in a transparent desiccator as shown in image below (NalgeneTM Transparent
Polycarbonate Classic Design Desiccator, Thermo Scientific, Waltham, MA, USA).

Figure 3.3: Experimental set-up to assess porosity in chronOS strip scaffolds with and
without fibers

The vacuum allows the ethanol to penetrate the scaffold and displace the air from
the scaffold. After no air bubbles were observed the volume of the ethanol was recorded
(V1). The graduated cylinder was removed from the desiccator and final volume (V2) was
determined by removing the scaffold from the ethanol and the measuring the remaining
ethanol volume in the graduated cylinder. To determine the porosity, ε, the following
equation was used.
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Equation 3.2: Porosity22
𝜀=

(𝑉0 − 𝑉1 )
(𝑉1 − 𝑉2 )

Statistical Analysis
JMP software was used to conduct an unpaired two-sample t-test to compare the
average porosity for chronOS strip samples with and without fibers using a significance
level of p<0.05.
Fluid Transport in Scaffolds
The vertical test method described in chapter 2 was used to assess absorption,
wicking, and distribution of fluid in chronOS strip samples of dimensions, 2.0 cm x 4.0
cm x 0.60 cm. One end of the chronOS strip samples with or without fibers was vertically
submerged in a reservoir of dye-solution that was comprised of phosphate buffered saline
(PBS, Invitrogen) and 10% green assorted food coloring (McCormick). The vertical
displacement of the fluid font was measured through video recording over a 30 minute
interval with the initial time point starting at the time the scaffolds contact the dye
solution, shown in image A of Figure 3.4 below. The rate of the capillary rise of the fluid
front was determined for each sample.
A “horizontal test” was also conducted to investigate absorption and distribution
of fluid in the chronOS strip samples with and without fibers of dimensions, 1.0 cm x 1.0
cm x 0.60 cm. To simulate direct cellular seeding, 50μL of a dye-solution containing PBS
and 10% blue green food coloring was pipette directly to the top face of the chronOS
strip scaffolds. The initial time point is shown in image B in Figure. After 24 hours, the
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scaffolds were sectioned in half lengthwise and the digital images of the cross-section
were imaged to analyze the distribution of the dye-solution.

Figure 3.4: (A) Initial time point of chronOS strips scaffolds with (Right) and without
fibers (Left) (B) Horizontal test initial time point

Results
Porosity Measurements
The average porosity for chronOS strip samples containing wicking fibers and
without fibers was 74.5% and 65.6%, respectively. The porosity of chronOS strip
samples with wicking fibers was significantly higher than the unmodified chronOS strip
samples (Figure 3.5).
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Figure 3.5: The wicking fibers increase the porosity of the chronOS strip samples by
~10%. The asterisk (*) represents statistically significant differences with p<0.05

Fluid Transport in Scaffolds
The vertical test of the dye-solution in scaffolds with and without fibers assessed
the wicking rate and absorption of fluid. The digital images in Figure 3.6 illustrate the
modified scaffolds enhanced the wicking rate and absorption of fluid over the 30 minute
time interval.
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Figure 3.6: (A) Digital image of vertical test after 5 minutes (B) Digital image of vertical
test after 30 minute. Images depict wicking fibers enhance fluid transport in scaffolds

The horizontal test evaluated fluid distribution in scaffolds with and without
fibers after applying the fluid through direct seeding method by directly pipetting the
solution to the front face of the scaffold. Image B of Figure 3.7 shows the spread of the
dye-solution in the cross-sectional images of the samples after 24 hours. Samples
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containing fibers showed more homogenous distribution of dye-solution along the
interior cross-section.

Figure 3.7: Results from horizontal test. (A) Scaffolds prior to directly seeding dyesolution to top face of scaffolds (B) Interior cross-sectional images of chronOS strips
with and without fibers. Scaffolds with fibers show more homogenous distribution of dyesolution
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Assessment of Progenitor Cell Recruitment into ChronOS strip
Materials and Methods
ChronOS strip Preparation
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA)
were sectioned into samples with length of 2.0 cm, width of 1.3 cm, and thickness of 0.61
cm. Samples were prepared with and without wicking fiber bundles (N=3). Poly-Llactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular crosssectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten wicking
fibers, 2.0 cm in length, were securely fit through three separately drilled tunnels with
diameter and length, 1.04 mm and 2.0 cm, respectively that parallel the long axis of
chronOS strip. ChronOS strip samples, with and without wicking fibers, were cleaned by
soaking in three changes of ethanol for 1 hour, and placed under ultraviolet light for 6
hours. After cleaning, the samples were soaked in three changes of phosphate-buffered
saline solution for 2 hours (Invitrogen; Grand Island, NY, USA) and soaked in growth
media consisting of Dulbecco’s Modified Eagle’s medium (Invitrogen; Grand Island,
NY, USA) supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA),
10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA) for 12
hours.
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Figure 3.8: Experimental set-up assessing if wicking fibers improve cellular penetration
and distribution in chronOS strip scaffolds

Progenitor Cell Distribution in chronOS Strip
Cellular recruitment and distribution was evaluated in modified and unmodified
chronOS samples of dimensions 1.3 x 2.0 x 0.61 cm using a vertical wicking procedure
illustrated in the figure below. The vertical wicking procedure involves submerging 10%
of a vertically aligned scaffold into a well of a low-attachment 24-well plate containing
500μL of cellular solution with 1 million cells, and analyzing the vertical wicking of
medium and cells into the scaffolds.
The wicking and distribution of D1 mouse mesenchymal stromal cells (ATCC;
Manassas, VA, USA) in chronOS scaffolds, with and without fibers, was evaluated using
the vertical test method. D1 cells were cultured in Dulbecco’s Modified Eagle’s medium
(Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco;
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Grand Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St.
Louis, MO, USA). These progenitor cells were labeled with CellTrackerTM Green
CMFDA probe (Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol,
using a long-term labeling concentration of 25μM. After samples were placed vertically
in cell-tracker solution for 12 and 48 hours, the samples were halved along the
longitudinal axis and the interior center region of the cross-section was imaged for each
scaffold, as shown in the figure above.
The distribution of green-labeled D1 cells was also assessed after directly seeding
the cell solution onto the top face of the scaffold, experimental set-up shown in Figure
3.9.

Figure 3.9: Schematic illustrating experimental set-up to assess the horizontal test of
green labeled cells in scaffolds with and without fibers
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One million D1 cells labeled with CellTrackerTMGreen were seeded on scaffolds
with and without fibers by pipetting 50 μL of cell solution directly on the top face of the
samples. After 24 hours, the scaffolds were bi-sectioned lengthwise to assess the cell
distribution of the samples in the central interior region. Fluorescent microscopy was
used to image the cell distribution in the cross-sectional regions of the scaffolds. Cell
penetration and attachment to wicking fiber bundles was also investigate.
Evaluation and Statistical Analysis of Cell Distribution
The images were semi-quantitatively analyzed using ImageJ cell counter software
and plugin from the National Institutes of Health. The graph in Figure 3.10 depicts the
percentage of cells in the center region of the cross-section images at the various time
points for scaffolds with and without wicking fibers. Statistical analysis was conducted
using an unpaired t-test through JMP statistical software to compare modified and
unmodified chronOS scaffolds.
Results
Cross-section images of chronOS strips containing fibers revealed an increase in
cell count and homogeneous distribution in the center region following the vertical test.
The cross-section images of samples without wicking fibers depicted fewer cells,
distributed mostly along the periphery of the scaffolds. The results showed a statistically
significant difference (p< 0.05) of percentage of cells in the center when comparing
scaffolds with fibers and scaffolds without fibers.
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Figure 3.10: The schematic illustrates the vertical wicking of cells into scaffolds with and
without fibers. (A) Fluorescent cross-section of densely populated green-tracked cells
distributed homogeneously in the center region of the scaffold with fibers (B) Fluorescent
cross-section of fewer green-tracked cells unevenly distributed in the center region of the
scaffold without fibers (C) Data associated with the fluorescent images comparing the
percentage of cells in the center region of the scaffolds with and without fibers using
image J software

The results from the horizontal test, conducted by directly seeding cell solution on
the top face of scaffolds with and without fibers, showed greater cell penetration and
distribution in scaffolds containing fibers. The fluorescent images below (Figure 3.11) are
of the central region of the cross-sectional regions of scaffolds with fibers (A) and without
fibers (B).
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The images depict enhanced penetration and distribution of the green-labeled bone
progenitor cells in scaffolds with fibers. The wicking fiber bundles were directly imaged
to assess if cells penetrate and attach to polylactide fibers. Images (C) and (D) below show
significant cell penetration and attachment to wicking fiber bundles after 24 hours.

Figure 3.11: Fluorescent images of central region of cross-sectional regions of chronOS
strips with and without fibers. (A) Scaffolds with fibers depict greater green-labeled cell
penetration and distribution (B) Unmodified chronOS strip scaffolds shows fewer cells
and less spread. (C) and (D) show significant cell penetration of the polylactide wicking
fiber bundles
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Cell Viability and Proliferation in ChronOS
Materials and Methods
ChronOS Strip Preparation
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) with
length of 1.0 cm, width of 1.0 cm and thickness of 0.61 cm were modified with wicking
fiber bundles. Poly-L-lactide (Natureworks; LLC, USA) wicking fibers were extruded
with non-circular cross-sectional dimensions of 0.12 mm x 0.05 mm. Three bundles
containing ten wicking fibers, 1.0 cm in length, were securely fit through two separately
drilled tunnels with diameter and length, 1.04 mm and 1.0 cm, respectively that parallel
the long axis of chronOS strip. ChronOS strip samples with and without wicking fibers,
were cleaned by soaking in three changes of ethanol for 1 hour, and placed under
ultraviolet light for 6 hours. After cleaning the samples were soaked in three changes of
phosphate-buffered saline solution for 2 hours (Invitrogen; Grand Island, NY, USA) and
soaked in growth media consisting of Dulbecco’s Modified Eagle’s medium (Invitrogen;
Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco; Grand
Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St. Louis,
MO, USA) for 12 hours.
Cell Seeding and Experimental Set-up
D1 cells were seeded on scaffolds with and without fibers by pipetting 50 μL of
cell solution containing 1 million cells in growth media along the tunnels or on the 1.0 x
0.61 cm face of samples not containing fibers. The samples were placed in a lowattachment 24-well plate and placed in the incubator for 3 hours to allow the progenitor
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cells to adhere. After 1 hour, 500 μL of growth medium was added to the scaffolds and,
after 3 hours, the samples were submerged in growth medium. Cell viability and
proliferation were assessed by Live/Dead viability/cytotoxicity assay (Life Technologies;
Grand Island, NY USA), ViaCount assay (Guava Technologies, Hayward, CA, USA)
using flow cytometry, and PicoGreen assay (Invitrogen; Grand Island, NY USA)
Live/Dead assay was used to qualitatively analyze the number of viable and dead cells
after 12 and 48 hours. ViaCount assay quantified the number of viable cells in both
experimental groups after days 1, 3, 7 and 10 were evaluated using flow cytometry
(Guava Technologies; Hayward, CA, USA). Cell proliferation was determined by
quantifying the total amount of double stranded DNA (dsDNA) on both sample types
using PicoGreen assay after days 4 and 7. The table below summarizes the experimental
set-up of the study including the time points and number of samples uses for each
analysis. Medium was replaced every two days for each experimental group.
Table 3.1: Experimental setup

chronOS strip
(unmodified)
chronOS strip
(with wicking
fibers)

Live/Dead
(12 and 48 hours)

PicoGreen
(Days 4 and 7)

ViaCount
(Days 1,3,7,10)

N=3

N=3

N=3

N=3

N=3

N=3
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Initial Cell Viability on Interior of Scaffolds
Live/Dead viability/cytotoxicity assay (Invitrogen; Grand Island, NY, USA) was
used to qualitatively access the initial cell viability in the interior central region of the
scaffolds after 12 and 48 hours of culturing cells. Two fluorescent probes, calcein AM
and ethidium homodimer-1, were used according to manufacturer’s protocol to determine
live and dead cells in the samples. Samples were bisectioned lengthwise to assess the
viability of the samples in the central interior region. The sections were washed with
phosphate-buffered saline (PBS, Invitrogen, Grand Island, NY) and 500μL of 2μM
calcein AM and 4μM of ethidium homodimer was added to each sample. After 45
minutes of incubation live and dead cells on the scaffolds were imaged using the
fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC)
filters, respectively, of the inverted fluorescent microscope (Zeiss Axiovert 135; Zeiss).
The CCD camera (ProgRes C10plus; Jenoptik) was used to capture images. Image J
processing was used to semi-quantitatively assess the number of live and dead cells in
each sample and overlay the respective red and green channels of the images. The
percentage of dead cells in the center interior region was determined for each scaffold
type.
Long-term Cell Viability
Cells were removed from scaffolds by pipetting 1mL of trypsin-EDTA solution
(Sigma; St. Louis, MO, USA) into each well and placing the plate on a flattop shaker
(VWR maybe) set at 200 rpm in a 37oC incubator for 20 min. Following cell removal, the
removed cells were resuspended in 1mL of growth medium and diluted with ViaCount
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reagent in a 96-well plate (Guava Technologies, Hayward, CA, USA). The flow
cytometer was calibrated using Guava Easy Check Kit (EMD Millipore, Billerica, MA,
USA). The ViaCount assay was conducted following the manufacturer’s instructions. The
ViaCount assay determines the total number of viable and non-viable cells based on a
fluorescent dye that stains nucleated cells. The number of viable cells and total cell count
was determined after Days 1, 3, 7 and 10 of culturing cells on scaffolds.
Cell Proliferation on Scaffolds
After culturing samples for 4 and 7 days cell proliferation of chronOS strip
samples with and without fibers was assessed using PicoGreen Assay (Quanti-iT
PicoGreen dsDNA Kit; Invitrogen). Samples were washed with PBS and 1 mL of 1X
Tris-EDTA buffer was added to each sample. The samples were lysed by ultasonicating
(Sonic Dismembrator, Fisher Scientific) the samples for two 30-second cycles. The lysate
was collected and stored in microcentrifuge tubes. The DNA concentration in each lysate
from both experimental groups was determined using the PicoGreen assay by following
the manufacturer’s protocol. Acellular chronOS strip samples were used as controls. The
number of cells for each scaffold was determined by using a calibration curve that was
found by correlating the amount of DNA isolated to a known number of D1 cells counted
using an automated hemocytometer (EMD Millipore, Billerica, MA,).
Statistical Analysis
Statistical analysis was conducted with JMP statistical software using a block model of
time to compare the amount of viable cells in modified chronOS strips with wicking
fibers and unmodified chronOS strips, with p<0.05.
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Results
Live/Dead assay investigated the number of viable and dead cells in the center
region of chronOS strip scaffolds with and without fibers. The fluorescent images of the
modified scaffolds illustrated significantly more viable cells (green) and less dead cells
(red) in the center region of the scaffolds than scaffolds without fibers at both 12 hour
and 24 hour time points as depicted in the figure. Image J software was used to quantify
the percentage of dead cells in both scaffolds types. The semi-quantitative data shown in
the chart shows significantly less dead cells in scaffolds with fibers than scaffolds
without at 12 and 48 hours.
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Figure 3.12: Top image shows an overlay of composite live/dead fluorescent images for
chronOS strip samples with and without wicking fibers. Bottom chart illustrates
percentage of dead cells in both scaffold types
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Cell proliferation was determined by quantifying the amount of DNA in each
scaffold type using PicoGreen assay. The amount of DNA was correlated to the number
of D1 cells using the established calibration curve shown in graph below.

Figure 3.13: Calibration line that relates a known number of D1 cells to the DNA
concentration found by using PicoGreen. Determined lysing a known number of cells
placed in microvials.

The PicoGreen results show greater amounts of D1 cells in scaffolds with fibers
than unmodified chronOS strip scaffolds after days 4 and 7. Both scaffold types show an
increase in D1 cell count from Day 4 to Day 7, which indicates cells are proliferating on
chronOS with and without fibers.
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Figure 3.14: Results of the PicoGreen assay. ChronOS strips with fibers show more D1
cell proliferation on Days 4 and 7

Cell proliferation and viability was also quantified using flow cytometry.
ViaCount assay successfully stained the viable and non-viable cells for each scaffold
type. The results of viable cells from Days 1, 3, 7, and 10 are shown in the graph below.
The results show the chronOS scaffolds containing fibers have significantly more viable
cells and a higher level of proliferation compared to scaffolds without fibers.
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Figure 3.15: Flow cytometry analysis indicate significantly more viable cells after days
3, 7, and 10 in scaffolds containing wicking fibers; *p<0.05.

Statistical analysis was conducted with JMP statistical software using a block
model of time to compare the amount of viable cells in modified and unmodified
scaffolds. The results showed the cell viability in scaffolds with fibers is significantly
greater (p< 0.01) than scaffolds without fibers. Both scaffold type results indicate a
significant difference of cell number between days (p<0.001).
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Effect of Wicking Fibers on Bone Formation
Methods and Materials
Scaffold Preparation
Commercially-available chronOS strips (Synthes Inc.; West Chester, PA, USA) with
length of 1.0 cm, width of 1.0 cm and thickness of 0.61 cm were modified with wicking
fibers. Poly-L-lactide (Natureworks; LLC, USA) wicking fibers were extruded with noncircular cross-sectional dimensions of 0.12 mm x 0.05 mm. Three bundles containing ten
wicking fibers, 1.0 cm in length, were securely fit through two separately drilled tunnels
with diameter and length, 1.04 mm and 1.0 cm, respectively that parallel the long axis of
chronOS strip. ChronOS strip samples with and without wicking fibers, were sterilized
with ethylene oxide for 12 hours in an AN74i cabinet sterilizer (Anprolene, Haw River,
NC) with sterilizing gas ampule of 5cc (Anprolene, Anderson Products Inc., Haw River,
NC). Samples were degassed in a chemical hood for 72 hours prior to use. Following the
degassing period, scaffolds were transferred to three 24-well plates using autoclaved
tweezers and were washed and soaked in PBS for two hours. The PBS was removed and
1.5 mL of growth media containing was added to each well containing scaffolds and
placed in the incubator (37°C and 5% CO2) overnight to allow protein attachment. The
growth media was comprised of Minimal Essential Medium α without ascorbic acid
(Gibco; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco;
Grand Island, NY, USA), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma; St.
Louis, MO, USA).
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Cell Seeding and Experimental Set-up
MC3T3E1 Subclone 4 (ATCC) mouse preosteoblast cells, were cultured by growing
cells until they reached confluence in a 75 cm2 size area culture flask (Corning, Fisher
Scientific) and splitting the smaller flask into four larger 150 cm2 area cell culture flasks.
The larger culture flasks were used to grow a large number of preosteoblast cells needed
for the study. The study required 54 chronOS strip samples with and without fibers total
with 1 million cells per sample. Cells were cultured with growth medium consisting of
Minimal Essential Medium α without ascorbic acid (Gibco; Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U
penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA). Once the large
culture flasks reach confluence the cells were split and one million MC3T3E1 cells were
seeded on scaffolds with and without fibers by pipetting 50μL of cell solution along the
tunnels or on the 1.0 x 0.61 cm face of samples not containing fibers. The samples were
placed in low-attachment 24-well plates and placed in the incubator for 3 hours to allow
the progenitor cells to adhere. After 1 hour, 500μL of growth medium was added to the
scaffolds and, after 3 hours, the samples were submerged in growth medium. Three lowattachment 24-well plates, containing nine samples for each group (chronOS with or
without fibers), were used for each endpoint of the study, which included Days 0, 7, and
14. Each endpoint assay contained three samples (n=3) of chronOS strip scaffolds with
fibers or without fibers as well control samples (n=3). The control group was MC3T3E1
cells cultured directly on the 2-dimensional surface of the well plate. The endpoint
analyses include: alkaline phosphatase (ALP) activity, PicoGreen assay,
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Immunohistochemistry (IHC), Histological staining, and reverse transcription real-time
polymerase chain reaction (qRT-PCR). The experimental set-up is depicted in the
schematic below.

Figure 3.16: Experimental set-up for each endpoint (Days 0, 7, and 14). Each 24-well
plate includes both experimental groups (chronOS with and without fibers) and a control
group with no scaffold

Osteogenic Medium
Samples were cultured in growth medium to promote cellular attachment
proliferation for 4 days on the scaffolds prior to adding osteogenic differentiation
medium. After cell growth for 4 days the samples and controls were stimulated with
osteogenic medium. Day 0 is considered the first day samples are cultured in the
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osteogenic medium. The osteogenic medium consists of Minimal Essential Medium α
without ascorbic acid (Gibco; Grand Island, NY) supplemented with 10% fetal bovine
serum (Gibco; Grand Island, NY), 10,000 U penicillin, and 10mg streptomycin/mL
(Sigma; St. Louis, MO), 10nM dexamethasone (Sigma; St. Louis, MO), 10mM βglycerophosphate (Sigma; St. Louis, MO), and 50μg/mL ascorbic acid (Sigma; St. Louis,
MO). The first 24-well plate initial time point samples (Day 0) were also collected
accordingly, as described in subsequent sections, for each endpoint analyses.
RNA Isolation and RT-PCR
Related bone forming gene expression markers were assessed for chronOS strip
samples. The related bone forming markers investigated in this assay, shown in table
below includes: BMP-2, osteopontin, RUNX2, ALP, and osteocalcin. At days 0, 7, and
14 chronOS strip samples with and without fibers and controls were collected for RNA
isolation using Trizol Reagent (Invitrogen; Grand Island, NY, USA). Prior to adding
Trizol, scaffolds were snap frozen using liquid nitrogen and pulverizer (Tissue pulverizer,
Cole-Parmer; IL, USA). One mL of Trizol reagent was added to samples containing
samples and controls to lyse the cells. To isolate the RNA 0.2 mL of chloroform
(Honeywell; Muskegon, MI, USA) was added to 1 mL Trizol reagent. The addition of the
chloroform results in a phase separation with the RNA in the aqueous top phase. The
aqueous phase was collected and isopropyl alcohol (VWR; Radnor, PA, USA) was added
to precipitate the RNA. The samples were centrifuged, and the RNA was isolated from
the samples by removing the supernatant. The samples were washed once with 1 mL of
75% ethanol (Sigma; St. Louis, MO), centrifuged, and the supernatant was carefully
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removed. Prior to resuspending the participated RNA in 30μL of nuclease-free water
(Life Technologies; Grand Island, NY, USA) the samples were air dried for 15 minutes.
DNA was removed from the isolated RNA samples using a TURBO DNASE-Free kit
(Life Technologies; Grand Island, NY, USA) and following manufacturer’s instructions.
The quality and quantity of the isolated RNA samples was determined using the
Nanodrop 2000 spectrophotometer (Thermo Fisher Scientifc Inc.; Waltham, MA, USA).
Reverse transcriptase was performed using 1μg of RNA for each sample and the
RETROscript kit (Ambion; Life Technologies; Grand Island, NY, USA) to synthesize the
RNA to cDNA with a final concentration of 25ng/1μl according to manufacturer’s
instructions.
Table 3.2: Primer Sequences for RT-PCR
Primer

Sequence

Tm (°C)

F 5’ - GCCTTCTCATCCAGTTCGTAT – 3’

54.2

R 5’ – CAAGGACATCGCATATCAGCTA – 3’

54.5

F 5’ – CGTCCACTGTCACTTTAATAGCTC – 3’

55.3

R 5’ – GTAGCCAGGTTCAACGATCTG – 3’

55.5

F 5’ – GCTTGGACATGAAGGCTTTG – 3’

54.5

R 5’ – ACCATCTTTCTGCTCACTCTG – 3’

54.5

F 5’ – ACACTCTCCATCACAGTAGTTG – 3’

54.1

R 5’ – AGAAGCATGAGCTCTATGTGAG – 3’

54.2

GAPDH

F 5’ - AATGGTGAAGGTCGGTGTG – 3’

54.3

(Internal Standard)

R 5’ – GTGGAGTCATACTGGAACATGTAG – 3’ 54.9

ALP

RUNX2

Osteocalcin

BMP-2
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Real-time PCR was performed using the primers shown in the table below and the
QuantiTech SYBR Green PCR kit (QIAGEN; Gaithersburg, MD, USA). The primers
used were predesigned assays with optimized sequences (PrimeTime qPCR Primers;
Integrated DNA Technologies; Coralville, Iowa, USA). However, prior to use the
efficiency of the primers were tested using the QuantiTech SYBER Green PCR kit. The
standard curve for each primer showed an efficiency greater than 99% for each primer
tested. PCR was performed using StepOnePlusTM Real-Time PCR System (Life
Technologies; Grand Island, NY, USA). The cycling parameters used were cycling for 40
cycles, denaturing at 94°C for 15 seconds, annealing at 54°C for 20 seconds, and
extending at 72°C for 20 seconds. The Comparative CT method or ΔΔCT method was
used to calculate the relative gene expression ratios using GAPDH as the internal
standard and comparing the target gene expression to the undifferentiated samples.
Equation 3.3: Comparative Ct Method
𝛥𝐶𝑡(𝑆𝑎𝑚𝑝𝑙𝑒) = 𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡) − 𝐶𝑡(𝐺𝐴𝑃𝐷𝐻)
𝛥𝐶𝑡( 𝐶𝑜𝑛𝑡𝑟𝑜𝑙) = 𝐶𝑡(𝑇𝑎𝑟𝑔𝑒𝑡) − 𝐶𝑡(𝐺𝐴𝑃𝐷𝐻)
𝛥𝐶𝑡 = 𝐶𝑡(𝑆𝑎𝑚𝑝𝑙𝑒) − 𝐶𝑇(𝐶𝑜𝑛𝑡𝑟𝑜𝑙)
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2−𝛥𝛥𝐶𝑡
Cell Proliferation Assay
Cell proliferation of the scaffold groups and the controls were assessed using
PicoGreen Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen) at days 0, 7, and 14.
Samples were washed with PBS and 1 mL of 1X Tris-EDTA buffer is was added to each
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sample. The samples were lysed by ultasonicating (Sonic Dismembrator, Fisher
Scientific) the samples for two 30-second cycles. The lysate was collected and stored in
microcentrifuge tubes. The DNA concentration in each lysate from both experimental
groups was determined using the PicoGreen assay by following the manufacturer’s
protocol. The amount of DNA determined in this assay was used to normalize the
determined ALP activity.
Alkaline Phosphatase (ALP) Activity
ALP activity of the scaffold groups and the controls were assessed using a
standard colorimetric enzyme ALP Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen)
at days 0, 7, and 14. This assay measures the amount of produced yellow p-nitrophenol
product by the cells due to the ALP-catalyzed hydrolysis reaction with p-nitrophenyl
phosphate (pNPP). The same lysate samples that were collected and stored for PicoGreen
assay were analyzed for ALP activity. A standard curve was prepared by diluting
phosphate substrate (pNPP, Sigma; St. Louis, MO) to concentrations shown in Table 3.3.
Table 3.3: Phosphate substrate dilutions for standard curve
Standard
Samples
Sample 1
Sample 2
Sample 3
Sample 4
Sample 5
Sample 6
Sample 7
Sample 8

Initial
concentration
pNPP solution
(μM)
0
1000
1000
1000
1000
1000
1000
1000

Initial volume
of pNPP
solution (μL)
0
1
2
4
8
16
20
40
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Final
Concentration
of pNPP
standard (μM)
0
8.33
16.67
33.33
66.67
133.33
166.67
333.33

Final Volume
of standard
solution (μL)
120
120
120
120
120
120
120
120

The phosphatase substrate was made by dissolving pNPP in ALP buffer,
comprised of 16.7 mL of 1.5M Alkaline buffer (Sigma; St. Louis, MO), deionized (DI)
water, and 50mg MgCl2 (Sigma; St. Louis, MO). Each 96-well plate contained two sets
of the ALP standard. In the remaining wells, 80 μL of lysate sample and 50 μL of pNPP
solution were added accordingly. Each sample was added in triplicate. One mg/mL ALP
enzyme solution (Sigma; St. Louis, MO) was added to the standard wells. The plate was
covered with foil and incubated for 1 hour at room temperature. Following incubation,
3M NaOH solution (Thermo Fisher Scientific Inc.; Waltham, MA, USA) was added to
each well to stop the reaction. The absorbance of the samples was read at 410 nm using a
Synergy MX Multi-Mode Reader (BioTek; Winooski, VT USA). A standard curve with a
linear curve fit and equation was generated using the known ALP dilutions. The ALP
activity was determined by the fit equation and the following ratio.
𝐴⁄
𝑉
𝐴𝐿𝑃 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑇
𝐴 = 𝐴𝑚𝑜𝑢𝑛𝑡 (𝜇𝑚𝑜𝑙)𝑜𝑓 𝑝ℎ𝑜𝑠𝑝ℎ𝑎𝑡𝑒 𝑠𝑢𝑏𝑠𝑡𝑟𝑎𝑡𝑒 𝑏𝑎𝑠𝑒𝑑 𝑜𝑛 𝑙𝑖𝑛𝑒𝑎𝑟 𝑐𝑢𝑟𝑣𝑒
𝑉 = 𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑠𝑎𝑚𝑝𝑙𝑒 (𝑚𝐿)
𝑇 = 𝑅𝑒𝑎𝑐𝑡𝑖𝑜𝑛 𝑡𝑖𝑚𝑒 (𝑚𝑖𝑛𝑢𝑡𝑒𝑠)
Histology and Immunohistochemistry
At days 0, 7, and 14 samples for histological an immunohistochemistry (IHC)
analysis were fixed in 10% formalin solution (Sigma; St. Louis, MO) and stored in PBS
at 4°C. Prior to cryosectioning samples the scaffolds were decalcified for approximately
four days using decalcifying solution (Sigma; St. Louis, MO). Routine chemical test for
determining the end of decalcification was performed by preparing a working solution of
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equal parts 5% ammonium hydroxide solution and 5% ammonium oxalate solution.
Decalcification solution below samples was removed and mixed with the working
solution. No precipitate was observed confirming the end of the decalcification process.
Following decalcification, optimal cutting temperature (OCT) tissue freeze
medium (Tissue-Tek O.C.T. Compound; VWR, Radnor, PA) was used to infiltrate the
scaffolds. OCT medium was used to completely submerge the samples in a disposable
mold prior to sectioning with the cryostat. To enhance infiltration of freeze medium
samples were covered with parafilm and placed in the vacuum overnight. After 12 hours
under vacuum samples were removed and placed on cryostat chuck in the cryostat to
freeze at -26°C. Samples were sectioned with 6μm thickness and mounted on a positively
charged microscope slides (Superfrost Plus Microscope Slides; Fisher Scientific;
Waltham, MA, USA). Sections were taken from the top, middle, and bottom regions of
the sample. Frozen sectioned samples were immersed in acetone for 24 hours prior to
histological stains and IHC to improve the adherence of the section to the slide. Sections
were stained hematoxylin and eosin (H&E) following the protocol outline below in the
table.
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Table 3.4: H & E procedures for frozen sections

Prior to performing IHC, frozen sections were immersed in acetone for 24 hours
to improve the sample adherence to the slide. Samples were rinsed extensively in PBS
and blocked at room temperature for 1 hour in a blocking solution containing 2% BSA,
5% goat serum, and 0.1% triton X. Following the blocking step, the samples were
incubated overnight at 4°C with primary antibodies BMP-2 (mouse anti-human), Abcam;
Cambridge, MA, USA) and osteopontin (rabbit-anti-mouse, Abcam; Cambridge, MA,
USA) using a 1:500 dilution for both antibodies. After the overnight incubation the
primary was removed and stored for later use and the samples were gently washed with
PBS and incubated in the diluted secondary antibody solution at room temperature for 2
hours. The secondary antibodies used include Alexa Fluor 488 goat anti-mouse antibody
(Life Technologies Molecular Probes; Grand Island, NY, USA) and Alexa Fluor 568 goat
anti-rabbit antibody (Molecular Probes; Grand Island, NY, USA). The antibodies used for
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immunofluorescence staining and the dilutions are summarized in the table below.
Following the 2 hour incubation with the secondary antibody the sections were washed
three times with PBS and coverslips were mounted using 40μL of ProLong Gold
Antifade Mountant with DAPI (Molecular Probes; Grand Island, NY, USA). Samples
were stored at 4°C away from light until the samples were imaged with the fluorescent
microscope.
Table 3.5: Antibodies used for IHC staining
Primary Antibody
Anti-BMP2 (mouse)
Anti-Osteopontin (rabbit)
Secondary Antibody
Alexa Fluor 488 goat anti
mouse
Alexa Fluor 568 goat anti
rabbit

Dilution
1:500 dilution (1μg/mL)
1:500 dilution
Dilution
1:1000 dilution
1:1000 dilution

Statistical Analysis
For each target gene the average relative gene expression and standard deviation
were determined. JMP 11 was used to perform a student’s t-test to determine significant
differences in average gene expression between fibers and no fibers for each time point.
A student’s t-test was also used to compare the average ALP activity at each time point
for chronOS strips with or without fibers.
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Results
Alkaline Phosphatase Activity
The outcomes from the ALP activity assay depicted in Figure 3.17 showed the modified
chronOS strip samples had significantly higher ALP activity after Days 0 and 7. The
unmodified chronOS strip samples demonstrated significantly higher ALP activity after
Day 14. The modified samples showed a decrease in ALP activity at Day 14.

Figure 3.17: ALP activity of chronOS strips with and without fibers normalized by
amount of DNA. Day 0 and Day 7 show chronOS samples with fibers had significantly
higher ALP activity than chronOS without fibers. Day 14 showed significantly higher
ALP activity for chronOS samples without fibers; *p<0.05.
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Real Time-PCR
The osteogenic differentiation of MC3T3E1 cells was analyzed by monitoring
gene expression of ALP, Runx2, osteocalcin, and BMP-2. Relative expression of
osteocalcin showed no significant difference between modified and unmodified chronOS
strip samples. The modified chronOS strip samples showed higher Runx2 expression
after Days 0 and 14. Similarly, the modified samples showed higher levels of ALP after
Days 7 and 14. BMP-2 is a late osteogenic marker and was only observed for both
samples at the Day 14 time point and showed no significant difference.

Figure 3.18: qRT-PCR results for osteoblastic differentiation markers: osteocalcin (A),
Runx2 (B), ALP (C), and BMP2 (D). Modified chronOS showed significantly higher
Runx2 expression than unmodified chronOS, *p<0.05.
154

Histology
The H&E staining for chronOS strips samples are illustrated in Figure 3.19.
Sections were obtained from the interior regions of the scaffolds. For both groups the
staining showed greater cell densities after Days 7 and 14. Modified chronOS scaffolds
show more cellular content and collagen than scaffolds without fibers. Image E shows the
fibers have oriented the cellular and collagen content.
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Figure 3.19: H&E staining for chronOS strip samples with fibers after Day 0 (A), Day 7
(C), and Day 14 (E), as well as chronOS strip samples without fibers after Day 0 (B),
Day 7 (D) and Day 14 (F). Images show more cells in samples containing fibers. Day 14
samples with fibers show the aligned cells and formation of collagen.
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Immunohistochemistry (IHC)
IHC was used to analyze the amount of osteoblast related proteins. The protein
expression of BMP-2 and osteopontin was analyzed in sections from the interior of
modified and unmodified chronOS scaffolds. Fluorescent images after Day 0, Figure
3.20, showed higher expression of BMP-2 in modified scaffolds. Both scaffolds types
show low expression of osteopontin.

Figure 3.20: IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for
Day 0 time point. Top row and bottom row depict chronOS with fibers and without,
respectively. (A) Overlaid images of BMP-2, osteopontin, and nuclei. (B) Osteopontin
expression and nuclei staining (C) BMP-2 and nuclei staining. ChronOS containing
fibers shows greater expression of BMP-2. Both scaffold types show low expression of
osteopontin.

After Day 7 both scaffold types showed an increase in BMP-2 and osteopontin
expression. However, the modified chronOS strip samples showed significantly more
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BMP-2 and osteopontin expression after Day 7 as indicated by the fluorescent images in
Figure 3.21.

Figure 3.21 IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for Day
7 time point. Top row and bottom row depict modified and unmodified chronOS,
respectively. The modified chronOS scaffolds show significantly more (B) osteopontin
expression and (C) BMP-2 expression compared to the unmodified scaffolds.

Day 14 shows the greatest expression of BMP-2 and osteopontin for chronOS
with and without fibers. The chronOS strip samples with fibers show greater expression
of BMP-2 and osteopontin, depicted in Figure 3.22. The modified scaffold showed a
significant increase in osteopontin expression, fluorescently labeled red in image B.
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Figure 3.22: IHC staining for BMP-2 (green), osteopontin (red), and nuclei (blue) for
Day 14 time point. Top row and bottom row depict modified and unmodified chronOS,
respectively. The modified chronOS scaffolds show significantly more (B) osteopontin
expression and (C) BMP-2 expression compared to the unmodified scaffolds.

Discussion
The goal was to investigate the effects of wicking fibers on a commercially
available bone graft with limited diffusion to the central region due to the thickness of the
scaffold. The fluid transport, cell viability, distribution, proliferation, and osteogenic
differentiation were assessed in both the available scaffold and the wicking fiber altered
scaffold. Changes in porosity by the incorporation of the wicking fibers into the chronOS
strip samples were also investigated.
Fluid and cellular infiltration and distribution were investigated using horizontal
and wicking tests of the chronOS strip scaffolds. The scaffolds were bi-sectioned
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longitudinally for both tests to investigate the ability of the fibers to improve both
transport of cells and fluid to the central region of the scaffold, where transport via
diffusion is most limited. The outcomes depict the wicking fibers enhance both fluid and
cell infiltration especially to the central region of the scaffold. Fluid and cell transport
assessment showed the wicking fibers also significantly improved the distribution of cells
and fluid in both the central and peripheral regions of the scaffold. Adequate cell
infiltration to the central region is essential to promote cell growth on the surface and the
interior regions simultaneously reducing the potential for heterogeneous bone formation
in the central and peripheral regions. The outcomes from these studies suggest the
architecture and transport capabilities of the wicking fibers promote cell penetration and
distribution. The bundled wicking fibers provide increased micro-conduits as well as
nano-sized and macro-sized channels that greatly enhance the fluid and cellular transport.
The twisted configuration of the wicking fibers creates inter- and intra- fiber spaces of
micro-sized channels of limited tortuosity. Micro-size pores have been shown to promote
cell migration and movement. The bundling effects of the fibers increases the number of
micro-channels, which will increase the initial fluid and cell transport through enhanced
capillary action. Furthermore, the fiber bundles greatly increase the surface area to
volume ratio as well as the porosity and interconnected pores. The results from the
porosity tests showed the wicking fibers increases the porosity of the chronOS strip
scaffolds by approximately 10%. It is well documented that higher porosity will improve
cell infiltration and diffusion. The increased scaffold porosity by the wicking fiber
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bundles, limited tortuosity, and interconnectivity by the channels provides more efficient
mass transport and channels to facilitate cell movement and attachment.
Fluorescent images of the D1 green-labeled cells on the wicking fibers after 24
hours of direct cell seeding show increased amount of cell penetration and attachment
along the wicking fiber bundles. As mentioned in chapter 2, the contact angle of
polylactide fibers with the wicking fiber 8-grooved cross-sectional shape is significantly
lower than round cross-sectional fibers resulting in a more hydrophilic fiber compared to
a similar round cross-sectioned polylactide fiber. The enhanced wettability and grooved
surface promote cell infiltration and cell adhesion, which is mirrored by the fluorescent
images of the wicking fiber bundles. Interestingly, the wicking fiber architecture of the
polylactide improves cell adhesion of progenitor cells. Typically polylactide surfaces are
modified structurally through microtexture, adsorption of adhesive proteins, or chemical
modifications, to enhance cell adhesion23–25. The results suggest the 8-grooved
architecture of the wicking fibers promote the adhesion of cells. This outcome may be a
result of the hydrophilic and transport properties of the polylactide wicking fibers and
their ability to enhance the accumulation of extracellular matrix proteins providing a
favorable environment for the progenitor cells to adhere26.
The outcomes assessing cell viability and proliferation suggest the wicking fibers
improve both cell viability and proliferation of chronOS strip scaffolds. The Live/Dead
results showed the wicking fibers significantly improved the amount of viable cells in the
scaffold as well as a significant reduction in the percentage of dead cells in the interior
central region of the scaffolds. These results suggest the wicking fiber bundles increase
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mass transport and cells to the central region of the scaffold due to the increased porosity,
micro-sized conduits, and increased surface area architecture. The ViaCount assay
quantified the number of viable and dead cells after days 1, 3, 7 and 10 and PicoGreen
assay assessed proliferation after days 4 and 7. The outcomes showed a significant
increase in viable cells initially after a week of culture and increase in cell proliferation
after Day 4. This suggests the wicking fiber may provide enhanced mass transfer both
initially and long-term.
The effect of wicking fibers on osteogenic differentiation of pre-osteoblast cells
was investigated in this chapter. The RT-PCR results showed significantly higher
expression of the early bone differentiation marker, RUNX2. No significant difference
was observed for ALP, BMP-2, or osteocalcin. The ALP assay showed significantly
higher activity for chronOS with fibers at the earlier time points. These outcomes suggest
the scaffolds with fibers showed earlier differentiation than scaffolds without fibers.
Furthermore, the immunohistochemistry results revealed high levels of expression of
BMP-2 and osteopontin for chronOS scaffolds containing fibers after days 7 and 14.
These results also indicate that differentiation may occur faster in scaffolds containing
fibers and may improve the amount of bone formation. The limitation of this study was
the scaffold size used. The chronOS strip samples used for this study were 1cm x 1cm x
0.6 cm (length x width x thickness) and completely submerged in media. Due to the small
geometry used there may not be a significant mass transport deficiency to the central
regions of the scaffold. Future work will investigate bone formation in larger scaffolds in
a more physiologically relevant environment.
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CHAPTER FOUR
IMPROVING CELL SEEDING OF LARGE SCAFFOLDS
Introduction
Another limitation of bone scaffolds is effective cell seeding. This includes cell
distribution as well as cell viability in all regions of the scaffold. Large scaffolds are
limited by the ability of cells to fully penetrate scaffolds and retain cell viability.
Researchers have well established these limitations with large scaffold and have shown
viable cells to proliferate only on the periphery of the scaffold approximately 250 to 500
μm from the interface of fluid and the scaffold in vitro or the vascular source and implant
in vivo1. The architecture of bone scaffolds is designed to provide a network for cells to
proliferate, migrate, and develop matrix. As cells proliferate and form matrix within the
scaffold, nutrients are diminished in the interior of the scaffold and the developed matrix
provides a barrier for diffusion. Cells remain along the peripheral regions where
sufficient nutrients and biomolecules are diffusing. This leads to viable tissue along the
peripheral regions of the scaffold and limited tissue formation in the interior. Karande
and coworkers describe this process as an “M&M effect”2. This analogy correlates the
hard shell of the M&M candy with the peripheral tissue formation and the soft interior of
the candy with the lack of formation of tissue in the center. Furthermore, researchers have
correlated cells in different spatial regions of the scaffold alter the diffusion profile of
nutrients, oxygen, and waste products leading to non-homogeneous tissue formation3.
Adequate cellular distribution and viability in large scaffold is dictated by the scaffold
architecture, vascularization, porosity, and other factors discussed in Chapter 2. However,
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just as importantly, the sufficient uniform cellular seeding with high cellular infiltration
plays a critical role in homogeneous bone formation.
Various cellular seeding methods have been explored by previous work conducted
in our lab as well as by numerous researchers in the field1,4,5. Typically, cell seeding
approaches are described as static, perfusion, or dynamic techniques. Static techniques
are the most commonly used and typically involve direct surface seeding and spinner
flask seeding methods. Table 4.1 shows the outcomes of using various seeding methods.
Table 4.1: Limitations of various cell seeding strategies
Approaches to improve
cell seeding
Oscillating Perfusion
Bioreactors

Orbital shaker seeding

Static seeding
Low pressure vacuum

Outcomes
Perfusion improves the cell
distribution compared to
static approaches
Homogeneous distribution
on surface but distribution
interior depends on
scaffold
Homogeneous distribution
on surface with limited cell
penetration
Vacuum seeding showed
less homogeneous

Reference
Wendt. et al. 20033

Thevenot et al. 20085

Thevenot et al. 20085
Buizer et al. 20146

The effectiveness of seeding methods can vary based on scaffold type, which is
defined by the architecture, porosity, overall size, and pore size 7. The aim of this chapter
is to modify the chronOS strip using a passive transport system to more effectively
distribute high densities of cells homogeneously on the surface and interior of the
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scaffold. The chronOS strip is frequently augmented with bone marrow aspirate prior to
implantation in the defect site. Typically the scaffolds are seeded with cells by injecting
the scaffold with bone marrow aspirate (BMA). Synthes has developed a perfusion pack
system to more effectively distribute cells from the BMA within the scaffold. The
perfusion pack, shown in image below, is a vacuum-sealed system that allows the
surgeon to inject and cycle BMA using a syringe.

Figure 4.1: Synthes developed perfusion pack for chronOS strip (www.synthes.com)

Synthes Spine has conducted an in vitro study comparing the cell seeding of
progenitor cells isolated from BMA by applying the cells with the perfusion pack seeding
method or by the direct seeding method. The outcomes of this study showed no
significant difference in cell viability between the two seeding methods, but around a
40% increase in cell count using the perfusion pack method. The distribution of cells was
also analyzed in this study. Synthes showed the perfusion pack allowed more cells to
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infiltrate the central region and bottom face of the scaffold compared to the direct seeding
method. Although the perfusion method is better than direct application, the amount of
cells on the top surface is still significantly greater than the amount of cells in the center
and bottom surface of the scaffold as shown from the fluorescent images below captured
in this study.

Figure 4.2: Results from Synthes in vitro assessment of the perfusion pack seeding. (A)
Top surface of scaffold shows significantly more cells than the central region (B) and
bottom surface of the scaffold (C)

The limitations of the current cell seeding systems have motivated the development
of this system that has the potential to be incorporated into other large dense scaffolds with
limited mass transport and cell infiltration. The objective of this study was to develop and
evaluate if our proprietary passive transport system, comprised of bundled wicking fibers
and an absorbent alginate cap (referred to as a “modified wicking bundle”) will improve
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cell seeding efficiency of the chronOS strip samples. The wicking fiber and absorbent cap
construction mimics a passive pump that creates an intrinsic cell seeding system within the
scaffold. The absorbent cap component provides high absorption that enhances transport
through the wicking fiber bundles and provides a sink to direct and collect progenitor cells.
Each hydrogel cap encloses one end of the wicking fiber bundle. The cap increases the
volume, rate, and duration of the transported liquids and cells. The first phase of this
chapter characterized and assessed the fluid transport properties of the modified wicking
bundle, as well as, the ability of this system to transport biomolecules and progenitor cells.
The second phase of this chapter involved the development of a vacuum-sealed perfusion
pack to assess the perfusion cell seeding efficiency in (1) chronOS strip samples containing
the modified wicking bundle (referred to as a “modified chronOS strip”) and (2)
unmodified chronOS strip scaffolds. To assess cell seeding, assays were performed
investigating cell viability, proliferation, and count in varying locations of the scaffolds.

Characterizing the Modified Wicking Fiber Bundle
Fluid Transport Tests
Production of the Modified Wicking Bundle
Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm and poly-L-lactide round
fibers were extruded with cross-sectional diameter of 0.5 mm. Wicking fibers were sliced
with razor blade into individual single wicking fibers of 10 cm lengths. The 10 cm wicking
fibers were used to form wicking fiber bundles. Ten individual fibers were twisted, using
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an apparatus, at 11 rotations per centimeter twist. The bundle was sliced into 10 cm, 2 cm,
and 3 cm long sections. Single and bundled wicking fibers were cleaned by soaking in three
changes of ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples
were then soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and
air-dried overnight in a sterile hood. The alginate cap was formed by dipping one end of
the wicking fiber bundle in 100 μL of 5M CaCl2 solution (Fisher Scientific; Waltham, MA,
USA) in a well of a 96-well plate and pipetting 100 μL of 1.4% (w/v) alginate solution,
comprised of alginic acid sodium salt from brown algae (Sigma; St. Louis, MO) in 155
mM NaCl (Sigma; St. Louis, MO), directly on the submerged fiber tip in the well. The
alginate immediately adheres to the fiber end and solidifies forming the modified fiber
construct shown below.

Figure 4.3: Modified wicking bundle comprised of 1.4% alginate hydrogel cap and a
wicking fiber bundle
171

Wicking Tests of Modified Wicking Bundle
The wicking behavior of the modified wicking bundles were assessed using the
vertical test methods introduced in Chapter 2. The first test assessed the wicking rate of
modified and unmodified wicking fiber bundles by evaluating the change in mass of the
fluid reservoir over regular time intervals depicted in image A of Figure 4.4. The second
test (image B) investigated the amount of fluid absorbed in modified and unmodified
wicking bundles after 12 and 24 hours by measuring the volume of fluid remaining in the
well. The final test assessed the wicking capabilities of the modified wicking bundles,
unmodified wicking bundles, and unmodified round bundles by recording the wicking
height of the fluid front moving vertically upward along the fiber at various time points
shown in image C.

Figure 4.4: Wicking behavior tests. (A) Assessing the change in mass over various time
intervals. (B) Measuring fluid absorbed after 12 and 24 hours in modified and
unmodified fiber bundles (C) Measuring fluid height front every minute for a 10 minute
interval.
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Both tests methods were used to evaluate the wicking capabilities of round and
wicking fibers. The experimental groups are described in table below.
Table 4.2: Experimental groups of twisted bundle configurations for round and wicking
fibers
Experimental
Groups

Fiber Type

Bundle
Configuration

Number of Fibers
in Bundle

1
2
3

Round
Modified Wicking
Unmodified Wicking

Twisted bundle
Twisted bundle
Twisted bundle

10
10
10

Vertical Test 1 – Fluid Height Assessment
One end of the various 10 cm long fiber bundles was placed in a dye-solution
reservoir and held vertical using a custom-made apparatus shown in Figure 4.4 image C.
The bundles were dipped in the reservoir to assess the wicking height of the dye-solution
comprised of phosphate buffered saline (PBS, Invitrogen) and 10% blue assorted food
coloring (McCormick). The fluid front vertical displacement of each sample was
measured every minute for a 10 minute interval. The capillary rise rate of the fluid front
was determined for each sample.
Vertical Test 2 – Volume of Fluid Absorbed
The amount of fluid absorbed in modified and unmodified wicking bundles was
determined after 12 and 24 hours. Samples were vertically placed in individual wells of a
12-well plate with 1 mL of dye-solution, 10% blue assorted food coloring in PBS, using a
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custom lid to hold the samples vertical. After 12 and 24 hour time points the bundles
were removed and the amount of fluid remaining was measured.
Vertical Test 3 – Wicking Rate Assessment
To determine the change of mass in the liquid reservoir over time, the balance
was connected to the computer using a USB to RS232 cable. PuTTY software was used
to connect to the serial port and transfer information from the balance to the computer.
The balance was programmed to continuously measure the weight of the reservoir at a
rate of two measurements per second. After 10 minutes, the continuous function was
stopped and the recorded data was saved as a text file and imported into Excel for further
analysis. To measure the amount of fluid the bundles transported, the fibers were
suspended so only the tip was interfacing the fluid. The wicking rate for each sample was
calculated from the mass (mg) by time (minutes) plot. The average wicking rate was
determined in one minute intervals (0-1 minutes, 1-2 minutes, and 2-3 minutes) to
determine the average instantaneous wicking rate. The change in wicking rate was
determined by plotting the instantaneous wicking rate at each time point.
Statistical Analysis
JMP 10 software was used to conduct an unpaired two-sample t-test to compare
the average volume of liquid drawn out of the reservoir by modified and unmodified
wicking bundles at 12 and 24 hours using a significance level of p<0.05. The same
analysis was used to compare the change in wicking rate of unmodified and modified
wicking bundles using a significance level of p<0.05.
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Results
Vertical Test 1 – Fluid Height Assessment
Test 1 evaluated the fluid height change between experimental bundles over a 10
minute interval. The results presented in Figure 4.5 image A show the modified wicking
bundles have a significantly greater wicking rate (change in height/time interval)
compared to the unmodified wicking bundles and unmodified round bundles. The digital
image (Image B) shows the enhanced fluid transport of the modified wicking bundle
(left) compared to the unmodified (right).

Figure 4.5: (A) The modified wicking bundle depicts the greatest change in fluid front
height over a 10 minute interval (B) Modified wicking bundles on left depicts
significantly greater fluid absorption and fluid height than unmodified wicking fiber
bundles on the right

Vertical Test 2 – Volume of Fluid Absorbed
The second test evaluated the amount of fluid absorbed by the modified and
unmodified wicking bundles. The modified wicking bundles absorbed significantly more
fluid after 12 and 24 hours compared to the unmodified (Image A below). Digital images
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after 5 minutes and 12 hours qualitatively show significantly more fluid transport in
modified wicking bundles.

Figure 4.6: (A) Modified wicking bundles absorb significantly more fluid after 12 and 24
hours than unmodified (*) indicates significant difference of p<0.05 (B) Qualitatively
illustrates enhanced fluid absorption by modified wicking bundles after 5 minutes and 12
hours

Vertical Test 3 – Wicking Rate Assessment
The final test investigated the change in wicking rate of modified and unmodified
wicking bundles. The linear plot of the wicking rate versus time (Figure 4.7) shows the
modified bundles have an acceleration of 0.2934 mg/min2 with increasing wicking rate
over time and the unmodified wicking fiber bundles show a deceleration of 0.4022
mg/min2.
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Figure 4.7: Plot of the change in wicking rate over a 3 minute time interval. Modified
wicking bundles show an increasing wicking rate over time

Unimolecular Diffusion of FITC-Conjugated Bovine Serum Albumin in a Hydrogel
Protein movement in a 3D system was evaluated by analyzing the unimolecular
diffusion of FITC-conjugated bovine serum albumin (Sigma; St. Louis, MO, USA) in a
composite hydrogel containing modified wicking bundles, unmodified wicking bundles,
or no fibers.
Using the methods described in chapter 2, a 50:50 collagen-agarose hydrogel was
formed in half of an individual well on a 2-well chamber slide by turning the chamber
slide on its side and loading it with 1 mL of collagen-agarose solution. Three modified
wicking bundles (2 cm in length), unmodified wicking bundles (2 cm in length), or no
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fibers were placed vertically in the center of the hydrogel while the chamber slide was on
its side and before the hydrogel solidified, as shown in image A of (Figure 4.8).
Following hydrogel solidification, 1 mL of 100μg/mL solution of FITC-conjugated
bovine albumin and serum free medium was pipetted into the section of the chamber well
without the hydrogel, as shown in Figure 4.8.

Figure 4.8: Schematic of experimental set-up of collagen-agarose hydrogel containing
modified or unmodified wicking bundles. (A) Digital image of rotated chamber well to
apply hydrogel to half the well (B) Fluorescent microscopy to image diffusion of FITCalbumin into hydrogel using time-lapse

The rate of FITC-albumin diffusing horizontally through the different
experimental groups was evaluated using time-lapse fluorescent microscopy (EVOS;
Floid Cell Imaging Station, Life Technologies); Image J imaging software was used to
combine the 3D time-lapse images into a z-stack stack and measure the average intensity
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of a 350x350 pixel square region of interest (ROI) for each time frame. The intensity was
measured in 1 minute intervals for 30 minutes along the center image frame containing
the fiber. The rate of FITC-albumin movement was determined in a ROI adjacent the
interface of the collagen-agarose gel and FITC-albumin solution shown in the schematic
below.

Figure 4.9: (A) Schematic of an individual well in a 2-well chamber slide filled partially
containing with collagen-agarose gel containing either modified or unmodified wicking
fiber bundles. The other portion of the well is filled with medium containing the BSAFITC solution. (B) Image frame from time-lapse video of the BSA-FITC diffusion into the
collagen-agarose gel. Average intensity was measured from labeled ROI adjacent to
interface
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Statistical Analysis
Statistical analysis was performed in JMP 10 using a Student’s t-test to compare
the average rate of protein movement between each treatment group using significance
level of p<0.05.
Progenitor Cell Transport through Modified Wicking Fiber Bundle
This study tested the ability of the modified wicking fiber bundles to transport
progenitor cells by wicking phenomena. D1 mouse mesenchymal stromal cells (ATCC;
Manassas, VA, USA) were cultured in Dulbecco’s Modified Eagle’s medium (DMEM,
Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco;
Grand Island, NY, USA), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma; St.
Louis, MO, USA). D1 cells were labeled with CellTrackerTM Green CMFDA probe
(Invitrogen; Grand Island, NY, USA), following the manufacturer’s protocol using two
different concentrations of 25μM and 0.5μM, to evaluate the movement of cells through
modified and unmodified wicking bundles using fluorescent microscopy and flow
cytometry (Guava EasyCyteTM, Guava Technologies), respectively. The CellTracker
Green label was optimized for flow cytometry use with D1 cells prior to performing this
study (See appendix A for cell tracker optimization for flow cytometry study). Six polyL-lactide modified (with alginate cap) and unmodified wicking fiber bundles were made
using the wicking fiber of 3 cm lengths. Lids, with fitted holes and plastic tubes, were
custom-made for the 12-well plate to securely hold the fiber bundles vertical. One million
D1 cells tracked with 25μM were pipetted into 6 wells of a low attachment 12-well plate.
The remaining 6 wells contained 1 million D1 cells of 0.5μM tracker concentration as
180

shown in the experimental set-up below Figure 4.10. Immediately following cell seeding
the modified and unmodified wicking bundles were vertically placed into each well and
secured by the custom-made lid.

Figure 4.10: Schematic represents experimental set-up evaluating cell wicking in
modified and unmodified wicking bundles

The vertical displacement of the cells along the unmodified and modified wicking
bundles were determined after 1 hour with the initial time point being fiber placement into
the cell solution. To assess the cell vertical displacement, the fibers were transferred to
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microscope slides and were evaluated using fluorescent microscopy and imaging software.
To quantify the cell recruitment into the fiber bundles, the cells were removed from the top
and bottom regions of the samples. The bundles were sectioned with a blade and the top
and bottom regions were placed into separate wells of a 24 well plate, Figure 4.11.

Figure 4.11: Schematic illustrating cell isolation from top and bottom regions of
unmodified and modified wicking bundles

Samples were rinsed with PBS and untwisted. Cells were removed by adding 500
μL of trypsin-EDTA solution into the well with the fiber region and placing the plate on a
flat-top (VWR) shaker at 200 rpm in a 37oC incubator. After 15 min the cells were
diluted in 500 μL of growth media and the number of D1 cells in both regions of the
constructs were evaluated using a Guava easyCyteTM flow cytometer (Guava
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Technologies). The number of green-labeled D1 cells in each region was evaluated by
following the manufacturer’s instructions for InCyte software (Guava Technologies). D1
cells of known cell densities with and without green tracker, were used as positive and
negative controls to calibrate the machine before measurements of the treatment groups
were made.
Statistical Analysis
Statistical analysis was assessed using JMP 10 software. An unpaired two-sample
t-test was conducted to compare the average cell count of D1 cells in the top and bottom
regions of the unmodified and modified wicking fiber bundles using a significance level
of p<0.05.
Cell Recruitment in a Submerged System
This study investigated the ability of the modified wicking bundles to recruit
fluorescently green-labeled D1 cells in a submerged system. D1 mouse mesenchymal
stromal cells (ATCC; Manassas, VA, USA) were cultured in Dulbecco’s Modified
Eagle’s medium (Invitrogen; Grand Island, NY, USA) supplemented with 10% fetal
bovine serum (Gibco; Grand Island, NY, USA), 10,000 U penicillin, and 10 mg
streptomycin/mL (Sigma; St. Louis, MO, USA). D1 cells were labeled with
CellTrackerTM Green CMFDA probe (Invitrogen; Grand Island, NY, USA), following the
manufacturer’s protocol using 25μM, to fluorescently image the movement of cells
through the bundles.
Poly-L-lactide modified (with alginate cap) and unmodified wicking bundles
(n=6) were made using 10 wicking fibers of 3 cm lengths. Samples were added to a well
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of a low-attachment 6 well plate and submerged in 4 mL of growth media and incubated
for 30 minutes at 5% CO2 and 37°C on an orbital shaker. Following incubation 500μL of
500,000 fluorescently green-labeled D1 cells were pipette into each of the wells. After 12
hours of culture the samples were washed with PBS and fixed with 10% formalin.
Fluorescent microscopy was used to assess the cell infiltration and distribution in the top
and bottom regions of the unmodified and modified constructs.

Figure 4.12: Experimental set-up to assess cellular infiltration in a submerged system.
Modified and unmodified bundles were submerged in growth media in a 6-well culture
plate. Cell solution was added to the wells after the samples were submerged. After 12
hours, the cellular recruitment was assessed by imaging various regions of the modified
and unmodified bundles, depicted in schematic.

Results
Unimolecular FITC-albumin diffusion
The diffusion of FITC-albumin was analyzed in collagen-agarose hydrogels
containing unmodified or modified wicking bundles, as well as control samples without
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fibers. The plot depicted in Image A of Figure 4.13 shows the average intensity of
modified wicking bundles was greatest compared to the other experimental groups over
the 30 minute time-lapse interval. The results showed the rate of the FITC-albumin
movement in hydrogels with modified wicking bundles was significantly (p<0.05) greater
than in the gels containing unmodified wicking bundles and hydrogels without fibers
(Image B) Error! Reference source not found..

Figure 4.13: (A) Plot depicts the modified wicking fiber constructs show greatest
increase in intensity over 30 minute time interval (B) Hydrogel containing modified
wicking fiber constructs have significantly greater rate than samples with unmodified
wicking fibers and samples without fibers; *p<0.05.

Progenitor Cell Transport through Modified Wicking Bundle
Cell penetration by wicking phenomena was investigated in modified and
unmodified wicking bundles. Both fluorescent microscopy and flow cytometry analysis
(Image B and D) of bottom regions of samples showed similar cell densities in both
construct types. The outcomes from cell isolation from the top regions showed
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significantly more cell infiltration in the modified wicking bundles than in unmodified
samples. The fluorescent images confirm the quantitative data and illustrate considerably
more cell penetration in the top region of the modified wicking bundles.

Figure 4.14: (A) Shows significantly more cells isolated from top regions of the modified
wicking bundle than unmodified, *p<0.05. (B) No significant cell count in bottom regions
of bundles (C) Illustrates greater cell penetration in the top region of the modified
wicking bundle (D) Qualitatively shows no significant difference in cell count in bottom
regions

Cell Recruitment in a Submerged System
Modified and unmodified wicking bundles were submerged in growth media to
investigate if the modified wicking bundles would enhance cell infiltration in a fluid
environment. The fluorescent images showed higher cell influx into the modified
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wicking bundles than unmodified wicking bundles, shown in Figure 4.14. The modified
wicking bundle depicted greater cell penetration in the fiber bundle region (image C) as
well as in the absorbent component (image D).

Figure 4.15: (A and B) Ends of unmodified wicking bundle show less cellular infiltration
than (C) Modified wicking bundle end and (D) Alginate component

Cell Seeding Efficiency of Modified chronOS Strip
Development of Perfusion Pack
Six vacuum-sealed perfusion packs were custom-made using a Food Saver
Vacuum Sealing System (V2244; Sunbeam Products; Boca Raton, FL). Heat seal pre-cut
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bags (Food Saver; Sunbeam Products; Boca Raton, FL) were sliced into smaller 8 cm X 8
cm square plastic sheets. The ends of two square pieces were sealed along the edges of
the perimeter leaving two sides open to add an injection valve on one side and add the
sample through the other open edge. The injection valve was attached to the edge using a
hot glue gun to completely seal the interface between the valve and the plastic sheets. The
remaining edge containing the valve was heat sealed using the system. One edge was
remained unsealed to add the chronOS strip samples and vacuum seal the pack using the
system. Prior to use the perfusion packs were tested to confirm the sheets were sealed
sufficiently and there were no air leaks.
chronOS strip samples (Synthes Inc.; West Chester, PA, USA) of length of 2.0
cm, width of 1.0 cm, and thickness of 0.60 cm were prepared by incorporating modified
wicking bundles, (referred to as “modified chronOS strips”), N=30. To incorporate the
modified wicking bundles, containing a wicking fiber bundle and alginate cap, two
separate tunnels were drilled along the center region parallel to the long axis of the
chronOS strip with diameter and length, 1.04 mm and 2.0 cm, respectively. Poly-Llactide (Natureworks; LLC, USA) wicking fibers were extruded with non-circular crosssectional dimensions of 0.12 mm x 0.05 mm. Two bundles containing ten wicking fibers,
3.0 cm in length, were securely fit through two separately drilled tunnels of the chronOS
strip. The 1.4% alginate cap was formed on one end of both wicking fiber bundles. The
wicking fiber bundle was dipped in 100 μL of 5M CaCl2 solution (Fisher Scientific;
Waltham, MA, USA) in a well of a 96-well plate. Immediately following 100 μL of 1.4%
(w/v) (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO) was pipette
188

directly on the submerged fiber tip in the well. The alginate immediately adheres to the
fiber end and solidifies forming the cap. ChronOS strip samples directly used out of
packaging acted as the control (referred to as “unmodified chronOS strip”).
ChronOS strip samples, as well as the perfusion packs were cleaned by soaking in
three changes of ethanol for 1 hour, and placed under ultraviolet light for 6 hours. After
cleaning the samples were soaked in three changes of phosphate-buffered saline solution
for 2 hours (Invitrogen; Grand Island, NY, USA) and allowed to air dry for 24 hours prior
to vacuum sealing the samples in the perfusion packs. ChronOS strip samples were added
through the unsealed edge of the perfusion pack and oriented in the central region of the
pack below the inlet valve. Modified chronOS samples were positioned with the wicking
fiber bundles facing the inlet and the alginate cap distal the valve. The perfusion packs
were capped to prevent air from penetrating the packs and the unsealed edge was vacuum
and heat-sealed using the food saver system. The vacuum-sealed samples in the perfusion
packs are depicted below, Figure 4.16.

Figure 4.16: (A) Modified chronOS strip sample vacuum sealed with absorbent cap
positioned distal the inlet valve (B) Unmodified chronOS strip vacuum sealed
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ChronOS Cell Seeding and Experimental Set-up
MC3T3E1 Subclone 4, mouse preosteoblast cells, were cultured in a 150 cm2 size
area culture flask (Corning, Fisher Scientific) with growth media consisting of Minimal
Essential Medium α without ascorbic acid (MEMα; Gibco; Grand Island, NY, USA)
supplemented with 10% fetal bovine serum (Gibco; Grand Island, NY, USA), 10,000 U
penicillin, and 10mg streptomycin/mL (Sigma; St. Louis, MO, USA). Once the large
culture flasks reached confluence the cells were split and resuspended in 30 mL of
MEMα at a cell density of 500,000 cells per mL. A 10 mL Becton Dickinson (BD)
disposable luer-lock syringe (Cole-Parmer; Vernon Hills, IL) was used to seed the
scaffold in the perfusion packs. The syringe was filled with 5 mL of cell solution and
inserted securely on the insertion valve immediately after removing the cap, Figure 4.17
(Image A). The cell solution was injected into the perfusion pack and the syringe was
used to inject the cell suspension into the pack using 5 cycles of perfusion, following
manufactures recommended instructions for infiltrating the chronOS strip scaffolds.
Samples were incubated at room temperature for a clinically relevant waiting period of
60 minutes in the culture hood (Image B).
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Figure 4.17: (A) Injected progenitor cell solution into vacuum-sealed perfusion pack
through inlet valve (B) Incubated perfused samples with cell solution for 60 minutes at
room temperature

After 60 minutes of incubation, cell infiltration, distribution, viability, and
proliferation were assessed using the following assays shown in the Table 4.3
Table 4.3: Experimental set-up

Time
Points
Sample
size

Live/Dead
assay

ViaCount
assay

PicoGreen
assay

1 hour

1 hour

1 hour

N=3

N=3

N=3
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Cell
Cell
Dapi/Actin
Tracker
Metabolic
Distribution
Distribution Activity
1, 24, 48,
1 hour
72 hours
72 hours
N=3

N=3

N=3

Cell Viability and Total Cell Count
Initial cell viability was qualitatively assessed using Live/Dead
viability/cytotoxicity assay (Invitrogen; Grand Island, NY, USA) in the interior central
and peripheral regions after 1 hour. Samples were bisectioned lengthwise to assess the
viability of the samples in the central interior region. Two fluorescent probes, calcein AM
and ethidium homodimer-1, were used according to manufacturer’s protocol to determine
live and dead cells in the samples, respectively. The sections were with washed with
phosphate-buffered saline (PBS, Invitrogen, Grand Island, NY) and 500μL of 2 μM
calcein AM and 4 μM of ethidium homodimer was added to each sample. After 45
minutes of incubation live and dead cells on the scaffolds were imaged using the
fluorescein isothiocyanate (FITC) and tetramethyl rhodamine isothiocyanate (TRITC)
filters, respectively, of the inverted fluorescent microscope (Zeiss Axiovert 135; Zeiss).
The CCD camera (ProgRes C10plus; Jenoptik) was used to capture images. Image J
processing was used to semi-quantitatively assess the number of live and dead cells in
each sample and overlay the respective red and green channels of the images.
ViaCount assay using flow cytometry was used to quantify the number of dead
and viable cells. Cells were removed from scaffolds by pipetting 1 mL of trypsin-EDTA
solution (Sigma; St. Louis, MO, USA) into each well and placing the plate on a flat-top
shaker set at 200 rpm in a 37oC incubator for 20 min. Following cell removal, the
removed cells were resuspended in 1 mL of growth medium and diluted with ViaCount
reagent in a 96-well plate (Guava Technologies, Hayward, CA, USA). The flow
cytometer was calibrated using Guava Easy Check Kit (EMD Millipore, Billerica, MA,
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USA). The ViaCount assay was conducted following the manufacturer’s instructions. The
ViaCount assay determines the total number of viable and non-viable cells based on a
fluorescent dye that stains nucleated cells. The number of viable cells and total cell count
was determined after the 1 hour time point.
PicoGreen Assay (Quanti-iT PicoGreen dsDNA Kit; Invitrogen) was used to
determine the relative number of progenitor cells on each scaffold type by determining
DNA concentration. After 1 hour chronOS strip samples were washed with PBS and 1
mL of 1X Tris-EDTA buffer was added to each sample. The samples were lysed by
ultasonicating (Sonic Dismembrator, Fisher Scientific) for two 30-second cycles at 20
Hz. The lysate was collected and stored in microcentrifuge tubes. The double stranded
DNA concentration in each lysate from both experimental groups was determined using
the PicoGreen assay by following the manufacturer’s protocol.
Cell Infiltration and Distribution
Cell distribution after 1 hour was evaluated by fluorescently labeling the
MC3T3E1 preosteoblast cells with CellTracker Green CMFDA probe (Invitrogen; Grand
Island, NY, USA), following manufacturer’s protocol, using a long-term labeling
concentration of 25μM, before seeding the chronOS strips with perfusion packs. After 1
hour of incubation the scaffolds were removed from the perfusion packs, washed with
PBS, and fixed with 10% formalin for 20 minutes. Samples were sectioned in half along
the longitudinal axis and the cell infiltration and distribution was evaluated in the central
and peripheral regions of chronOS strips using fluorescent microscopy.
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Cell distribution and proliferation was assessed after 72 hours by tagging the cells
with nuclei and phalloidin molecular probes (Invitrogen). Following the 1 hour
incubation period the samples were removed from the perfusion packs and placed in a 6well plate. The samples were cultured for 72 hours at 37°C and 5% CO2. After the 72
hour culture period the samples were washed with PBS and fixed with 10% formalin for
20 minutes. Formalin was removed and samples were further rinsed in PBS. To stain for
actin and nuclei samples were blocked for 1 hour using blocking solution containing 2%
BSA (Sigma; St. Louis, MO, USA), 5% goat serum (Sigma), and 0.1% triton X
(ThermoScintific; Rockford, IL). Samples were washed with PBS and incubated in 500
μL of Alexa Fluor 488 phalloidin (Invitrogen; Grand Island, NY) solution using a 1:20
dilution for two hours at room temperature. Following the two hour incubation the
phalloidin solution was removed and 1 mL of a 2mg/mL Hoechst 33342 solution
(Thermo Scientific; Rockford, IL) of was added the samples at a 1:2000 dilution and
incubated for 5 minutes at room temperature. Samples were rinsed with PBS and stored
at 4°C. To analyze cell distribution and proliferation samples were transferred to a
microscope slide and imaged using fluorescent microscopy (EVOS; Floid Cell Imaging
Station, Life Technologies); Image J imaging software was used to overlay images.
Cell Metabolic Activity
After 1 hour incubation, 1 mL of media from perfusion pack was removed from
each sample to measure the amount of glucose consumption and lactic acid production
using a YSI 2900 biochemistry analyzer (Yellow Springs Instruments; Yellow Springs,
OH). Samples were removed from perfusion packs, transferred to a 6-well plate, and
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cultured in growth medium for 72 hours. A volume of 1 mL was removed from the
samples every 24 hours prior to a medium change for biochemical analysis. Samples
without cells were also cultured in growth media and collected as negative controls for
glucose and lactic acid concentrations. The YSI 2900 instrument was run according to
manufacturer protocol and the glucose and lactic acid measurements from each time point
were normalized to acellular controls.
Results
Cell Viability and Total Cell Count
The cell viability after 1 hour in modified and unmodified chronOS strip scaffolds
was analyzed in the central plane of the scaffolds. Fluorescent images of viable (green)
and dead cells (red) were obtained from the central and peripheral regions of the interior
of the samples, shown in Figure 4.18. The Live/Dead fluorescent images of the peripheral
regions of the modified chronOS scaffolds depicted more viable cells than unmodified
chronOS strips, Figure 4.19. Similarly, the central regions also illustrated significantly
more viable cells in the modified chronOS strip samples. The unmodified samples
showed greater number of dead cells, especially in the central regions as shown in Figure
4.20.
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Figure 4.18: The interior cross-section of the modified and unmodified chronOS strip
samples. Schematic illustrates central and peripheral regions along the cross-section
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Figure 4.19: Composite images of viable (green) and dead (red) cells in modified and
unmodified chronOS strip scaffolds. Illustrates more viable cells in modified chronOS
strip samples
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Figure 4.20: Unmodified chronOS scaffolds depict greater numbers of dead cells and
fewer viable cells than modified chronOS strip samples

The incorporated modified wicking bundles (both the bundle and the alginate cap)
were imaged to assess cell viability and recruitment of cells into the scaffolds. The
fluorescent images, Figure 4.21, depict Live/Dead images. The schematic shows the
regions where the fluorescent images were obtained along the bundle. The images
illustrate high densities of viable cells along the wicking fiber bundle and in the alginate
cap. The images suggest the modified wicking bundles significantly increase the amount
of viable cells penetration the interior regions of the scaffold.
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Figure 4.21: Schematic illustrations location of Live/Dead images along the modified
wicking bundles in the chronOS strip scaffolds. The Live/Dead composite images
illustrate significant cell penetration into the construct and high numbers of viable cells
along the wicking fiber and alginate component.
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Cell viability and total cell count was quantified using flow cytometry by removing cells
from modified and unmodified chronOS samples. The outcomes showed the modified
chronOS strip samples contained significantly more viable cells and total cells than the
unmodified samples, Figure 4.22 (Image A).

Figure 4.22: (A) Modified chronOS strip samples contained significantly more viable
cells and total cell than unmodified samples, *p<0.05. (B) Modified samples contained
four times the amount of DNA isolated from unmodified samples, *p<0.05

Cell Infiltration and Distribution
The modified and unmodified chronOS samples were perfused with fluorescently
green-labeled progenitor cells. The cellular infiltration and distribution in both scaffold
types was assessed with fluorescent microscopy. Cell densities and distribution were
assessed in the central and peripheral regions of the cross-section. The central regions
depicted in the fluorescent images below (Figure 4.23) show greater cell infiltration and
more homogeneous distribution of progenitor cells in the modified chronOS samples than
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the unmodified samples. The cell penetration and distribution in the peripheral regions of
the modified scaffolds were similar to the unmodified scaffolds, Figure 4.24. Progenitor
cell infiltration was also assessed in the modified wicking bundle that was incorporated
into the modified chronOS strip scaffolds. Figure 4.25 depicts high progenitor cell
recruitment into the modified wicking bundle.

Figure 4.23: Central regions of the modified chronOS strip scaffolds depict greater cell
penetration

201

Figure 4.24: Peripheral regions of modified and unmodified chronOS strips show similar
cell densities and distribution
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Figure 4.25: Depicts cell recruitment in modified wicking bundles of modified chronOS
strips. Images depict cells along the twisted fiber bundle embedded in the chronOS
scaffold.

The actin and nuclei fluorescent stains depicted cell distribution and proliferation after 72
hours. The images showed similar trends of cell distribution and penetration to the 2 hour
time point. The peripheral images of both scaffold types showed high cell densities with
increased proliferation and homogenous distribution (Figure 4.26).
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Figure 4.26: Actin and nuclei staining of progenitor cells shows high cell penetration and
proliferation in the peripheral regions of both modified and unmodified chronOS strip
scaffolds

The central region of the unmodified chronOS strip scaffolds illustrate
significantly less cell infiltration and proliferation than the modified samples, as shown in
unmodified labeled fluorescent images, Figure 4.27. The modified samples depict greater
cell infiltration and proliferation in the central region of the scaffold than unmodified
samples. The fluorescent images in Figure 4.28 show increased cell penetration and
proliferation along the modified wicking bundle component.
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Figure 4.27: Cell distribution and proliferation in central regions of modified and
unmodified chronOS strip scaffolds. Modified samples show significantly more cell
penetration and proliferation, as well as cell infiltration along the modified wicking
bundle component
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Figure 4.28: Images show significant cell infiltration along the wicking fiber - alginate
construct. Images depict high cell densities along the wicking fiber bundle component

Cell Metabolism
Lactic acid production was higher in modified scaffolds than unmodified
scaffolds for each time point, but only significantly higher at Day 2 with a significant
value of p<0.05. Both scaffold types also showed an increasing lactic acid production
over the 72 hour time interval. The glucose consumption of modified and unmodified
scaffolds were not significantly different. Both scaffolds showed increased glucose
consumption after the 72 hour time point.
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Figure 4.29: (A) Normalized glucose consumption after 2 hours, 48 hours, and 72 hours.
No statistical significance was observed on any time point. (B) Normalized lactic acid
production in modified and unmodified chronOS strip samples. Both scaffolds show
increase in lactic acid production after 72 hours. The modified scaffolds show greater
production than unmodified but are statistically significant after 1 hour.
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Discussion
In this chapter we developed a passive fluid-driving pump based on wicking, or
transport driven by capillary action. The outcomes of the fluid transport tests showed the
absorbent alginate cap enhances the wicking behavior and fluid transport of wicking fiber
bundles. The vertical test results demonstrated the absorbent cap significantly increases
the change in the fluid front height over a ten-minute time interval as well as the amount
of fluid absorbed after 12 and 24 hours. The final wicking test measuring the change in
mass of the fluid transported over time revealed the wicking rate for the modified
wicking bundle increases over time while the unmodified wicking bundle showed a
decreasing wicking rate over time. The wicking rate plot for the unmodified wicking
bundle will eventually plateau when the sample saturates. The saturation point of the
fiber correlated to when the wicking rate reaches zero and the fluid reaches the maximum
height. Interestingly, the wicking plot of the modified wicking bundle is parabolic with
an increasing wicking rate. This suggests the absorbent cap provides an accelerating
wicking rate. The acceleration is caused by the evaporation from the alginate cap. As the
water evaporates from the cap the change in pressure of the system increases driving an
increase in capillary pressure and consequently increasing the wicking rate. Root system
in trees analogous phenomena, the fluid in the xylem conduits of trees is driven up by
negative pressure or tension caused from the evaporation of water from the surface of
leaves8–10. The modified wicking bundle follows the same mechanism of action. As water
is evaporating from the alginate cap the water molecules from the conduits in the wicking
fiber bundle are pulled into the more hydrophilic alginate component by adhesive forces.
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The transport in the modified wicking bundle system can be described using tree
hydraulics. The pressure that causes the upward fluid movement in the modified wicking
bundle is due to the transpiration pressure from the absorbent material and the capillary
pressure developed from the surface tension of the fiber surface (Equation 4.1)8,11. The
capillary pressure generated from the surface tension of the wicking fiber bundle is
described using Laplace equation. The wicking rate is directly proportional to the change
in pressure of the system. Hagen-Poiseuille law is used to describe liquid capillary rise
(Equation 4.2). The modified wicking bundles contain the alginate cap that primes the
system. The change in pressure of the modified and unmodified wicking bundles is
illustrated in Equation 4.3 and Equation 4.4. The transpiration pressure generated from
the cap increases the change in pressure of the modified system, as reflected by the
equation. The modified wicking bundles shows a greater pressure change compared to
the unmodified bundles driving the enhanced wicking rate presented in the experimental
data.
Equation 4.1: Laplace Equation
𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 =

𝛾𝐿𝑉 𝑐𝑜𝑠𝜃
𝑅𝑐

𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦
𝛾𝐿𝑉 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑙𝑖𝑞𝑢𝑑 𝑎𝑛𝑑 𝑎𝑖𝑟
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Equation 4.2: Hagen-Poiseuille Law
dh
r2
r 2 2γcosθ
=
ΔP =
(
− ρgh)
dt 8ηh
8ηh
r
𝜃 = 𝐶𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑
𝜂 = 𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑣𝑖𝑠𝑐𝑜𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑
ℎ = 𝐻𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑎𝑐ℎ𝑒𝑑 𝑏𝑦 𝑙𝑖𝑞𝑢𝑖𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡
Δ𝑃 = 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒

Equation 4.3: Pressure Change of Modified Bundles
Δ𝑃 = 𝑃𝑇 + 𝑃𝐶 − 𝑃𝐻
𝑃𝑇 = 𝑇𝑟𝑎𝑛𝑠𝑝𝑖𝑟𝑎𝑡𝑖𝑜𝑛 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒
𝑃𝐶 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 =

𝛾𝐿𝑉 𝑐𝑜𝑠𝜃
𝑅𝑐

𝑃𝐻 = 𝐻𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 = 𝜌𝑔ℎ

Equation 4.4: Pressure Change in Unmodified Bundles
Δ𝑃 = 𝑃𝐶 − 𝑃𝐻
𝑃𝐶 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 =

𝛾𝐿𝑉 𝑐𝑜𝑠𝜃
𝑅𝑐

𝑃𝐻 = 𝐻𝑦𝑑𝑟𝑜𝑠𝑡𝑎𝑡𝑖𝑐 𝑝𝑟𝑒𝑠𝑠𝑢𝑟𝑒 = 𝜌𝑔ℎ
210

The bundling effect of the fibers creates inter-fiber spaces that will also generate
capillary pressure. This will increase the upward force moving the fluid. The additive
effects of bundling the fibers and the absorbent cap transpiration pressure contribute the
heightened wicking capabilities and fluid transport of this modified construct.
The improved fluid transport potential of the modified wicking bundle also
increased the rate of biomolecule transport and progenitor cell recruitment. The outcomes
revealed the modified wicking bundle increases the rate of FITC-albumin diffusion into a
hydrogel compared to unmodified wicking bundles and the control group, a hydrogel
without fibers. The intensity profiles over the first 5 minute time interval of the modified
wicking bundle showed a significantly steeper slope than the unmodified bundle.
Interestingly, we observed similar slopes after the first 5 minute interval. This profile
indicates the modified wicking bundle was initially primed by the alginate causing an
enhanced wicking rate. Once the alginate is saturated the wicking rates of the unmodified
and modified bundles were comparable. This suggests the modified wicking bundle can
initially improve the recruitment and distribution of biomolecules into a tissue engineered
construct. Increased transport of bone-forming biomolecules to all regions of the scaffold
will augment more homogeneous bone tissue formation. The results also depicted the
modified wicking bundles can increase the initial cell penetration to the top regions of the
fiber compared to the unmodified wicking bundles, implying the modified bundle may
improve cell penetration into 3-dimensional scaffolds. Similar to the analysis of protein
transport, the enhanced wicking is dependent on the saturation of the alginate. After the
alginate is saturated the system will reach equilibrium. Pilot studies were conducted
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investigating the equilibrium point of the alginate when submerged. Preliminary results
demonstrated the alginate saturates after being submerged for 3 hours. Future will
investigate the saturation point of the alginate and approaches to modify the absorbent
material to sustain transport beyond the initial seeding phase.
The final study of this chapter tested the capabilities of the modified wicking
bundle to recruit progenitor cells, provide homogeneous cell distribution, and improve
cell viability and proliferation in a commercially available large bone graft. The
outcomes showed we can effectively improve cell infiltration and distribution by
incorporating modified wicking bundles in a diffusion-limited scaffold. Cross-sectional
images of the central region of modified chronOS strip scaffolds demonstrated
significantly more cell penetration and distribution than those of unmodified scaffolds.
We also observed notable amounts of cell penetration along the wicking bundle and
alginate cap. This verifies the modified wicking system will enhance transport of cells in
a vacuum-sealed seeding technique. The high surface area of the wicking fiber bundles
and increased capillary pressure from the alginate cap drives a sizeable force to transport
not only fluid, but cell populations and biomolecules into a scaffold. In addition, the
inter- and intra- fiber spaces generated by the fiber bundle are of varying micro- macroand nano- conduit sizes. The micro sized conduits promote the capillary action of fluid
and the nano- and macro- sized conduits have been shown to encourage cell adhesion and
tissue ingrowth, respectively12.
Modified chronOS strip scaffolds also revealed improved cell viability and cell
seeding. Qualitative fluorescent images depicted significantly more viable cells in the
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cross-sectional images of the modified scaffolds. The flow cytometry results validated the
high number of viable cells on the modified chronOS strips. The total cell count
determined by both DNA concentration and flow cytometry was significantly higher for
modified scaffolds indicating the modified wicking bundles provide a mechanism to
perfuse and distribute more cells in the scaffolds. The final assessment measuring lactic
acid production and glucose consumption showed significantly more lactic acid
production by the modified scaffolds than unmodified after the initial 1 hour waiting
period. The modified scaffolds showed increased lactic acid production for all time
points; however, no significant difference was observed after 48 and 72 hours. The
outcomes further confirm the modified scaffolds initially have improved cell seeding.
Future work will investigate proliferation after longer time points and bone
differentiation and formation both in vitro and in vivo in an animal model.

Conclusion
Typically seeding progenitor cells on large-sized bone grafts for bone
regeneration in critical defects have not been successful due to the diffusion limitations of
the scaffold as well as the ability of the scaffold to effectively infiltrate cells and promote
homogeneous bone formation. This work with the modified wicking bundle provides an
intrinsic passive transport system, without the need for an external seeding system, to
effectively infuse the scaffold with sufficient amounts of progenitor cells and
successfully distribute the cells in the interior and surface regions.
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CHAPTER FIVE
DEVELOPMENT OF AN ANTIBIOTIC RELEASE SYSTEM
Introduction
The incidence of infection is another major limitation of critical bone defects.
Although the infection rate will vary based on type of fracture and patient indications, the
addition of bone supplementation to the procedure increases the propensity to infection
and can reach rates of 13%1. These cases of infection become problematic as the
treatment for infection is costly and risk for reinfection is very high1–3. Conventional
systemic antibiotic delivery limitations involve systemic toxicity and poor penetration
into the postoperative tissue. As an alternative and more effective solution, local drugeluting antibiotic is used preoperatively to help prevent the primary infection. The host
matrix, the type of drug used, and the clearance rate dictate the efficiency of the current
local release systems4. The major disadvantage of these delivery systems is the shortterm burst release profile. Many systems release high effective concentrations of
antibiotic up to 120 hours but subsequently drop out of the therapeutic window
potentially resulting in resistant subpopulations of infective agents2,53. Prolonged high
antibiotic concentrations are needed to eradicate bacteria and prevent the formation of
any resistant bacteria2,6. Conversely, many of the current antibiotic eluting systems
release drugs at concentrations significantly higher than the minimal inhibitory
concentration (MIC) for preventing bacteria. High concentrations over the MIC can cause
local toxicity and adversely affect bone formation7. The pharmacokinetics of the current
systems is often not known and difficult to control and reproduce2.
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The goal of this chapter was to develop an antibiotic release system using the
wicking fiber-alginate construct to effectively elute antibiotic long-term at optimal
concentrations. The following studies tested the release profile of gentamicin for proofof-concept. Gentamicin is frequently used as a locally administered antibiotic for
orthopedic procedures. This antibiotic has the ability to eradicate staphylococcus aureus,
the most common pathogen in orthopedic procedure related infections. The goal for
antibiotic release of the system is to provide concentrations above the minimal inhibitory
concentration and below the nephrotoxicity concentration8. Additionally, we aimed to
maintain this range in effective concentration over a time span of 2 weeks to improve
upon current clinical systems. Specifically, we investigated three different antibiotic
loading mechanisms into the fiber bundles and tested the elution profile and effect on the
properties of the polylactide. This work also investigated the antibiotic loading of the
alginate cap and release profile over two weeks. The loading mechanisms were optimized
to provide a long-term antibiotic release profile at sufficient inhibitory concentrations to
reduce the rate of infection.
Gentamicin Release Profile from Fiber Bundles and Alginate Caps
Materials and Methods
Extrusion and Experimental Set-up of Fiber Bundles
Three different antibiotic loading mechanisms were tested with polylactide round
and wicking cross-sectional fibers. The first mechanism involved loading the fibers after
extrusion by wicking the antibiotic solution into the fiber bundles using the previously
discussed vertical test procedure. The second and third loading mechanisms incorporated
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the antibiotic during the polymer extrusion process. Briefly, the extrusion process, also
depicted in the schematic below, involves feeding polymer beads into a funnel through a
hopper that is connected to a barrel with a feed screw controlled by an electrical motor
that transports the polymer through a heated conduit. The pellets are incrementally heated
to a melting temperature, determined through differential scanning calorimetry (DSC),
producing an amorphous polymer melt. The extruder contains a pump that provides
pressure to push the polymer melt through the dye containing the cross-sectional mold.
Changes in fiber diameter can partially be attributed to changes in the rotational speed of
the pump motor. The extruded fiber is wrapped around sequential rollers and a spool,
which can be manipulated to control the drawing rate also affecting fiber diameter. A
water bath can be applied directly below the die to quench the polymer fibers
immediately after extruding to reduce the effects of drawing on the fibers
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Figure 5.1: Schematic shows the extruding process of polymer fibers. Polylactide beads
are inserted through a funnel into a hopper with a screw that transport the polymer
through a heating cylinder. The pump pushes the melted polymer through a die to form
the cross-section shape of the fiber

The second loading mechanism involves quenching the fibers immediately after
the polymer is drawn from the die (outlet) into a water bath containing antibiotic solution.
The final approach to incorporate antibiotic during the extrusion process involves mixing
antibiotic powder with the polylactide beads prior to adding the beads to the funnel. The
table below summarizes the antibiotic loading mechanisms and experimental groups
tested in this study.
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Table 5.1: Loading Mechanisms
Loading Mechanism 1
Description

Wicking antibiotic
solution into bundles

Round PLA
fibers

N=5

Wicking PLA
fibers

Loading Mechanism 2
Incorporate antibiotic
power with polymer
pellets prior to
extruding

Loading Mechanism 3
Quench the extruded
fiber in a water bath
containing antibiotic
solution

N=5

N=5

N=5

N=5 (Small wicking
Bundle)
N=5 (Large wicking
fiber)

Loading Mechanism 1
Round and wicking fiber bundles were extruded using a continuous melt-extruder
and spinneret system (Alex James and Associates, Inc.; Greenville, SC) Polylactide
(PLA) pellets (PL biopolymer ~228,000 Da; Natureworks LLC) were melt-spun into
monofilament fibers. The extrusion melt temperature of the PLA pellets was based on the
glass transition (Tg) and melt temperatures (Tm) previously determined using differential
scanning calorimetry (DSC). The pellets were melt-spun at 167°C. The melted polymer
was extruded through spinnerets containing either the wicking (eight-grooved) or round
cross-sectional die. The wicking die used has an irregular cross-section with a long axis
of 0.2045 inches and the short axis of 0.1494 inches as depicted in image A of the
drawing below. The die used to extrude the round fibers had a diameter of 0.1500 inches.
A slower pump speed of 5 RPMs was used to extrude both round and wicking fibers to
produce monofilaments of smaller cross-sections. A water bath was used to quench the
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fibers directly 12 inches below the die at the outlet of the system. The water bath system
was modified with a rolling track to feed the polymer fiber through the quenching liquid
and onto the successive rollers as demonstrated in the digital image below.

Figure 5.2: Depicts the feeding of the polymer monofilament from the outlet through the
water bath and along the rollers

The extruding monofilament was wrapped around five successive rollers
controlled by motors to effectively draw and collect the fiber onto a spool. The motor
speed of the pump used in the extrusion process produced round extruded monofilaments
with a cross-sectional diameter of 0.50 mm. The extruded wicking fibers had dimensions
of 0.51 mm and short axis 0.33 mm, depicted in image B of figure 5.1.
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Figure 5.3: (A) Long and short axis dimension of the die used for extruding the wicking
fibers. (B) Cross-sectional image of the PLA extruded wicking monofilament

Round and wicking bundles were sliced into individual fibers of 3 cm length from
the spool. Ten of the individual fibers were twisted to form fiber bundles of round or
wicking fibers. The fiber bundles were vertically placed in a 12-well plate with a custommade lid to hold the fiber bundles vertically. Each well contained 1 mL of gentamicin
sulfate salt powder (Sigma; St. Louis, MO) and phosphate-buffered saline (PBS,
Invitrogen, Grand Island, NY) at a concentration of 150 μg/mL. . The gentamicin solution
was loaded into the fiber bundles by allowing the solution to wick into the bundles. After
1 hour of vertical wicking, the samples were removed and transferred to a 6-well plate
containing 2 mL of PBS containing eluted gentamicin. This procedure was performed to
determine the amount of gentamicin elution over 14 days. The initial time point was
collected immediately following the placement of the wicking fiber bundles in the well
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plates. The PBS was collected in 1.5 mL microcentrifuge tubes and stored at -20°C until
the gentamicin analysis was performed. The wells were refilled with 2 mL of PBS and
incubated at 37°C and 5% CO2 until the next time point. Samples were collected initially
for short time intervals after 15, 30, 45 minutes, and 12 hours. Samples were also
collected for longer time intervals with daily collection after days 1-7. After the day 7
time point, samples were collected after day 10, 14, 21, and 28.
Loading Mechanism 2
The extrusion system and settings were used to extrude the round and wicking
fiber bundles as in the first loading mechanism. However, instead of wicking the
gentamicin solution, 250 mL of gentamicin solution (Sigma) was added directly to the
water bath used to quench the fibers. The gentamicin solution again was at a
concentration of 150 μg/mL in PBS. After the round and wicking fibers were extruded
bundles were formed, and the elution profile was determined using the same procedure
described in mechanism 1.
Loading Mechanism 3
The gentamicin solution was incorporated into the PLA by mixing a 1% w/w
gentamicin sulfate salt powder (Sigma) with polylactide pellets (Natureworks) prior to
loading the pellets into the extruder. Specifically, 500 mg of gentamicin sulfate was
added to 50 g of PLA pellets. The inlet of the extruder is illustrated in figure 5.2. After
mixing, the gentamicin coated polylactide beads were loaded into the inlet of the
extruder. Wicking fibers were extruded with the melt-extruder and spinneret system with
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the same extruding settings described in mechanism 1 with removal of the water bath.
This approach drew the fibers directly onto the rollers without quenching the fibers with
the water bath prior, shown in schematic below.

Figure 5.4: Depicts third approach for incorporating antibiotic into extruded polymer
fibers by mixing the gentamicin powder and polylactide pellets prior to loading the
extruder

The third mechanism investigated gentamicin elution from wicking fiber
monofilaments extruded with two different cross-sectional sizes. The experimental
groups of this loading approach involved two different sized wicking fiber filaments. The
first experimental group (N=5) included a twisted fiber bundle of 10 individual small
extruded filaments with cross-sectional dimensions of 0.51 mm x 0.33 mm and of 3 cm in
length. The second experimental group (N=3) for this loading mechanism analyzed a
single large wicking fiber that was extruded by removing all drawing functionality of the
spooling process. The extruded large wicking fiber had dimensions of 1.4 mm and short
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axis 0.83 mm. The large monofilaments were sliced into individual samples each 3 cm in
length. Both experimental groups were placed in 2 mL of PBS and incubated at 37°C and
5% CO2. Samples for this mechanism were collected after days 1, 2, 4, 10 and 14.
Experimental Set-up for Alginate Caps
The elution profile from the alginate caps was also investigated. The gentamicin
loaded caps were formed by first creating an alginate-gentamicin solution of 1.4% (w/v)
alginic acid sodium salt from brown algae (Sigma; St. Louis, MO) and 150 μg/mL of
gentamicin sulfate salt (Sigma; St. Louis, MO) in 155 mM NaCl. The solidification
agent, 5M CaCl2 solution (Fisher Scientific; Waltham, MA, USA), was pipetted at 100 μL
into a well of a 96-well plate. To form the cap, 100 μL of the alginate-gentamicin
solution was directly added to the CaCl2 solution in the well and immediately solidified.
The alginate caps (N=5) were transferred to a 6-well plate containing 2 mL of PBS. To
determine the elution profile of gentamicin from alginate the PBS was collected and
replaced at the initial time point, immediately after submerging the caps in PBS, as well
as after short term time points of 15 min, 30 min, 45 min, 1 hour, and 12 hours. Samples
were also collected to investigate long term release after Days 1-3, 7, 14, 21, and 28.
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Determining the Total Amount of Incorporated Gentamicin
This assay determined the total amount of gentamicin bound and incorporated
into the round and wicking fibers from the various loading mechanisms. All sample types
from each fiber loading mechanism (N=3) were dissolved in 1 mL chloroform
(Honeywell; Muskegon, MI, USA) in glass microvials at room temperature for 10
minutes and mixed with a vortex mixer (VWR; Radnor, PA, USA) every 5 minutes. To
isolate the gentamicin from chloroform 500 μL of distilled water was added to the
chloroform and mixed with the vortex. The samples were centrifuge resulting in a phase
separation with water-soluble gentamicin in the aqueous phase. The aqueous phase was
collected and analyzed using the following described gentamicin detection assay.
To assess the amount of gentamicin that was bound to the alginate, the hydrogel
was dissolved in a dissolution buffer comprised of 100mM sodium citrate (Fisher
Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO USA),
and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The alginate
caps were transferred to a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis,
MO USA) containing 1 mL of the stock dissolution buffer. The alginate caps were
dissolved for 30 minutes at 37°C and mixed vigorously using the vortex every 5 minutes.
Following complete dissolution of the alginate cap the amount of gentamicin left in the
solution was analyzed following the detection assay.
Gentamicin Detection Assay
The amount of gentamicin over the 28 day time interval was determined using a
spectrophotometric technique developed by Frutos and coworkers. To create a detectable
226

compound the gentamicin was derivatized by adding equal proportions of fluorescent
agent o-phthaldialdehyde (OPA)9. Specifically, the OPA reagent reacts with the primary
amine functional groups on the gentamicin forming a fluorescent detectable complex.
Prior to analyzing the samples, a standard curve was generated and tested by creating the
gentamicin in PBS concentrations seen in the table below. 100 μL of each standard
concentration was added to a well of a black-bottom 96 well plated (Corning; Fisher
Scientific, Waltham, MA USA). To detect the gentamicin, 100 μL of phthaldialdehyde
regent (Sigma; St. Louis, MO) was added and mixed with each well containing standard
sample. The plate containing the standard was incubated at room temperature for 10
minutes and read with a Synergy MX Multi-Mode Reader (BioTek; Winooski, VT USA)
at an excitation wavelength of 340 nm and an emission wavelength of 455 nm. The
standard curve was generated using the fluorescent readings and a linear curve fit was
performed to determine the equation.
Table 5.2: Standard curve concentrations for gentamicin detection assay
Standard
curve
concentrations

0

𝜇𝑔
𝑚𝐿

1

𝜇𝑔
𝑚𝐿

2

𝜇𝑔
𝑚𝐿

5

𝜇𝑔
𝑚𝐿

10

𝜇𝑔
𝑚𝐿

20

𝜇𝑔
𝑚𝐿

100

𝜇𝑔
𝜇𝑔
150
𝑚𝐿
𝑚𝐿

To analyze the elution profile the samples stored at -20°C were thawed to room
temperature and 100 μL of the sample were added to a black clear-bottom 96-well plate
(Corning; Fisher Scientific, Waltham, MA USA). Subsequently, 100 μL of ophthaldialdehyde regent was added and mixed with each well containing sample. Due to
the variability of readings between plates each 96-well plate containing samples
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contained standard gentamicin samples in duplicate to generate a standard curve for each
plate. The sample was incubated at room temperature for 10 minutes and the fluorescent
spectrometry was performed using a Synergy MX Multi-Mode Reader (BioTek;
Winooski, VT USA) at an excitation wavelength of 340 nm and an emission wavelength
of 455 nm.
Differential Scanning Calorimetry
Differential scanning calorimetry (DSC) was used to investigate any effects of the
loaded gentamicin on the melting point and glass transition temperature as well as the
endothermic and exothermic processes during the physical transitions of the polylactide
monofilaments. The experimental groups analyzed were (1) polylactide monofilaments
without gentamicin (2) polylactide monofilaments with gentamicin from the loading
approach using the water bath (Mechanism 2) and (3) polylactide monofilaments with
gentamicin from incorporating antibiotic with pellets prior to extrusion (Mechanism 3).
Fiber samples were sliced with a razor and added to the bottom of a standard aluminum
pan. Approximately 2-3 g of sample were added to each pan bottom. A lid was used to
cover the pan and tweezers were used to manually crimp the pan to seal the edges. The
DSC was performed using a TA instruments Q1000 DSC (TA Instruments; New Castle,
DE) using helium purge gas. The scans were performed from 10°C to 200°C with a
heating rate of 10°C/minute. Universal Analysis 2000 software was used to integrate the
peaks. The melting point and glass transition temperatures were compared for each
experimental group. The DSC curves were also qualitatively analyzed to determine any
alterations in percent crystallinity.
228

Statistics
JMP 10 software was used to conduct an unpaired two-sample t-test to compare
the average gentamicin concentration release from round and wicking fibers for both
loading mechanisms 1 and 2 for each time point. The average amount of antibiotic
initially loaded in round fiber bundles by mechanism 2 was compared to the initial
antibiotic loaded in wicking fiber bundles using an unpaired two-sample t-test.

Results
Elution Profile from Fiber Bundles (Mechanism 1 and 2)
Gentamicin was incorporated into extruded round or wicking fibers by wicking
the antibiotic solution into the bundles (Mechanism 1) and by quenching the fibers in a
water bath (Mechanism 2). The loading mechanisms were tested by analyzing the elution
profile of gentamicin from both round and wicking fiber bundles at various time points.
The short-term release of gentamicin by the fiber bundles was evaluated for the first 45
minutes. The outcomes depicted the highest release of gentamicin at the initial time point
from the fiber bundles for all experimental groups, presented in image A of Figure 5.5.
The wicking fiber bundles loaded through mechanism 1 showed significantly more
release of antibiotic initially than any other group (p<0.05). The gentamicin released from
the wicking fibers modified with mechanism 2, showed significantly higher
concentrations at the initial time point than round fiber bundles loaded with gentamicin
from either mechanism. After 15 minutes the wicking fibers incorporated with antibiotic
through mechanism 1, showed significantly more release of gentamicin than round fibers
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loaded with antibiotic through the same mechanism. The later time points show no
significant difference in gentamicin release from any of the experimental groups. The
results demonstrate that the loading mechanism and fiber type will affect the initial
release of antibiotic but neither factor plays a significant role after 15 minutes. The
minimal inhibitor concentration (MIC) for various bacterial strands is considered around
1μg/mL, indicated by the red dotted line. Ideally, the antibiotic delivery system should
elute above the MIC value. The outcomes show only the wicking fiber groups reach this
concentration after the initial time point, and none of the experimental groups reach the
MIC concentration after time zero. The results illustrated in image B of Figure 5.5 shows
the cumulative release of gentamicin from the fiber bundles after 45 minutes. This can be
used to determine how much antibiotic is left in the fiber bundles.
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Figure 5.5: (A) Gentamicin release from round or wicking fiber bundles loaded with
gentamicin from mechanism 1 or 2. At the initial time point all the experimental groups
show a significantly different concentration of gentamicin (#,$,*,+) signify each group is
significantly different within the initial time point (p<0.05). After 15 minutes the wicking
fiber group loaded by mechanism 1 is significantly greater than the round fiber group
loaded by the same mechanism, (*) signifies statistical differences between these groups
with p<0.05. The red dotted line indicates the target elution concentration. (B) Depicts
the cumulative release of gentamicin from each experimental group
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The release profile of gentamicin was also analyzed over longer time intervals.
The results shown in Figure 5.6 below show similar eluted concentrations of gentamicin
from each experimental group for each time point. From 12 hours to 2 days all
experimental groups depicted negligible concentrations of gentamicin except the wicking
fiber group loaded by mechanism 2. However, after days 7 and 14 gentamicin was
released and detectable. After days 7 and 14 there is no significant difference in eluted
concentrations between fiber bundle groups. Image B depicts the cumulative release
profile of gentamicin from each experimental group. The wicking fiber bundle group
loaded with gentamicin through mechanism 2 shows the greatest cumulative
concentrations over time compared to the other experimental groups.

232

Figure 5.6: (A) Release of gentamicin from wicking fiber bundles after longer time
intervals. Gentamicin was undetectable in early time points for all experimental groups.
No significant difference in gentamicin elution was found at any of the time points (B)
Cumulative release profile of the gentamicin elution from each experimental group shows
the wicking fiber loaded by mechanism 2 has the greatest cumulative elution over this
time interval.
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Gentamicin Elution from Mechanism 3
This study investigated the elution profile of gentamicin in a bundle of small
wicking fibers and a single large fiber to explore the effect of cross-sectional size on
elution of gentamicin. This mechanism incorporated the antibiotic by mixing the PLA
pellets and gentamicin prior to extruding. The release profile, shown in image A of
Figure 5.7, shows both wicking fiber types eluted above the MIC concentration for the
duration of the study. Both fiber types showed an initial burst release of gentamicin. The
burst release from the large wicking fiber was much greater than the release from the
small fiber bundle. The cumulative release for each time point from the large single
fibers, Image B, of gentamicin was greater than the release from the small fiber bundles.
Amount of Antibiotic Loaded for Mechanism 2 and 3
The amount of antibiotic loaded into each of the fiber types by mechanism 2 or
mechanism 3 was determined by dissolving the PLA fibers and isolating the gentamicin
in the aqueous phase. The amount of antibiotic loaded by mechanism 3 was significantly
greater than the second loading mechanism, Figure 5.8. The wicking fiber loaded by
mechanism 2 contained ten times the amount of gentamicin loaded by the same
mechanism. This confirms the high surface area of the wicking fiber can incorporate
more gentamicin. The large single fiber loaded by mechanism 3 has less total gentamicin
loaded than the single fiber bundles.

234

Figure 5.7: Release profile of gentamicin loaded by mechanism 3. (A) Elution profile of
small bundled wicking fiber and a single large wicking fiber (B) Cumulative release of
both wicking fiber types over a 14 day time period.
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Figure 5.8: The amount of gentamicin incorporated into the PLA fibers from loading
mechanisms 2 and 3

Elution Profile from Alginate Caps
The gentamicin release profile from the alginate caps is depicted in Figure 5.9.
The results demonstrate a burst of antibiotic from the initial time point and slower steady
release of antibiotic after 15 minutes. The total amount of gentamicin loaded in the caps
was determined by dissolving the alginate, indicated by the “dissolved” group in Figure
5.9. Image B depicts the cumulative release of gentamicin from the alginate caps. The
profile illustrates by 15 minutes almost half of the total concentration of antibiotic has
been eluted and by day 14, the entire loaded antibiotic was released. Image A also depicts
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the red dotted line that correlates to the target elution concentration. The outcomes reveal
the alginate reaches this target concentration until Day 7.
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Figure 5.9: (A) Elution from alginate caps shows an initial burst and steady release of
gentamicin. The total amount of gentamicin loaded in the alginate is depicted in both
graphs. The red dotted line indicates MIC. The release from the alginate cap reaches the
target concentration until Day 7. (B) The cumulative release profile shows that all of the
gentamicin loaded was completely eluted by day 14.
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Differential Scanning Calorimetry
The DSC plots of the control polylactide wicking fiber group and the
experimental groups containing gentamicin through loading mechanisms 2 and 3 are
shown in Figure 5.10. Plot A shows the DSC curve after the first heat cycle. Mechanism
2 (red) and the control group (green) show similar glass transition temperatures (Tg) and
melting temperatures (Tm). Mechanism 3 (blue) depicts similar Tg value with different
heat flow values compared to Mechanism 2 and the control group. Mechanism 3 also
shows two different melting temperatures, as indicated by the double blue peaks (Image
A). Mechanism 3 also demonstrates a different crystallinity profile than both the control
group and mechanism 2. Image B shows the DSC plots after the second heating cycle.
The Tg values and heat flows are similar for all groups. The melting curves show similar
melting temperatures for each group but different heat flow values. The table reported
below summarizes the Tg and Tm values for the control and experimental groups. The plot
also shows varying crystallinity curves for each group. The DSC preliminary results
suggest the gentamicin may alter the crystallinity and raw properties of the
monofilaments, which may affect the mechanical performance and degradation rate.
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Table 5.3: Results from DSC showing Tg and Tm for each polylactide wicking fiber
experimental group
Tm (Cycle 1)

Tg (Cycle 1)

Tm (Cycle 2)

Tg (Cycle 2)

No Gentamicin

149.6

59.42

151.68

57.87

Mechanism 2

150.98

60.55

150.98

59.41

62.00

150.87

59.07

147.61
Mechanism 3
154.47
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Figure 5.10: (A) DSC plot after first heating cycle of the experimental and control group.
The control group and Mechanism 2 show different heat flow curves at the Tg value.
Control group and Mechanism 2 show the same Tm values. Mechanism 3 depicts a
different Tm value with two melting temperatures. All the groups show a varying
crystallinity curve (B) DSC curve after second heat cycle shows similar Tg and Tm values
but different crystallinity curves than the control polylactide group
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Discussion
The outcomes demonstrate the fiber type, round or wicking, will affect the elution
of gentamicin. Mechanism 1 successfully incorporated the gentamicin by wicking the
antibiotic solution through round or wicking fiber bundles. Mechanism 2 loaded the fiber
bundles by quenching the monofilaments in a water bath containing the gentamicin
solution. The wicking fiber bundles loaded by mechanism 1 showed greater gentamicin
release initially. By wicking solution into the bundles the gentamicin remains on the
surface of the bundles trapped between the inter fiber spaces and grooves. Since
gentamicin is water-soluble we expect to see high releases of the antibiotic from the
surface initially for samples loaded by mechanism 1. The wicking fiber bundles showed
significantly greater release of gentamicin at the initial time point than round fibers. This
suggests the wicking fibers incorporate more gentamicin through wicking than the round
fibers. The later time points show the wicking fiber bundles loaded by mechanism 2 has
the greatest cumulative release from day 1 to day 14. By incorporating the antibiotic
during the quenching process the gentamicin will bind more strongly to the surface, since
the polymer has not quite solidified. The results show the antibiotic is released more
slowly from mechanism 2 compare to mechanism 1. The wicking fibers loaded by
mechanism 1 and 2 reached the minimal inhibitory concentration (MIC) of 1μg/mL at the
initial time point and remained below the MIC for the remaining time points. This
implies the loading concentration of the water bath should be increased or the amount of
fibers used should be increased to produce higher elution concentrations. The results
demonstrate the wicking fibers initially elute significantly higher concentrations of
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antibiotic compared to the round fibers suggesting the increased surface area and
geometry of the fibers plays a role in the gentamicin elution profile. This was also
confirmed by the dissolution of the PLA fibers to determine the total concentration of
antibiotic loaded. The wicking fiber loaded by mechanism 2 showed a ten-fold increase
in gentamicin loaded than the round fibers loaded by the same mechanism.
Mechanism 3, however, showed a rapid burst release of the antibiotic after 24
hours and a steady release of the antibiotic above the minimal inhibitory concentration
for 14 days. This high release can be attributed to incorporating the gentamicin into the
raw material. Mechanism 1 and mechanism 2 incorporate gentamicin primarily on the
surface leading to quick release of the antibiotic. The large single fiber showed a much
higher burst release and cumulative release of the gentamicin. Interestingly, the amount
of gentamicin loaded in the large single fibers was less than the gentamicin incorporated
into the small wicking bundles. This implies the bundle has a slower release profile than
the single large wicking fiber. The large fiber bundle has significantly greater surface
area in contact with the buffer solution compared to the small fiber bundle. The reduced
surface area in contact with the buffer and the tortuosity of the small fibers may
contribute to the slower release from the bundle. After Day 14 most of the gentamicin has
eluted from the large fiber bundle. The small fiber bundle, however, has eluted
approximately 30% of the total antibiotic incorporated. We would expect consistent
release from the bundles for 4 more weeks. Future work will investigate the long-term
release from mechanism 3.

243

The antibiotic loading mechanisms 2 and 3 incorporate the antibiotic into the
polylactide fiber. This was confirmed by the change in crystallinity of the DSC plots.
Further work will investigate if the gentamicin will alter the degradation of the polymer.
Other research has been conducted investigating the release of gentamicin from
polylactide beads or films for bone regeneration applications. Methods to incorporate
gentamicin into polylactide involve creating a polymer solvent with gentamicin and
casting the solution to form a film7,10. Other methods have created polylactide beads
loaded with gentamicin by sintering the polymer and antibiotic into a mold to form the
bead10. Wang et al. has correlated the degradation of polylactide and antibiotic release.
This research showed significant degradation and weight loss of the polymer at the
surface with fractures and holes forming in the interior of the material over time. After 1
week, the surface degradation showed large holes on the surface and small holes
initiating in the center. The increased concentration of gentamicin at days 7 and 14 in our
study can correlate to the degradation rate of the polylactide. This suggest the fiber
bundles may provide a long-term sustained release critical to preventing infections over
months. Future work needs to investigate the release over longer periods of time. The
water bath mechanism may not have bound gentamicin to the interior bulk of the polymer
fibers.
The combined elution profiles of the alginate and wicking fiber construct has the
potential to elute high concentrations of antibiotic initially when there is high infection
risk for the patient by the alginate and also sustain release long-term with polylactide
fibers.
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CHAPTER SIX
DEVELOPMENT AND TESTING OF THE MODIFIED WICKING BUNDLE FOR
CELL SEPARATION AND ISOLATION
Introduction
The National Cancer Institute estimates ten million Americans have or have had
some form of cancer. The annual economic cost of cancer is $126 billion1. The high
incidence rate of cancer drives the need for reliable and accurate testing. While testing
ability has increased, the incidence of diagnostic error, including failure to diagnosis the
existing cancer and delayed diagnosis can occur as frequently as 1 in 5 cancer cases2. A
major contributing factor for this error is the extensive oncologic pathology testing
process. From the time the test for a patient is ordered to the time the test result is
obtained the oncology pathology testing consists of 200-300 individual steps. This
extensive process provides frequent opportunities to switch or contaminate samples, as
well as chances to inadequately prepare, analyze, or interpret specimen properly3. The
process can take up to ten days and often requires multiple pathologists and oncology
specialists to confirm and analyze results. This system is time-consuming, expensive, and
the testing frequently delivers subjective results.
The in vitro diagnostic (IVD) tests including histological analysis use biomarkers
as an essential component for detection. The world market for IVD testing is expected to
reach $7 billion this year4. This technology is a relatively established market for biopsy
analysis. However, the biomarker market is emerging for technologies that analyze liquid
biological samples such as blood, serum, and urine5. Although the use of biomarkers has
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improved prognosis of patients and developing therapeutics it considerably contributes to
the incidence of oncology diagnostic error. A major limitation in using biomarkers to
identify cancer is that there is no universal tumorigenic marker. The complexity and
heterogeneity of the cancer cells within a tumor create a challenge for researchers to
characterize the tumor based on phenotypic and genotypic biomarkers. Tumors are
reported to have different subpopulations of cancer cells with varying phenotypes and
degrees of tumor initiating capabilities 6. Cancer stem cells are primarily considered to be
a tumor propagating subpopulation that have the ability to self-renew and differentiate to
form a hierarchy of cancer cells with varying metastatic potential and tumorigenic
capabilities7–12. The transient phenotypes of these cells create complexities for current
detection methods and treatments 13. For instance, cancer stem cells have the potential to
be dormant or aggressive 14. This ability to phenotypically change may cause resistance
to treatment and recurrence 15. The origin of these cancer stem cells remains elusive;
however, researchers are finding cancer stem cells to have similar functions and protein
expressions as progenitor cells16. The conventional methods for identifying progenitor or
cancer cells involve detecting biomarkers and analyzing gene expression7. The use of
phenotypic and genotypic biomarkers to identify progenitor lacks specificity, and
provides limited information regarding the stem cell potential. Similarly, the use of
biomarkers to detect cancer is very limited due to the heterogeneity of the cancer cells
and plasticity of the expressed biomarkers.
Diagnostic techniques are shifting from invasive tissue samples towards liquid
biopsy analysis, such as blood biopsy. A non-invasive blood biopsy sample can be used
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for detecting circulating tumor cells (CTCs) to diagnose the cancer stage, monitor
treatments, and provide insight into the metastatic process4,17. However, major limitations
for detecting CTCs are the exceedingly low concentrations of CTCs in blood samples and
the heterogeneous phenotypes within the CTC population18,19. As a result, the current
CTC detection and isolation systems have low capture efficiencies and low specificity.
Technologies for CTC detection and separation include macro-scale systems and
microfluidics that use physical characteristics of the cells as well as surface labels. Most
macro-scale systems use antibody-dependent techniques that detect epithelial markers to
target CTCs. These approaches assume all CTCs are expressing epithelial markers, which
therefore limit these approaches to a specific subpopulation of CTCs. Aggressive CTC
populations may have mesenchymal phenotype that lack epithelial markers in the
bloodstream are missed by these conventional technologies13,20–23. Other CTC detection
methods include microfluidic devices and chips that use both antigen-dependent and –
independent techniques to detect and separate cancer cells. These approaches have better
specificity and isolation efficiency but are restricted to small volumes of sample and low
yield of isolated CTCs19,24.
We have investigated the use of wicking fibers to separate cancerous from normal
cell types, as well as, progenitor cell types from more differentiated cells. One aspect of
this chapter was to evaluate the capability of wicking fibers to identify and isolate cancer
cells from benign cells and metastatic cells from non-metastatic cells in heterogeneous
cellular solutions. The other aspect was to assess the cell separation and isolation of
progenitor cells and differentiated cell lines.
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We first tested the ability of the single and bundled wicking fibers to (1) separate
a mixture of normal mouse mammary epithelial cells (MMTV-neu) from mouse
epithelial breast cancer cells (NMuMG), (2) separate and isolate malignant human breast
epithelial cells (MCF-7) and benign human breast epithelial cells (MCF-10A), and (3)
separate a mixture of mouse mesenchymal progenitor cells (D1) from mouse preosteoblast cells (MC3T3E1).
In the subsequent analysis, the ability of the modified wicking bundle (previously
described in Chapter 4) to increase the rate and number of cells recruited and separated
was investigated and tested. The cell separation and isolation of various cell types in the
modified wicking bundle was investigated using (1) Human cancerous breast epithelial
cells (MCF-7) and benign breast epithelial cells (MCF-10A), (2) Metastatic human breast
cancer epithelial cells (MDA-MB-231) and benign breast epithelial cells MCF-10A, (3)
Non-metastatic cancer cells (MCF-7) and metastatic cancer cells (MDA-MB-231), (4) a
tri-culture mixture of benign (MCF-10A), non-metastatic (MCF-7), and metastatic
(MDA-MB-231), and (5) Mouse mesenchymal progenitor cells (D1) and mouse preosteoblast cells (MC3T3E1). In this work we analyzed the wicking behavior,
displacement, and isolation of various cell lines. We believe cellular characteristics
including cell size, deformability, shape, cell surface charge, and cell surface adhesion
molecules play a role in the cellular wicking of various cell lines. This chapter
investigated if various cancer cell types can be distinguished based on their wicking
behavior. Furthermore, the wicking behavior of progenitor cells and more differentiated
cell lines was analyzed to compare similarities of progenitor and cancer cells. A summary
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of the cell lines used and the wicking fiber tests performed in this chapter are presented in
Table 6.1.
Table 6.1: Summarizes the cell lines used in this chapter
CELL LINE
MMTV-NEU
NMUMG
MCF-7
MCF-10A
MDA-MB-231
D1
MC3T3E1
RAW

DESCRIPTION
Normal mouse mammary epithelial cells
Mouse epithelial breast cancer cells
Human cancerous breast epithelial cells
Human benign breast epithelial cells
Human metastatic breast epithelial cells
Mouse mesenchymal stem cells
Mouse pre-osteoblast cells
Mouse macrophage cells

To investigate the cell wicking behavior the cell lines were labeled with a
fluorescent tracker or transfected with fluorescent protein. Fluorescent microscopy and
imaging software were used to semi-quantitatively analyze cell displacement. Cells were
isolated from various regions of the construct and quantified using flow cytometry.
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Table 6.2 summarizes the wicking fiber configuration used, the cell types
investigated, and the analysis used to determine the wicking behavior.
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Table 6.2: Summarizes the type of wicking fiber construct used to cell wicking, the cell
types analyzed, and the type of analysis
Wicking fiber
configurations used
Single wicking fiber
Single wicking fiber
Bundled wicking fiber
Modified wicking bundle
Modified wicking bundle

Modified wicking bundle

Modified wicking bundle

Modified wicking bundle

Cell types used

Analysis

Mouse cancer (NMuMG) and
normal (MMTV-neu) cells
Human cancer (MCF-7) and
benign (MCF10-A) cells
Human cancer (MCF-7) and
benign MCF-10A cells
Human cancer (MCF-7) and
benign (MCF-10A) cells
Human metastatic (MDA-MB231) and benign (MCF-10A)
cells
Human metastatic (MDA-MB231) and non-metastatic cancer
(MCF-7) cells
Human metastatic (MDA-MB231), cancer (MCF-7), and
benign cells (MCF-10A)
Progenitor (D1) and
differentiated pre-osteoblast
(MC3T3E1) cells

Fluorescent microscopy and
imaging software
Fluorescent microscopy and
imaging software
Fluorescent microscopy and
flow cytometry
Fluorescent microscopy and
flow cytometry
Fluorescent microscopy and
flow cytometry
Fluorescent microscopy and
flow cytometry
Fluorescent microscopy
Fluorescent microscopy and
flow cytometry

Cell Separation along Single and Wicking Fiber Bundles
Materials and Methods
Mouse Cancer Cell Separation Using Single Wicking Fibers
Cell Culture
Cells from a normal mouse mammary epithelial cell line, NMuMG (ATCC), were
stably transfected with Green Fluorescent Protein (NMuMG-GFP). Cells from a cancer
mouse epithelial cell line (cells isolated from a mammary tumor that spontaneously arose
in a MMTV-neu transgenic female mouse) were stably transfected with Red Fluorescent
252

Protein (MMTV-neu-RFP). NMuMG-GFP cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Gibco), and Mammary Epithelial Cell Growth Medium (MEGM) single quots (Lonza)
while MMTV-neu-RFP cells were cultured in DMEM (Invitrogen) supplemented with
10% FBS (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich).
Cells were cultured in a T150 flask (Corning) and maintained in a humidified incubator at
37°C and 5% CO2. Once cells were confluent, NMuMG-GFP and MMTV-neu-RFP were
detached using trypsin-EDTA solution (Sigma) and resuspended in growth media to
prepare for the vertical test.
Fiber Preparation
Poly-L-lactide (Natureworks) wicking fiber was extruded to non-circular crosssectional dimensions of 0.72 mm x 0.55 mm. Wicking fibers were sliced into individual
single wicking fibers of 3.5 cm. The fibers were cleaned by soaking in three changes of
ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples were then
soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and air-dried
overnight in a sterile hood.
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Figure 6.1: Schematic shows cell vertical wicking test set-up. The wells contain 1 mL of
media consisting of equal densities of normal and cancer cells. The fiber is vertically
placed into the cell solution so only 3 mm of the fiber is submerged. The cell movement is
analyzed at various time points

Cellular Vertical Wicking Test
The vertical wicking test of cells, shown in Figure 6.1, involved a custom-made
culture lid for a low-attachment 12-well plate (Corning). The lid provided holes with
columns to securely hold the 3.5 cm wicking fibers and wicking fiber bundles in a
vertical position. Both NMuMG-GFP and MMTV-neu cell lines were seeded in each well
of a low attachment 12-well plate at a density of one million cells per well, along with 1
mL of growth media. Single wicking fibers were vertically inserted through the columns
so only the bottom 3 mm of the fiber was contacting the cell solution. The custom 12well plate set up was placed on a flattop shaker (VWR) at 100 rpm in a humidified
incubator at 37oC and 5% CO2. The vertical displacement of the mouse cancer and
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normal mammary cells along the wicking were determined at time points of 0.5 and 24
hours, with an initial time point at the time of fiber placement into the cell solution.
To assess the cell displacement of both cell types the fibers were transferred to
each well of 6-well plate, rinsed twice with phosphate buffered saline (PBS; Invitrogen),
and fixed for 15 min with 4% paraformaldehyde. After the cells on the wicking fiber
constructs were fixed, the fibers were transferred to microscope slides and the entire
length of the fiber was imaged, using fluorescent microscopy, beginning with the seeded
end of the wicking fiber construct using 25x total magnification. A FITC filter was used
to view the vertical movement of normal cells transfected with Green Fluorescent
Protein, and a TRITC filter was used to view the vertical movement of cancer cells
transfected with Red Fluorescent Protein. Imaging software was used to determine the
vertical displacement (μm) of the cells in each image taken along the fiber. Images were
aligned to qualitatively show the total displacement of both normal and cancer cells, with
total vertical displacement quantified by the summation of the individual images.
Statistical Analysis
Matched pairs analysis was conducting using JMP statistical software to compare
(p<0.05) the vertical displacement of MMTV-neu-RFP (cancer cells) and MMuMG-GFP
(normal cells) at each of 0.5 and 24 hours.
Human Cancer Cell and Isolation Using Wicking Fiber Bundles
Cell Culture
Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A
(ATCC), were stably transfected with Green Fluorescent Protein (MCF-10A-GFP).
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Cells from a human breast cancer cell line, MCF-7, (ATCC) were stably transfected
with Red Fluorescent Protein (MCF-7-RFP). MCF-10A-GFP cells were cultured in
DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM
single quots (Lonza). MCF-7-RFP cells were cultured in DMEM (Invitrogen)
supplemented with 0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1%
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich).
Cells were cultured in a T-150 flask (Corning) and maintained in a humidified incubator
at 37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA
solution (Sigma-Aldrich) and resuspended in culture medium to prepare for vertical
testing.
Fiber Preparation
For this assessment, bundled fibers were used to increase the amount of cells along
the fiber to quantify using the flow cytometer. Poly-L-lactide (Natureworks) wicking fiber
was extruded to non-circular cross-sectional dimensions of 0.72 mm x 0.55 mm. Wicking
fibers were sliced into individual single wicking fibers of 10 cm in length. Three of these
fibers were twisted, using an apparatus, at 11 rotations per centimeter twist to create the
wicking fiber bundle. The bundle was sliced into 3.5 cm long sections. Similar to the single
fibers the bundles were cleaned by soaking in three changes of ethanol for 1 hour each, and
placed under ultraviolet light for 6 hours. Samples were then soaked in PBS solution for 2
hours and air-dried overnight in a sterile hood.
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Cellular Vertical Wicking Test
The vertical wicking test of cells as described above was performed using the
wicking fiber bundles to analyze the wicking behavior of the cancerous cells, MCF-7-RFP,
and the benign cells, MCF-10A-GFP. The vertical displacement of these cell lines along
the fibers were determined at time points of 0.25 hours, 2 hours, 12 hours and 24 hours,
with the initial time point being fiber placement into the cell solution. The fluorescently
red-labeled cancer and green-labeled normal cells were imaged along the fiber bundles
with fluorescent microscopy using 25x total magnification and following the same
procedure described above.
Isolation of Cancer and Normal Cells from the Fibers
After 24 hours the vertical wicking fiber bundles were removed from the custom
12-well plate and the fibers were sectioned with a blade into top and bottom fiber regions
(Fig 2). The top and bottom regions were placed in separate wells of a 24-well plate. The
samples were rinsed with PBS twice and untwisted using forceps. The cells were
removed by adding 500 μL of trypsin-EDTA solution into the well with the fiber region
and placing the plate on a flat-top (VWR) shaker at 200 rpm in a 37oC incubator. After 2
hours the cells were resuspended in 500 μL of growth media and the number of MCF10A and MCF-7 in both regions of the fiber were evaluated using a Guava easyCyte flow
cytometer (Guava Technologies). We evaluated the number of MCF-10A-GFP and MCF7-RFP in each region by following the manufacturer’s instructions for InCyte software
(Guava Technologies). Positive and negative controls with known cell densities were
used to calibrate the machine before measurements of the treatment groups were made.
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Figure 6.2: Left schematic shows the vertical test set-up of human cancer and benign
cells. The right schematic shows the isolation of cells from the top and bottom regions of
the wicking fiber bundle for analysis.

Statistical Analysis
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the
fraction of MCF-7-RFP cells in top and bottom regions of the fiber bundle.
Separation of Mouse Progenitor and Monocyte Cells
Cell Culture
Mouse mesenchymal stromal cells, D1 (ATCC), and mouse monocytes, RAW
264.7 (ATCC), were both cultured in growth media consisting of Dulbecco’s Modified
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich). Cells were
cultured in a T150 flask (Corning) and maintained in a humidified incubator at 37°C and
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5% CO2. Once cells were confluent, D1 and RAW cells were detached using trypsinEDTA solution (Sigma) and resuspended in growth media to prepare for the vertical test.
RAW and D1 cells were fluorescently labeled with CellTracker Green CMFDA probe
and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA),
respectively, following the manufacturer’s protocol and using a long-term labeling
concentration of 25μM.
Fiber Preparation
Poly-L-lactide (Natureworks) wicking fiber was extruded to non-circular crosssectional dimensions of 0.72 mm x 0.55 mm. Wicking fibers were sliced into individual
single wicking fibers of 3.5 cm. The fibers were cleaned by soaking in three changes of
ethanol for 1 hour each, and placed under ultraviolet light for 6 hours. Samples were then
soaked in a phosphate-buffered saline (PBS, Invitrogen) solution for 2 hours and air-dried
overnight in a sterile hood.
Vertical Test Set-Up and Analysis
The vertical wicking test of D1 and RAW cells was performed using single
wicking fibers. Both cell types were seeded in each of the wells of a low attachment 12well plate with a cell density of 1 million cells per mL. The fibers were vertically inserted
into the custom-made lids designed to keep the fiber vertical and only 3 mm of the tip
submersed. The displacement of the D1 and RAW cells was determined at time points of
1 and 24 hours using fluorescent microscopy and imaging software. Imaging software
was used to determine the vertical displacement (μm) of the cells in each image taken
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along the fiber. Images were aligned to qualitatively show the total displacement of both
normal and cancer cells, with total vertical displacement quantified by the summation of
the individual images.
Results
Mouse Cancer Cell Separation Using Single Wicking Fibers
We developed a vertical test method to assess the vertical movement of different
cell mixtures along the fiber. The vertical displacements of mouse mammary normal cells
expressing green fluorescent protein (NMuMG-GFP) and mouse mammary cancer cells
expressing red fluorescent protein (MMTV-neu-RFP) were determined at time points of
0.5 and 24 hours using fluorescence microscopy. Figure 6.3 is a composite of fluorescent
images, showing the cancer and normal cells along the length of the fiber, aligned to
qualitatively show the total displacement of both cell types after 24 hours of contacting
cell solution. Image A demonstrates that MMTV-neu-RFP cells have vertically displaced
16.2 mm along the wicking fiber after 24 hours. Image B shows NMuMG-GFP cells
vertically moved 3.0 mm, significantly less than the MMTV-neu-RFP cells, on the same
wicking fiber. Images also depict higher cell densities of MMTV-neu-RFP cells along the
fiber. Images qualitatively show a vertical separation of MMTV-neu-RFP and NMuMGGFP cells, indicating the wicking fibers move different cell types various distances.
Imaging software was used to quantify the vertical displacement (μm) of the cells. The
total vertical displacement was found from assessing each individual image. The vertical
displacement of the cancer cells, MMTV-neu-RFP, along the wicking fiber was
significantly (p<0.05) greater than that of the normal cells (NMuMG-GFP) at the 24-hour
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time point (Image C). No significant difference was shown after 0.5-hour time point.
Results suggest wicking fibers can separate and allow the rapid identification of cancer
cells from a liquid with heterogeneous mix of cells.
C

Figure 6.3: (A) Depicts compiled fluorescent images of the vertical displacement of
MMTV-neu-RFP, cancer cells, along the length of the fiber. (B) Shows NMuMG-GPF,
normal cells, progressed significantly less than the cancer cells. (C) Graph shows
quantitative analysis of the vertical displacement of cancer cells (2759 ± 928.9 (SD),
n=4) and mouse normal cells (2219 ± 940.6 (SD), n=4) after various time points. After
24 hours there was significantly greater vertical displacement of MMTV-neu-RFP (14380
± 1192 (SD), n=4) than displacement of NMuMG-RFP (6220 ± 994.2 (SD), n=4)
(p<0.05), indicated by (*) in graph.

Human Cancer Cell Separation and Isolation Using Wicking Fiber Bundles
To observe and quantify the effects of wicking fibers on human cancer cell
separation and isolation, we developed a wicking fiber bundle that enhances the rate of
separation and increases cell capacity. The bundles demonstrated enhanced wicking
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properties, i.e. the overall wicking rate and volume of liquid transported were enhanced.
The wicking fiber bundle was used to separate and isolate malignant human breast
epithelial cells expressing red fluorescent protein (MCF-7-RFP) from benign human
breast epithelial cells expressing green fluorescent protein (MCF-10A-GFP). Fluorescent
images of the bundles were used to evaluate the vertical displacement and separation of
MCF-7-RFP and MCF-10A-GFP after 0.25, 2, 12, and 24 hours. Images show that, after
15 minutes and 2 hours, MCF-7-RFP cells have progressed along the entire fiber but in
low numbers. After 12 hour and 24-hour time points, much higher numbers of MCF-7RFP have traveled to the top region of the fiber. Fluorescent images indicate after 2 hours
and the later time points, few benign epithelial cells progressed to the top region of the
fiber bundles, Figure 6.4.

Figure 6.4: (Left) Approximately equal densities of red and green fluorescently labeled
cancer and normal cells depicted in bottom region of the fiber. (Right) Mostly
fluorescently labeled red cells in top region indicating cancer cells displace the entire
wicking fiber bundle

262

To quantify the number of cancerous and benign cells along the fiber bundles,
cells were removed from top and bottom regions of the bundles Figure 6.5. The number
of MCF-7-RFP and MCF-10A-GFP was determined using flow cytometry (Guava
Technologies) with InCyte software (Guava Technologies). The chart illustrates the
percentage of each cell type in top and bottom regions; there is a significant difference
(p<0.05) between the percentage of MCF-7-RFP and the percentage of MCF-10A-GFP in
the top region of the fiber bundles. These results strongly suggest that the wicking fiber
bundles can separate and isolate cancerous cells, with high accuracy, from a mixture; as
the graph indicates, 82% of cells isolated from the top fiber bundle regions are cancerous.

Figure 6.5: Schematic of the fiber regions and data depicting percentage of each cell
type in fiber regions. Left image illustrates axial slicing of fiber bundle to extract cells
from top and bottom regions. Graph exhibits quantitative analysis of top and bottom
region of the fiber bundle, demonstrating significantly higher concentration of MCF-7RFP cells in the top region of the fiber bundle (82.4 ± 4.3 (SD), n=3) than the bottom
region of the fiber bundle (61.6 ± 3.04 (SD), n=3) The graph indicates a significantly
lower concentration of MCF-10A-GFP cells in top region (17.6 ± 4.3 (SD), n=3) than
bottom region (38.4 ± 3.04 (SD), n=3), (*) indicates significant difference, p<0.05
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Mesenchymal Stem Cell and Monocyte Separation Using Single Wicking Fibers
The outcomes of the vertical wicking of D1 and RAW cells along a single
wicking fiber showed greater displacement of D1 cells after 1 hour and 24 hours than
RAW cells, Figure 6.6. The composite fluorescent image of RAW and D1 cells after 1
hour shows higher cell density of D1 cells, labeled red, penetrating the bottom region of
the fiber. Image J software was used to measure the total displacement of each cell line
along the fiber. The total vertical displacement of D1 cells along the fiber was greater
than RAW cells after 1 hour and 24 hours (Image B). The outcomes suggest the
displacement of different cell types along the wicking fiber may provide a method to
identify progenitor cells and more a differentiated cell line, monocytes.
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Figure 6.6: (A) Fluorescent image shows vertical displacement of RAW and D1 cells
along the bottom region of the wicking fiber bundle. Image shows higher densities of red
fluorescently labeled D1 cells. (B) D1 cells show increased vertical displacement after 1
hour and 24 hours
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Cell Separation and Isolation along Modified Wicking Bundle
Materials and Methods
The modified wicking bundle, comprised of wicking fibers and an absorbent cap,
was developed and tested to separate and isolate different cancer cell types. As shown
from chapter 4 the absorbent cap enhances the fluid flow and infiltration of cells. The
modified bundle was used in the following tests to more rapidly separate and isolate
different cell types and isolate large numbers of cells to quantitatively analyze with flow
cytometry.
Human Breast Cancer and Normal Cell Separation and Isolation along Modified
Wicking Bundle
Cell Culture
Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A
(ATCC), and human breast cancer cell line, MCF-7, (ATCC) were cultured in DMEM
(Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM single
quots (Lonza) and DMEM (Invitrogen) supplemented with 0.01 mg/mL human
recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and
10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells were cultured in a T-150
flask (Corning) and maintained in a humidified incubator at 37°C and 5% CO2. Once
confluent both cell types were removed with trypsin-EDTA solution (Sigma-Aldrich) and
resuspended in culture medium to prepare for vertical testing. MCF-10A and MCF-7
cells were fluorescently labeled with CellTrackerTM Green CMFDA probe and
CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY, USA), respectively
following manufacturer’s protocol. Samples were prepared for both imaging and flow
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cytometry analysis. To fluorescently image cells along the fibers, a long-term labeling
concentration of 25 μM for both red and green cell tracker was used to label the cells.
The red and green cell tracker was optimized for each cell line to detect using the flow
cytometry (Appendix). To detect isolated cells from the wicking fiber-alginate constructs
with flow cytometer, MCF-7 cells were labeled with 5.0 μM cell tracker red and MCF10A cells were labeled with the optimized cell tracker green concentration of 0.05 μM.
Modified Wicking Bundle Preparation
Poly-L-lactide (Natureworks LLC, USA) wicking fibers were extruded with
irregular cross-sectional dimensions of 0.72 mm by 0.55 mm. Wicking fibers were sliced
with a razor blade into individual single wicking fibers of 10 cm lengths. The 10 cm
wicking fibers were used to form the wicking fiber bundles comprised of ten individual
and three individual fibers. The fiber bundles were twisted, using an apparatus, at
approximately 11 and 5 rotations per centimeter twist for the large and small fiber
bundles, respectively. The bundle was sliced into 3 cm long sections. Bundled wicking
fibers were cleaned by soaking in three changes of ethanol for 1 hour each, and placed
under ultraviolet light for 6 hours. Samples were then soaked in a phosphate-buffered
saline (PBS, Invitrogen) solution for 2 hours and air-dried overnight in a sterile hood. The
alginate cap was formed by dipping one end of the wicking fiber bundle in 100 μL of 5M
CaCl2 solution (Fisher Scientific; Waltham, MA, USA) in a well of a 96-well plate and
pipetting 100 μL of 1.4% (w/v) alginate solution comprised of alginic acid sodium salt
from brown algae (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO)
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directly on the submerged fiber tip in the well. The alginate immediately adheres to the
fiber end and solidifies forming the modified wicking bundle.
Experimental Set-up
The vertical wicking test of MCF-7 and MCF-10A cells was performed using the
modified wicking bundle. Both cell types were seeded in each of the wells of a low
attachment 12-well plate with a cell density of 500,000 cells per mL. MCF-7 and MCF10A cells labeled with 25 μM cell tracker were seeded into six wells for fluorescent
microscopy analysis. The remaining six wells were seeded with MCF-7 labeled with 5.0
μM red tracker and MCF-10A cells labeled with 0.05 μM of green tracker for flow
cytometry analysis. Modified wicking bundles containing only 3 individual fibers were
vertically inserted into the wells containing cells for fluorescent imaging, and bundles
containing 10 fibers were vertically placed in wells containing cells for flow cytometry
analysis. The bundles containing three fibers were used for imaging to improve the
contrast and image deeper into the bundle. The bundles for flow cytometry contained 10
fibers to isolate enough detectable cells for the instrument to analyze. The experimental
set-up is shown below in a 12-well plate. Immediately following the vertical placement of
the modified fiber bundles in the appropriate wells the 12-well plate was placed on a
flattop shaker (VWR) at 100 rpm in a humidified incubator at 37oC and 5% CO2. The
vertical displacement of the human cancer and benign breast epithelial cells along the
wicking were determined after 2 hours of incubation, with the initial time point being
fiber placement into the cell solution.
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Figure 6.7: Set-up to analyze cell separation and isolation

Analysis of Cell Separation and Isolation
To qualitatively assess the cell separation along the modified wicking bundle the
samples were transferred to a well of 6-well plate, rinsed twice with phosphate-buffered
saline solution, and fixed for 15 min with 4% paraformaldehyde. After the cells on the
modified wicking bundle were fixed, the fibers were transferred to microscope slides and
the vertical displacement was evaluated using fluorescent microscopy and imaging
software was used to overlay the images. Various regions of the construct were imaged
using fluorescent microscopy, shown in the schematic below.
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The bottom, middle, top, alginate-bundle interface, and alginate cap regions of the
modified wicking bundle were imaged with a 20x or 40x total magnification. A FITC
filter was used to view the vertical movement of normal cells labeled green, and a TRITC
filter was used to view the vertical movement of cancer cells labeled red.

Figure 6.8: Schematic depicts fluorescent microscopy analysis and regions of interest
images

To quantify the cancer normal cell separation the construct was sectioned into top,
bottom and alginate regions and the cells were removed from each region, illustrated in
schematic. The alginate caps were first removed from the fiber bundles and transferred to
a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis, MO USA) containing 1 mL
of the stock dissolution buffer. The buffer was comprised of 100mM sodium citrate
(Fisher Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO
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USA), and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The
alginate caps were dissolved for 30 minutes at 37°C and mixed vigorously using the
vortex every 5 minutes. The wicking fiber bundle region was sectioned with a blade into
top and bottom regions were placed into separate wells of a 24 well plate, Samples were
rinsed with PBS and untwisted. Cells were removed by adding 500 μL of trypsin-EDTA
solution into the well with the fiber region and placing the plate on a flat-top (VWR)
shaker at 200 rpm in a 37oC incubator. After 15 min the cells were resuspended in 500 μL
of growth media and the number of red labeled MCF-7 and green labeled MCF-10A cells
were determined from the alginate caps and top and bottom regions of the fiber bundles
using a Guava easyCyte flow cytometer (Guava Technologies). The number of cancer
and normal cells in each region was evaluated by following the manufacturer’s
instructions for InCyte software (Guava Technologies). MCF-7 and MCF-10A cells of
known cell densities with and without red and green tracker, were used as positive and
negative controls to calibrate the machine before measurements of the treatment groups
were made.
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Figure 6.9: Schematic shows regions cancer and normal cells were isolated from along
the modified wicking bundle

Statistical Analysis
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the
fraction of red-labeled MCF-7 cells in top and bottom regions of the fiber bundle and the
alginate cap.
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Benign
Breast Epithelial Cells along Modified Wicking Bundle
Cell Culture
Cells from a mammary epithelial cell line from benign breast tissue, MCF-10A
(ATCC), and metastatic breast epithelial cells, MDA-MB-231, (ATCC) were cultured in
DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM
single quots (Lonza) and DMEM (Invitrogen) supplemented with 10% FBS, 1%
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich),
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respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to
prepare for vertical testing. MCF-10A and MDA-MB-231 cells were fluorescently
labeled with CellTracker Green CMFDA probe and CellTracker Red CMTPX probe
(Invitrogen; Grand Island, NY, USA), respectively following manufacturer’s protocol.
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and
green cell tracker was used to label the cells. The red and green cell tracker was
optimized for each cell line to detect using the flow cytometry (Appendix). To detect
isolated cells from the wicking fiber-alginate constructs with flow cytometer, MDA-MB231 cells were labeled with 5.0 μM cell tracker red and MCF-10A cells were labeled with
the optimized cell tracker green concentration of 0.50 μM.
Experimental Set-up and Analysis
The cell separation and isolation of metastatic cancer cells, MDA-MB-231, and
benign epithelial cells, MCF-10A, were investigated using the modified wicking bundle.
The modified wicking bundles were formed using the same procedure above. Those
containing three wicking fibers were used for imaging analysis and those containing ten
wicking fibers were used for flow cytometry analysis. Following the vertical wicking
procedure previously described, 500 μL of cell solution containing a cell density of
500,000 cells per mL was pipette in each of the wells of a low attachment 12-well plate
with a custom-made lid to secure the modified fibers vertically in the well. Six samples
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were prepared for fluorescent microscopy and six samples were prepared for flow
cytometry analysis. The experimental set-up is shown below in Image A of Figure 6.10.
Following the procedures above, the plate was placed on a flattop shaker at 100 rpm in a
humidified incubator at 37oC and 5% CO2. The separation of the human metastatic cancer
and benign breast epithelial cells along the constructs were determined after 2 hours of
incubation, with the initial time point being fiber placement into the cell solution. The
samples were fluorescently imaged (Image B) and analyzed using flow cytometry (Image
C) following the procedures from the preceding section.

Figure 6.10: (A) Experimental set-up investigating vertical displacement of metastatic
cancer cells and benign epithelial cells (B) Qualitative analysis using fluorescent
microscopy (C) Flow cytometry analysis

274

Statistical Analysis
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the
fraction of metastatic cancer cells (MDA-MB-231) in top and bottom regions of the fiber
bundle and the alginate cap.
Investigating Cell Separation and Isolation of Metastatic Cancer Cells and NonMetastatic Cancerous Breast Epithelial Cells along Modified Wicking Bundle
Cell Culture
Non-metastatic cancerous breast epithelial cells, MCF-7 (ATCC), and metastatic
breast epithelial cells, MDA-MB-231, (ATCC) were cultured in DMEM (Invitrogen)
supplemented with 10% FBS (Gibco), 1% Fungizone, and 0.01 mg/mL human
recombinant insulin (Gibco) and DMEM (Invitrogen) supplemented with 10% FBS, 1%
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich),
respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to
prepare for vertical testing. MDA-MB-231 and MCF-7 cells were fluorescently labeled
with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe
(Invitrogen; Grand Island, NY, USA), respectively following manufacturer’s protocol.
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and
green cell tracker was used to label the cells. The red and green cell tracker was
optimized for each cell line to detect using the flow cytometry (Appendix). To detect
isolated cells from the wicking fiber-alginate constructs with flow cytometer, MCF-7
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cells were labeled with 5.0 μM cell tracker red and MDA-MB-231 cells were labeled
with the optimized cell tracker green concentration of 0.50 μM.
Experimental Set-up and Analysis
The cell separation and isolation of non-metastatic cancer cells (MCF-7) and
further metastatic cancer cells (MDA-MB-231) were investigated using the modified
wicking fiber bundle construct. The wicking fiber-alginate cap constructs containing
three wicking fibers for imaging analysis or ten wicking fibers for flow cytometry
analysis were formed using the same procedure above. Following the vertical wicking
procedure previously described, 500 μL of cell solution containing a cell density of
500,000 cells per mL from each cell type was pipette directly in each of the wells of a
low attachment 12-well plate with a custom-made lid to secure the modified fibers
vertically in the well. Six samples were prepared for fluorescent microscopy and six
samples were prepared for flow cytometry analysis. After performing the vertical test the
samples were fluorescently imaged and analyzed using flow cytometry following the
procedures from the preceding section.
Statistical Analysis
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the
fraction of metastatic cancer cells (MDA-MB-231) in top and bottom regions of the fiber
bundle and the alginate cap.
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Investigating Cell Separation of Metastatic Cancer Cells, Non-Metastatic Cancerous
Breast Epithelial Cells, and Benign Breast Epithelial Cells along Modified Wicking
Bundle
Cell Culture
Benign breast epithelial cells (MCF-10A), Non-metastatic cancerous breast
epithelial cells, MCF-7, and metastatic breast epithelial cells, MDA-MB-231, were
cultured in were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Gibco),
1% Fungizone, and MEGM single quots (Lonza), DMEM (Invitrogen) supplemented
with 10% FBS (Gibco), 1% Fungizone, and 0.01 mg/mL human recombinant insulin
(Gibco), and DMEM (Invitrogen) supplemented with 10% FBS, 1% Fungizone (Gibco),
10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells
were cultured in a T-150 flask (Corning) and maintained in a humidified incubator at
37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA
solution (Sigma-Aldrich) and resuspended in culture medium to prepare for vertical
testing. MCF-10A and MCF-7 cells were fluorescently labeled with CellTrackerTM Green
CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island, NY,
USA), respectively following manufacturer’s protocol using the recommended long-term
labeling concentration of 25 μM. MDA-MB-231 cells were fluorescently labeled blue
using a 1:500 dilution of a 2mg/mL Hoechst solution (Sigma; St. Louis, MO USA).
Experimental Set-up and Analysis
This study assessed the cell separation from a tri-culture of human cancer cells of
varying metastatic potential. The vertical displacement and separation of metastatic
cancer cells, MDA-MB-231, non-metastatic cancerous breast epithelial cells, MCF-7, and
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benign breast epithelial cells was investigated using the modified wicking bundle.
Modified wicking bundles were formed using the same procedure above. Those
containing three wicking fibers were used for imaging analysis. Following the vertical
wicking procedure previously described, 500 μL of cell solution from each fluorescently
labeled cancer cell line containing a cell density of 500,000 cells per mL was pipette in
each of the wells of a low attachment 12-well plate with a custom-made lid to secure the
modified fibers vertically in the well. Following two hours of incubation, the samples
were removed, fixed with paraformaldehyde, and imaged using fluorescent microscopy.

Figure 6.11: Schematic depicting experimental set-up to analyze a tri-culture of benign
and of cancer cells of varying metastatic potential

Cell Separation and Isolation of Mesenchymal Stem Cells and Pre-Osteoblast Cells
Cell Culture
Mouse mesenchymal stem cells, D1 (ATCC), and mouse pre-osteoblast cells,
MC3T3E1 (ATCC), were cultured in growth media consisting of Dulbecco’s Modified
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Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), and Minimal
Essential Medium Alpha without ascorbic acid (MEMα, Gibco) supplemented with 10%
fetal bovine serum (Gibco), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma),
respectively. Cells were cultured in a T150 flask (Corning) and maintained in a
humidified incubator at 37°C and 5% CO2. Once cells were confluent, D1 and MC3T3E1
cells were detached using trypsin-EDTA solution (Sigma) and resuspended in growth
media to prepare for the vertical test. D1 and MC3T3E1 cells were fluorescently labeled
with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe
(Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol, respectively.
Samples were prepared for both imaging and flow cytometry analysis. To fluorescently
image cells along the fibers, a long-term labeling concentration of 25 μM for both red and
green cell tracker was used to label the cells. The red and green cell tracker was
optimized for each cell line to detect using the flow cytometry (Appendix). To detect
isolated cells with flow cytometer, MC3T3E1 cells were labeled with 5.0 μM cell tracker
red and D1 cells were labeled with the optimized cell tracker green concentration of 0.50
μM.
Statistical Analysis
A matched pairs analysis was conducted in JMP 10 to compare (p<0.05) the
fraction of mouse mesenchymal stem cells (D1) in top and bottom regions of the fiber
bundle and alginate cap.
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Experimental Set-up and Analysis
The cell separation and isolation of bone progenitor cells, D1, and further
differentiated pre-osteoblast cells, MC3T3E1, were investigated using the modified
wicking bundle. The modified wicking bundles containing three wicking fibers for
imaging analysis or ten wicking fibers for flow cytometry analysis were formed using the
same procedure above. Following the vertical wicking procedure previously described,
500 μL of cell solution containing a cell density of 500,000 cells per mL from each cell
type was pipette directly in each of the wells of a low attachment 12-well plate with a
custom-made lid to secure the modified fibers vertically in the well. Six samples were
prepared for fluorescent microscopy and six samples were prepared for flow cytometry
analysis. After performing the vertical test the samples were fluorescently imaged and
analyzed using flow cytometry following the procedures from the preceding section.
Results
Human Breast Cancer and Normal Cell Separation and Isolation along Modified
Wicking Bundle
The fluorescent images, Figure 6.12, of regions along the modified wicking
bundle depict a clear separation of benign epithelial cells (MCF-10A) labeled green and
cancerous epithelial cells (MCF-7) labeled red.
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Figure 6.12: Fluorescent images of the cancerous MCF-7 (red) and benign MCF-10A
(green) epithelial cell displacement along the modified wicking bundles. (A) Depicts
more MCF-10A cells in the bottom region of the fiber bundle where the cell solution
contacts the fiber bundle. (B) Similar cell densities of MCF-7 and MCF-10A cells in the
middle region of the fiber bundle. (C) Depicts primarily MCF-7 cells along the top
region of the fiber in the alginate cap. (D) Reveals significantly more cancer cells in the
alginate cap
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The flow cytometer was used to quantify the amount of green and red
fluorescently labeled cells in each region of the construct. The flow cytometer scatter
plots and fluorescent intensity plots indicate the cancer cell lines contain cells of different
sizes and shapes. The MCF-7 cells depict a wider range of cell sizes and the MCF-10A
cells illustrate a range of complexities (Figure 6.13). The results in Figure 6.14 report the
percentages of benign and cancerous cells from each region. Image A shows more than
80% of the cells isolated from the alginate cap are cancerous cells. Similarly, the
outcomes presented in image B demonstrate approximately 80% of the cells isolated from
top region of the fiber bundle are the cancerous MCF-7 cells. The bottom region shows
comparable amounts of benign and cancer cells. Although there were larger percentages
of cancer cells in the top region of the bundle and the alginate cap, there were
significantly less total cells in these regions as indicated by the scatter and fluorescent
intensity in the decreased amount of cells in the top bundle regions and the alginate cap is
likely due to the processing methods. The dissolution of the alginate cap may cause
debris, as well as cell debris and clumping that will limit the number of cells detected.
Furthermore, cells are tightly bound within the grooves of the fiber bundles, and the
removal procedures used to isolate cells from the fibers may not reach the cells tightly
bound in the inter-fiber and groove conduits. However, the amount of cancerous cells
isolated from the regions is significantly higher than the benign cells and verifies the
fluorescent images. The outcomes of both analyses show the modified wicking bundles
can separate cancer cells from benign cells by isolating the cancer cells in the top fiber
region and alginate cap. The modified wicking bundles enhanced the amount of cells that
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penetrated the fiber compared to the unmodified wicking bundle and single wicking fiber
samples. The alginate provided a collection sink for cancer cells as demonstrated by the
images and by the flow cytometry analysis.

Figure 6.13: Scatter plots of control groups from flow cytometry analysis. Depicts the
forward and side-scattering plots of MCF-7 (Top Row) and MCF-10A (Bottom Row. The
red and green fluorescent intensity plots show the MCF-7 cells are labeled with red
fluorescence and the MCF-10A cells are labeled with green fluorescence.
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Figure 6.14: Flow cytometry results investigating the number of cancer and benign cells
in each region. Chart illustrates significantly higher percentage of MCF-7 in alginate
cap (A) and in top region of wicking fiber bundle (*) indicates significant difference of
p<0.05 (B). No comparable difference in percentage of MCF-7 and MCF-10A cells in
bottom region of the wicking fiber bundle
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Figure 6.15: Forward scatter plots and fluorescence intensity of MCF-10A and MCF-7
cells in each region. The forward scatter plot shows greater numbers of both cell types in
the bottom region compared to the top fiber region and the alginate cap. The bottom
region depicts similar red and green fluorescent intensities. The top fiber region and
alginate cap show high red fluorescent intensity counts correlating to mainly cancer cells
in these regions

Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Benign
Breast Epithelial Cells along Modified Wicking Bundle
This test investigated the separation of cancer cell line with greater metastatic
potential than the MCF-7 cells. The fluorescent images (Figure 6.16) show greater
vertical displacement of the metastatic cancer cells (MDA-MB-231) labeled red into the
middle and top regions of the fiber bundle. The bottom region (Image A) of the wicking
fiber bundle depicts comparable cell densities of the MDA-MB-231 cells and benign
breast epithelial cells (MCF-10A) labeled green. Higher cell densities of the metastatic
cancer cells are collected in the top region (image C) of the fiber and alginate cap (image
D).
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Figure 6.16: Fluorescent images analyzing the vertical displacement of metastatic breast
cancer cells (red) and benign breast epithelial cells (green). Comparable cell densities
are depicted in the bottom or seeded region of the fiber (A). Greater numbers of
metastatic cancer cells (red) wick to the middle (B) and top (C) regions of the fiber. (D)
The alginate cap consists of greater numbers of the metastatic cancer cells.
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The flow cytometry outcomes illustrated analogous results to the previous study
assessing separation of MCF-7 and MCF-10A cells. Both regions of the wicking fiber
bundle and the alginate cap contained significantly more red-labeled metastatic cancer
cells, MDA-MB-231 than the benign epithelial cells, as presented in Image C of Figure
6.19. The outcomes show modified wicking bundle provides a method to separate the
metastatic cancer cells and benign cells along the fiber bundles.

Figure 6.17: (A) Scatter and fluorescent intensity plots confirming the red-label of the
MDA-MB-231 metastatic cancer cells. (B) Scatter and fluorescent intensity plots of
green-labeled benign cells. (C) Depicts separation of the metastatic cells, MDA-MB-231
from MCF10A cells in each region of the fiber bundle and alginate cap.

Investigating Cell Separation and Isolation of Metastatic Cancer Cells and Nonmetastatic Cancerous Breast Epithelial Cells along Modified Wicking Bundle
The fluorescent images in Figure 6.18 show more metastatic cancer cells (labeled
green) in the top region (Image C) of the wicking fiber bundle and the alginate cap
(Image D). Non-metastatic cancer cells (red) were still observed in the alginate cap but
show in fewer numbers. The bottom and middle regions of the wicking fiber bundle
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(Image A and B) show greater metastatic cancer cell infiltration. To enhance separation
of the metastatic and non-metastatic cancer cells further work will increase the specificity
of the construct by altering the cross-sectional sizes of the wicking fiber bundle and
modifying the absorbent material.
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Figure 6.18: (A) and (B) depict similar cell densities of metastatic cancer cells (MDAMB-231) labeled green and non-metastatic cancer cells (MCF-7) labeled red. (C) Top
region of the wicking fiber bundle shows more metastatic cancer cells and (D) alginate
cap depicts both metastatic and non-metastatic cancer cells.
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The outcomes from flow cytometry depicted similar trends. The controls
confirmed the metastatic cancer cells and non-metastatic cancer cells were successfully
labeled with green and red cell tracker (Image A and B). The percentage of nonmetastatic and metastatic cancer cells was measured from the cells removed from each
region. The alginate and bottom region of the wicking fiber bundle contained similar
amounts of non-metastatic and metastatic cells. The top region contained significantly
more metastatic cancer cells (MDA-MB-231) than non-metastatic (MCF-7), using a
significance value of p<0.05.

Figure 6.19: (A) Scatter plot of MDA-MB-231 metastatic cells. Red and green
fluorescence intensity plots shows high green intensity and low red intensity confirming
labeling procedure. (B) Scatter plot of MCF-7 non-metastatic cancer cells shows
variation in size and shape of cells within cell line. The fluorescence intensity plots show
high red intensity confirming the cells are fluorescently tagged red. (C) Comparable
amounts of metastatic and non-metastatic cells in bottom region of the fiber bundle and
the alginate cap. The top region depicts significantly more MDA-MB-231 cells than
MCF-7 cells, (*) indicates significant difference, p<0.05
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The flow cytometry scatter plots showed significantly less total cells from the top
region of the fiber bundle and the alginate cap. The low cell count detected by the flow
cytometry in the alginate and wicking fiber bundle is due to the cell removal processing
technique. More work is needed to improve the cell removal methods to increase the
amount of cells removed without altering the cells and to obtain a more representative
number of cells.

Figure 6.20: Scatter and fluorescent intensity plots depict low amounts of cell removal
from the top fiber region and the alginate cap
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Investigating Cell Separation of Metastatic Cancer Cells, Non-metastatic Cancerous
Breast Epithelial Cells, and Benign Breast Epithelial Cells along Modified Wicking
Bundle
The vertical displacement of a tri-culture was investigated along the modified wicking
bundle using fluorescent microscopy, Figure 6.21. The bottom (Image A) and middle
region (Image B) of the wicking fiber bundle depict all cell types consisting of MCF-10A
cells labeled green, MCF-7 cells labeled red, and MDA-MB-231 cells labeled blue. The
top region of the wicking fiber bundle (Image C) and the alginate cap (Image D) depict
significantly more metastatic cancer cells, MDA-MB-231 cells than benign or cancerous
cells. Interestingly, the MDA-MB-231 cells spread out in the alginate more than the other
cell types.

292

Figure 6.21: Cell displacement of metastatic cancer cells, MDA-MB-231 (blue), nonmetastatic cancer cells, MCF-7 (red), and benign breast epithelial cells (green). The
bottom (A) and middle (B) region of the fiber bundle depict all cancer cell types along the
fiber. High densities of MDA-MB-231 are depicted in the top region of the fiber bundle
(C) and the alginate cap (D).
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Cell Separation and Isolation of Mesenchymal Stem Cells and Pre-Osteoblast Cells
The final assessment evaluated the potential of the modified wicking bundle to
separate D1 mouse mesenchymal stem cells from MC3T3E1 pre-osteoblast cells, a
further differentiated mouse cell type. The fluorescent images depicted cell separation of
D1 progenitor cells labeled green and from MC3T3E1 pre-osteoblast cells labeled red.
The bottom region (Image A) and the middle region (Image B) of the wicking fiber
bundle illustrate a mixture of both cell types. The top and alginate cap (Images C and D)
depict high cell counts of green-labeled progenitor cells. The outcomes of this assessment
suggest similarities between the wicking behavior of progenitor and cancer cells.
The amount of progenitor and pre-osteoblast cells was quantified in each region
of the wicking fiber bundle and the alginate cap presented in Figure 6.23. The forward
scatter and fluorescent intensity plots (Images A and B) show the D1 cells and MC3T3E1
cells were successfully labeled with green and red fluorescent cell tracker. The top and
bottom regions of the wicking fiber bundle, as wells the alginate cap (Image C) consisted
of significantly more D1 progenitor cells, labeled with green tracker than MC3T3E1
cells, p<0.05. The outcomes suggest the modified wicking bundle has potential to sort the
progenitor cells and pre-osteoblasts. This also implies the progenitor cells may have
similar behaviors to cancer cell types along the construct. It is also important to note,
similar to the previous assessments, the alginate and top regions of the construct show
less cell numbers than the bottom region of the wicking fiber bundle. Again, this is due to
the inconsistencies and limitations of the cell removal process.
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Figure 6.22: (A) and (B) Bottom and middle regions of the wicking fiber bundle show
similar cell densities of D1 cells (green) and MC3T3E1 cells (red). (C) and (D) depict
more D1 progenitor cells in top region and alginate cap.
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Figure 6.23: (A) Scatter and fluorescent intensity plots for MC3T3-E1 cells show cells
were labeled with red tracker. (B) Scatter and fluorescent intensity plot for green
fluorescently labeled D1 cells. (C) Quantifies the wicking displacement of D1 cells and
MC3T3E1 cells. Depicts significantly more D1 cells (p<0.05) in the alginate cap and
fiber bundle regions than MC3T3E1 cells.

Discussion
The first part of this chapter explored the use of unmodified single and wicking
fiber bundles to sort cancer and normal cells by their wicking behavior along the fibers.
The outcomes from the single and bundled fibers assessments showed mouse and human
cancer cell separation from normal or benign cells in the top region of the fiber. In both
studies the cancer cells have greater vertical displacement and are presented in the top
region of the fiber. The single wicking fiber was used to evaluate the vertical
displacement of mouse mesenchymal stem cells and differentiated mouse monocytes.
The semi-quantitative data showed progenitor cells displace to the top region of the fiber.
The outcomes suggest the progenitor cells may share similar physical properties to the
cancer cells.
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We previously showed in Chapter 4 the wicking fiber bundles with an alginate
cap (modified wicking bundles) greatly enhance the fluid transport and amount of cells
collected within the construct after performing a vertical test assessment. The remainder
of the chapter explored the use of the modified wicking bundle to separate various cancer
cell types as well as progenitor cells from further differentiated cells. The wicking tests
also investigated the use of the alginate cap as a collection source to isolate a cell type
from a mixture of different cell types. The outcomes revealed the modified wicking
bundle can be used to separate cancerous cells from benign cells. The isolation from
various regions showed a significant increase in either metastatic or non-metastatic
cancer cells along the fibers and in the alginate cap when tested with benign epithelial
cells. Flow cytometry results investigating the movement of metastatic and nonmetastatic cancer cells demonstrated a decreased ability to separate as compared to
separation from benign cells. To increase specificity to isolate metastatic cancer cells in
the alginate cap various approaches can be used to alter the system. The inter-fiber and
intra-fiber spaces of the wicking fiber bundle can be altered, as well as, the polymer of
choice used and the stiffness of the hydrogel.
Limitations of using the modified wicking bundle approach include
inconsistencies between the fabricated samples, as well as, the processing technique to
remove cells from the construct. The fabrication process of the modified wicking bundle
involves the extrusion and twisting of fibers, as well as, the formation of the alginate cap.
Inconsistencies between samples develop from the variation in cross-section sizing of the
extruded fibers as well as the bundling process. To improve specificity the processing
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technique of the constructs should be improved. The cell removal technique also presents
a limitation. The cells are wicked through the conduits of the fibers as well as the
compact intra-fiber spaces. The high tortuosity of the fiber component presents
difficulties of using trypsin as a cell removal agent. The dissolution of the alginate cap
takes approximately 30 minutes to dissolve the hydrogel. Small pieces of dissolute
hydrogel may interfere with removal of cells as well as with detection during flow
cytometry. Other cell removal techniques may need to be employed to ensure all cell
information is obtained to provide precise results.
The mechanism for separation between different cell types is due to the physical
and functional properties of the cells, wicking characteristics of the fiber bundle, and the
cell-fiber interaction. Physical properties that may play a role include cell size,
deformability, surface friction or charge, and expression of cell adhesion molecules. The
size and shape of the cells may play a role in the ability for cells to penetrate the smaller
channels created from the bundling of the fibers. Fiber bundle architecture will affect the
wicking rate and vertical displacement of different cell types. The size of the individual
fibers, the tension of the bundle, the hydrophobicity, and the inter-fiber space will play a
role in the wicking of liquid and cell-interaction. These factors can be altered to increase
the specificity of the system and increase the amount of cells reaching the top region of
the fiber bundle and the alginate cap.
Other cellular properties influencing vertical movement include membrane
impedance, expression of adhesion molecules, and cells stiffness. Membrane impedance,
cell dielectric properties, or cell electric properties vary between cell types25,26. Electrical
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properties of the cell will influence the cell-interaction with the fiber based on the
inherent charge of the fibers and the resultant vertical movement. Cells with greater
impedance or surface charge may have more interactions with the fiber, thus hindering
the vertical cell movement. Abdolahab and coworkers evaluated the cellular impedance
for cancer cells of varying aggressiveness and demonstrated that a more aggressive
cancer cell type (MDA-MD-231) has a significant reduction in impedance than a less
aggressive cancer cell (MCF-7). Additionally they found a correlation between metastatic
progression and membrane impedance reduction27. Cell-fiber interaction and overall cell
displacement will be affected by different membrane impedances and overall surface
charge. The specificity and amount of cells wicked into the construct may be improved
altering the hydrophobicity of the polymer wicking fibers.
Expression of cell adhesion molecules, such as EpCAM, can play a role in the
cell-fiber interaction and ability of a cell to move through a confined space. Metastatic
cells, as shown by the MDA-MB-231, are known to lose endothelial adhesion molecules
and transition into a more motile mesenchymal phenotype22. Cancerous cells with fewer
adhesion molecules may have less surface friction and altered shape that have less
interaction with the fiber, allowing the cells to wick greater distances. The MDA-MB-231
cells are characterized with a mesenchymal phenotype and are classified as EpCAMnegative, CD24-negative, and CD44 positive with spindle-like shape 28,29. The high
penetration of the MDA-MB-231 cells into the alginate cap as shown from the tri-culture
separation assessment is due the ability of these cells to individually migrate and
penetrate tissues, whereas MCF-7’s require cell-cell interactions to maintain and
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function. Future work can modify or layer the alginate to distinguish non-metastatic and
metastatic cancer cells based on their dispersal through the hydrogel.
Cell deformability is another factor that will influence the ability for cells to
deform, penetrate, and wick vertically through the twisted channels. In general, research
shows cancer cells have a significantly lower Young’s modulus compared to normal
cells30–32. Researchers have found that cancer cells of increased metastatic potential have
higher deformability33,34. This point suggests that MCF-7 cells are much softer and
deform more easily than normal cells, allowing the cancer cells to migrate more readily.
Microfluidic devices have been employed to distinguish cancer and normal cells, based
on cellular deformability, by analyzing the ability of cells to squeeze and pass though
confined constrictions31,35,36. Indeed, Li and coworkers found the apparent Young’s
modulus of MCF-10A, non-malignant breast epithelial cells, to be significantly higher
than MCF-737. The softer cytoskeleton and deformability of the MCF-7 cells may play a
role in their ability to squeeze through channels and wick upward through the confined
space.
Undifferentiated and differentiate stem cell separation shown in these tests are
also affected by the same physical factors. Subpopulations of progenitor cells of varying
differentiation potential are shown to have different electrical and mechanical properties,
which can be used to identify the cell differentiation potential. Flanagan and coworkers
used dielectrophoresis (DEP), a technique that detects the inherent charge characteristic
of the cells, and established electrical signatures for progenitor cells of varying
differentiation potential38. Darling and coworkers characterized progenitor cells based on
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their elastic and viscoelastic properties. The outcomes showed subpopulations of
progenitor cells can be distinguished based on their mechanical markers39,40. Progenitor
cells of high differentiation potential are shown to have weaker cell membranecytoskeleton interaction as compared to mature cells. Similar to the cell separation of
cancer cell types the alginate-modified wicking fiber construct was shown to identify
progenitor cells from a more differentiated pre-osteoblast cell type. The physical
properties of the cells such as size, shape, electrical charge, cell stiffness, and expression
of adhesion molecules will also impact the movement of mesenchymal stem cells and
differentiated cell types.

Conclusion
The outcomes of this chapter showed the prototype design of the modified
wicking bundle separated various cell types based the cancer type and differentiated state
of the cell. This work also showed similarities in wicking behavior of cancer cells and
progenitor cell types. Further work needs to investigate the mechanisms affecting cell
movement along the wicking fiber construct separation to optimize the design to improve
specificity. The work in Chapter 7 will analyze some of the factors affecting the cell
wicking behavior of different cell lines to improve the specificity and efficacy of the
system.
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CHAPTER SEVEN
INVESTIGATING THE CELLULAR SEPARATION MECHANISM OF WICKING
FIBERS
Introduction
Technologies for CTC isolation and detection include macro-scale systems and
microfluidics that use physical characteristics of the cells as well as antigen surface
labels. Microfluidic devices have better specificity and isolation efficiency than macroscale systems but are restricted to small volumes of sample and low yield of isolated
CTCs1,2. Many microfluidic devices and macro-scale systems use antibody-antigen
interactions for binding epithelial markers to isolated CTCs. Many isolation methods use
antibodies interacting with epithelial cell adhesion molecules (EpCAMs) and
cytokeratins1,3. These approaches assume CTCs are expressing epithelial markers,
therefore limiting these approaches to a specific subpopulation of CTCs and missing
aggressive CTC populations with mesenchymal phenotype4–8. Other microfluidic devices
and chips use antigen-independent techniques to detect and separate cancer cells. These
approaches use physical characteristics of the cancer cells, including size, deformability,
and charge9. Methods that singularly use cell size to isolate CTCs, such as porous
membrane cell filtration techniques, are limited due to the large variation in size of
cancer cells10. Methods involving cell stiffness and impedance have established
correlations between the biomechanical and electrical properties of cells and their
metastatic state. Biomechanical measurements of cell stiffness confirm that cancer cells
are significantly softer than normal cells, relating to the cancer cell’s increased
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deformability and metastatic potential11,12. Cell-capture microfluidic devices or chips,
based on the cell deformability or impedance, have higher capture efficiency and purity,
but can only process small amounts of volume, therefore limiting the number of isolated
cancer cells. Furthermore, most microfluidic approaches are complex and require a
perfusion system with an optimum flow rate and shear stress that may alter or damage the
isolated cells10. The current limitations of the both antigen-independent and -dependent
microfluidic devices have motivated the simple, bundled fiber design that can rapidly
analyze large volumes of sample and that may better capture different CTC
subpopulations.
Similar limitations are found with progenitor stem cell isolation techniques. Adult
tissue contains subpopulations of progenitor cells that are used widely in tissue
engineering applications. Isolating progenitor cells from these tissues is challenging and
inefficient due to the heterogeneity and lack of universal biomarkers that identify
progenitor cells. Methods to isolate progenitor cells are costly, slow, and inefficient. Cell
adherence assays, colony forming units-fibroblastic (CFU-F) assays, and methods of
biomarker identification are most commonly used to isolate progenitor cells. The current
isolation techniques isolate progenitor cells with different phenotypic and molecular
differences that result in functional variability and different in vitro differentiation
capabilities. Multiple epitopes or phenotypic biomarkers are used to identify progenitor
cells. Mesenchymal stem cells (MSCs), also described as bone marrow derived cells,
have the ability to differentiate into lineage-specific cell types including osteoblasts,
chondrocytes, and adipocytes13. MSCs are routinely used in surgical procedures that
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require tissue regeneration. Bone marrow aspirate containing MSCs is commonly used in
orthopedic applications where the normal bone formation process is compromised to
facilitate the regeneration of bone as well as other tissues. The outcomes of using isolated
MSCs from patient or donor tissue have limited success in regenerative applications.
MSC populations vary from donor-to-donor and contain intra-population heterogeneity
affecting the functionality of the progenitor cells to differentiate and produce the
appropriate tissue 13,14. The intrinsic heterogeneity of MSCs and other progenitor cells
creates a challenge for researchers to develop efficient isolations techniques. The
standard approach to identify MSCs uses expression of multiple biomarkers including
CD29, CD44, and CD10514. This method can identify MSCs but does not predict the
function of the MSCs or identify the differentiating potential of the MSC. Approximately
1 in 4 MSCs isolated have the ability to differentiate into three pathways. Most isolated
MSC clones have potential to differentiate into one or two pathways14. There is a need for
alternative methods to identify and isolate subpopulations of MSCs based on their
potency and ability to differentiate toward specific lineages14.
In addition to providing a novel technique to identify and separate progenitor cells
of varying differentiation potential and different cancer cell types, this work may provide
more insight into the stem-cell hypothesis15. This theory proposes the metastatic cancer
cells that disseminate from the tumor have stem-cell properties. Researchers have found
that subpopulations within tumor cells contain stem-cell like functions have
differentiating potential. This work further investigated similarities between progenitor
and derived cell separation with cancer and normal cell separation.
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The previous chapter investigated the potential use of the modified wicking
bundle approach to separate varying cancer cell types and progenitor cells. In this
chapter, the mechanisms for separation of varying cell types was explored. The physical
properties of the cells such as size, shape, electrical charge, cell stiffness, and expression
of epithelial adhesion molecules and mesenchymal proteins impact the vertical movement
and distribution in the wicking fibers. Various cross-sectional geometries of the wicking
fiber impact on cell separation were also explored. The first part of this chapter
investigated cell size and the effect of different cross-sectional geometries on cell
separation. The chapter further investigated cell mechanics of various cancer types and
progenitor cells along the fibers. The final assessment evaluated the percentage of
EpCAM expressed by the various cancer cell lines and changes in EpCAM expression
along the wicking fiber bundle construct. Preliminary work was also conducted to
investigate the mesenchymal phenotype of the cell lines by evaluating the expression of
CD44.

Impact of Cell Size and Fiber Geometry on Cell Type Separation
Materials and Methods
Cell Size
Determining Cell Size of MCF-7 and MCF-10A Cells in Suspension
This procedure evaluated the diameter of cancer and benign epithelial cells while
in cell suspension, prior to cell attachment, to mimic the cell behavior during the vertical
test using the modified wicking bundle. Cells from a mammary epithelial cell line from
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benign breast tissue, MCF-10A (ATCC), and human breast cancer cell line, MCF-7,
(ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% FBS (Gibco), 1%
Fungizone, and MEGM single quots (Lonza) and DMEM (Invitrogen) supplemented with
0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco),
10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), respectively. Cells
were cultured in a T-150 flask (Corning) and maintained in a humidified incubator at
37°C and 5% CO2. Once confluent both cell types were removed with trypsin-EDTA
solution (Sigma-Aldrich) and resuspended in culture medium. To determine the average
cell diameter, MCF-10A and MCF-7 cells were fluorescently labeled with CellTrackerTM
Green CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen; Grand Island,
NY, USA), respectively following manufacturer’s protocol using a long-term labeling
concentration of 25 μM for fluorescent imaging. Approximately 100,000 cells from each
cell line were suspended in 1 mL of growth media in separate 1.5 mL Eppendorf
microcentrifuge tubes (Sigma; St. Louis, MO USA).
The cells were mixed using the vortex to keep the cells homogeneously mixed in
solution. To determine cell diameter 100 μL of the cell solution we pipette directly onto a
microscope slide and imaged using a fluorescent microscope. Image J software was used
to determine the average diameter of each sample (n=3) from both cell lines in
suspension.
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Determining Cell Size of D1 and MC3T3-E1 Cells in Suspension
We also investigated the average cell diameter of D1 and MC3T3E1 cells in
solution prior to attaching to a surface. Mouse mesenchymal stromal cells, D1 (ATCC),
and mouse pre-osteoblast cells, MC3T3E1 (ATCC) were cultured in growth media
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM, Invitrogen) supplemented
with 10% fetal bovine serum (FBS, Gibco), 10,000 U penicillin, and 10 mg
streptomycin/mL (Sigma-Aldrich), and Minimal Essential Medium α without ascorbic
acid (Gibco) supplemented with 10% fetal bovine serum (Gibco), 10,000 U penicillin,
and 10mg streptomycin/mL (Sigma), respectively. Cells were cultured in a T150 flask
(Corning) and maintained in a humidified incubator at 37°C and 5% CO2. Once cells
were confluent, D1 and MC3T3E1 cells were detached using trypsin-EDTA solution
(Sigma) and resuspended in growth media. D1 and MC3T3E1 cells were fluorescently
labeled with CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe
(Invitrogen; Grand Island, NY, USA), following manufacturer’s protocol, respectively
using the long-term labeling concentration of 25 μM for both red and green cell tracker
was used to label the cells. Following the same procedure above, fluorescent microscopy
and Image J software were using to determine the average cell diameter for each cell line.
Cross-sectional Image of Single and Bundled Wicking Fibers
Wicking fiber bundles containing 3 individual extruded polylactide (Natureworks)
fibers of non-circular cross-sectional dimensions of 0.72 mm x 0.55 mm were sectioned
into 3 cm. The wicking fibers were dyed using a blue stain prior to embedding. Samples
were placed vertically in boxed molds and infiltrated and embedded with Embed-itTM
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Low Viscosity Epoxy Resin (Polysciences, Inc.). The wicking fiber samples were
embedded and sectioned following manufacture’s protocol. Sections, 5 μm in thickness,
were cut with a microtone and transferred to a microscope slide. The samples were
imaged with a light microscope and imaging software was used to measure and
characterize the inter- and intra- fiber spaces. To assess the cross-section of the single
fibers containing cross-sectional dimensions of 0.72 mm x 0.55 mm or 0.51 mm x 0.33
mm, the samples were sectioned and placed vertically on a microscope slide. A light
microscope was used to image the cross-section and imaging software was used to
measure the groove sizes.
Investigating the Displacement of Microbeads
To evaluate the role cell size plays in the vertical displacement along the wicking
fiber bundles, polystyrene beads of 6and 20 μm were used to mimic cells of different
sizes. The vertical wicking test was conducted with a bead solution containing beads of
both sizes and using the modified wicking bundles. The vertical movement of beads was
assessed in twisted polylactide wicking fiber bundles containing 10 individual fibers with
cross-sectional dimensions of 0.72 mm x 0.55 mm (“large fiber bundle”) or 10 individual
fibers with cross-sectional dimensions of 0.51 mm x 0.33 mm (“small fiber bundle”). The
bundles were formed by twisting the individual small or large fibers using a twisting
apparatus at 11 rotations per centimeter twist. The bundles were sliced into 3 cm long
sections to mimic the bundles used to separate cells. The alginate caps were formed on
each twisted fiber bundled by dipping one end of the wicking fiber bundle in 100 μL of 5
M CaCl2 solution (Fisher Scientific; Waltham, MA, USA) in a well of a 96-well plate and
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pipetting 100 μL of 1.4% (w/v) alginate solution comprised of alginic acid sodium salt
from brown algae (Sigma; St. Louis, MO) in 155 mM NaCl (Sigma; St. Louis, MO)
directly on the submerged fiber tip in the well. The alginate immediately adhered to the
fiber end and solidified forming the modified wicking bundle.
Following the fabrication process, the modified wicking bundles were added
vertically to a 12-well plate containing a custom-made lid to hold the samples vertical
and 1 mL of bead solution was added to a 12-well plate containing 500,000 beads of each
size. The samples were placed in the incubator at 37°C and 5% CO2 for 2 hours. After the
incubation period the samples were removed and beads were isolated from the top and
bottom regions of the wicking fiber bundle as well as the alginate cap to analyze the
amount of each bead type in each region using the flow cytometer. Similar to the cell
removal process, the alginate caps were removed and transferred to 1.5 mL Eppendorf
microcentrifuge tubes (Sigma; St. Louis, MO USA) containing 1 mL of the stock alginate
dissolution buffer. The buffer was comprised of 100mM sodium citrate (Fisher Scientific;
Waltham, MA USA), 10 mM HEPES buffer (Sigma; St. Louis, MO USA), and 27 mM
NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled water. The alginate caps were
dissolved for 30 minutes at 37°C and mixed vigorously using the vortex every 5 minutes.
The wicking fiber bundle region was sectioned with a blade into top and bottom regions
that were placed into microcentrifuge tubes containing 1 mL of PBS. The samples were
mixed using the vortex and the fibers were removed. The amount of 6 μm and 20 μm
beads in each fiber bundle region and the alginate cap were determined using Guava
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easyCyteTM flow cytometer (Guava Technologies) and InCyte software (Guava
Technologies).
Investigating Separation of MCF-10A and MCF-7 Cells in Large and Small Modified
Wicking Bundles
To further explore the effects of size on the system. The vertical test method was
conducted with benign and cancer cells using modified wicking bundles consisting of
small or large wicking fibers. The wicking fiber bundles were constructed using 10
individual fibers with cross-sectional dimensions of 0.72 mm x 0.55 mm (“large fiber
bundle”) or 10 individual fibers with cross-sectional dimensions of 0.51 mm x 0.33 mm
(“small fiber bundle”). After the bundles were twisted the samples were cleaned by
soaking in three changes of ethanol for 1 hour each, and placed under ultraviolet light for
6 hours. Samples were then soaked in a phosphate-buffered saline (PBS, Invitrogen)
solution for 2 hours and air-dried overnight in a sterile hood. The 1.4% alginate cap was
formed using the same methods previously described.
The benign breast epithelial cells, MCF-10A (ATCC), and breast cancer cells,
MCF-7, (ATCC) were cultured in DMEM (Invitrogen) supplemented with 10% FBS
(Gibco), 1% Fungizone, and MEGM single quots (Lonza) and DMEM (Invitrogen)
supplemented with 0.01 mg/mL human recombinant insulin (Gibco), 10% FBS, 1%
Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich),
respectively. Cells were cultured in a T-150 flask (Corning) and maintained in a
humidified incubator at 37°C and 5% CO2. Once confluent both cell types were removed
with trypsin-EDTA solution (Sigma-Aldrich) and resuspended in culture medium to
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prepare for vertical testing. MCF-10A and MCF-7 cells were fluorescently labeled with
CellTrackerTM Green CMFDA probe and CellTrackerTM Red CMTPX probe (Invitrogen;
Grand Island, NY, USA), respectively following manufacturer’s protocol. To detect
isolated cells from the modified wicking bundles with flow cytometer, MCF-7 cells were
labeled with 5.0 μM cell tracker red and MCF-10A cells were labeled with the optimized
cell tracker green concentration of 0.05 μM.
Both labeled cell types were seeded in each of the wells of a low attachment 12well plate with a cell density of 500,000 cells per mL. The modified wicking bundles
containing small or large fibers (n=6) were placed into each of the wells, as shown in the
experimental set-up. The well plate containing the samples was placed on flattop shaker
(VWR) at 100 rpm in a humidified incubator at 37oC and 5% CO2. The vertical
displacement of the human cancer and benign breast epithelial cells along the wicking
were determined after 2 hours of incubation, with the initial time point being fiber
placement into the cell solution.
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Figure 7.1: Experimental set-up investigating cell separation of benign and cancerous
cells in modified wicking bundles containing small or large fibers

To quantify the cancer and normal cell separation, the construct was sectioned
into top, bottom, and alginate regions and the cells were removed from each region, as
illustrated in Figure 7.1. The alginate caps were first removed from the fiber bundles and
transferred to a 1.5 mL Eppendorf microcentrifuge tubes (Sigma; St. Louis, MO USA)
containing 1 mL of the stock dissolution buffer. The buffer was comprised of 100 mM
sodium citrate (Fisher Scientific; Waltham, MA USA), 10 mM HEPES buffer (Sigma; St.
Louis, MO USA), and 27 mM NaCl (Sigma; St. Louis, MO USA) in 50 mL of distilled
water. The alginate caps were dissolved for 30 minutes at 37°C and mixed vigorously
316

using the vortex every 5 minutes. The wicking fiber bundle region was sectioned with a
blade into top and bottom regions were placed into separate wells of a 24 well plate,
Samples were rinsed with PBS and untwisted. Cells were removed by adding 500 μL of
trypsin-EDTA solution into the well with the fiber region and placing the plate on a flattop (VWR) shaker at 200 rpm in a 37oC incubator. After 15 min the cells were diluted
with 500 μL of growth media and the number of red labeled MCF-7 and green labeled
MCF-10A cells were determined from the alginate caps and top and bottom regions of
the fiber bundles using a Guava easyCyteTM flow cytometer (Guava Technologies). The
number of cancer and normal cells in each region was evaluated by following the
manufacturer’s instructions for InCyte software (Guava Technologies). MCF-7 and
MCF-10A cells of known cell densities with and without red and green tracker, were
used as positive and negative controls to calibrate the machine before measurements of
the treatment groups were made.
Statistical Analysis
JMP 10 software was used to conduct an unpaired two-sample t-test to compare
the average cell diameter of MCF-10A and MCF-7 cells, as well as, D1 and MC3T3E1
cells using a significance level of p<0.05. The same analysis was used to compare the
mean cell count of 6 μm beads in each region of modified bundles of large fibers and
modified bundles of small fibers using a significance level of p<0.05. The mean cell
count of 20 μm beads in each region of the modified bundles containing large and small
fibers was also analyzed using a two-sample t-test. The average percentage of MCF-10A
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cells in each region of the modified bundles with small fibers was compared to modified
bundles with large fibers using an unpaired two-sample t-test.
Results
Average Cell Diameter of MCF-7 and MCF-10A Cells
To determine the cell diameter, benign and cancerous cells were labeled with
green and red cell tracker. The fluorescent label uniformly stains the cytoplasm as shown
in Images A and B of Figure 7.2. The fluorescent images were processed using Image J
software to determine the average cell diameter for each cell in the image. The average
diameter of the MCF-10A cells (~16 μm) was significantly larger than the average
diameter of the MCF-7 cells (~ 11 μm), shown in Image C. It is important to note within
cancer cell lines there are variances in cell size and shape.
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Figure 7.2: Fluorescently green labeled MCF-10A cells (A) and red labeled MCF-7 cells
(B) suspended in growth media. (C) The average diameter of the benign MCF-10A cells
is significantly larger than the cancerous MCF-7 cells, (*) indicate significant difference,
p<0.05

Average Cell Diameter of D1 and MC3T3E1 Cells
The average cell diameter of mesenchymal stromal cells and pre-osteoblasts were
also analyzed and compared. The fluorescent images depict the MC3T3E1 cells labeled
red (image A) have larger cell diameters than D1 cells labeled green (Image C). The
semi-quantitative results showed the D1 cells with average diameter of 11 am were
significantly smaller than the MC3T3E1 cells with an average diameter of 14 μm.
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Figure 7.3: Fluorescently red labeled MC3T3E1 cell and green labeled D1 cells
suspended in cell solution (C) The average cell diameter of D1 cells is significantly
smaller than the MC3T3E1 cells

Cross-sectional Analysis of Wicking Fibers and Bundles
The cross-sectional images of the individual small and large fibers are depicted
Images A and B of Figure 7.4. Using Image J software, the long and short axes of the
small fiber were 0.51 mm and 0.33 mm and the large fiber were 0.72 mm and 0.55 mm,
respectively. The groove sizes were also determined by measuring the length using Image
J software. The groove sizes for the small fiber ranged from 20 μm to 82 μm and the
large fiber groove sizes ranged from 34 μm to 150 μm. Histological processing was used
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to evaluate the cross-section of the wicking fiber bundle. Prior to sectioning a blue dye
was used to coat the fiber bundle. The cross-sectional image in Figure 7.4 shows blue dye
in between the grooves of the fibers as well as the inter-fiber spaces between the wicking
fibers. The image depicts a range in sizes of the micro channels along the bundle. The
twisting configuration of the bundles distorts the grooves and spaces into channels
smaller than along the single fiber. This suggests the small channels may prevent the
large cell types from penetrating the top region of the fiber bundles.
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Figure 7.4: (A) Section of polylactide wicking fiber bundle depicts a range of inter- and
intra- fiber spaces (B) and (C) depicts cross-sectional images of two different sized
polylactide fibers
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Bead Wicking Distribution in Modified Wicking Bundles
To investigate the role of size on the wicking behavior of cells through the
system, beads of 6 and 20 μm were used to mimic cells of varying size. The distribution
of the beads along the modified wicking bundles was investigated in bundles comprised
of small or large cross-sectional fibers. The various bundles containing different sized
fibers were used to explore the effect of fiber size on the bead movement. Beads were
isolated from the top and bottom regions of the fibers and from the alginate cap. The
results, Figure 7.5, show the forward scatter versus side scatter plot can be effectively
used to quantify the number of each bead type. Since the beads are different sizes, the
plots for each bead size were clearly distinguished (Image A). The scatter plots of the
beads isolated form the bottom region depict significantly more 6 μm sized beads than 20
μm beads for both large and small modified wicking bundles. The alginate and top region
showed more 6 μm beads in the modified constructs containing small fibers. Minimal 20
μm beads are detected in these regions for both fiber types.
The bead count was determined using the InCyte software and presented in the
graph below, Figure 7.5. Both large and small modified wicking bundles show
significantly more 6 μm beads in each region than the larger 20 μm beads (Image A). The
top and bottom regions of the small wicking bundle contained significantly more 6 μm
sized beads than the large wicking bundle. The percentage of the 6 μm beads in each
region was similar for large and small fiber bundle constructs (Image B).
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Figure 7.5: Bead wicking analysis with flow cytometry (A) Scatter plots showing the
regions of the 6 μm (right) and 20 μm beads
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Figure 7.6: Flow cytometry analysis of 6 μm and 20 μm diameter beads in alginate
modified fibers containing small or large individual fibers. (A) Both constructs showed
significantly more 6 μm diameter beads in each region than the 20 μm beads. The
modified fiber bundle containing the smaller bundles contained significantly more 6 μm
beads in the top and bottom regions of the fiber bundle than the modified construct
containing larger cross-sectional fibers. (B) The modified large and small fiber
constructs showed comparable percentages of both bead types in each region of the fiber
bundle and the alginate cap

Investigating Separation of MCF-10A and MCF-7 Cells in Large and Small Modified
Wicking Bundles
This study investigated the effect of the cross-sectional size of the wicking fiber
on the cell separation of benign and cancer cells. Modified wicking bundles of small and
large individual fibers were used to test the vertical cell wicking of MCF-7 and MCF325

10A cells. The flow cytometry results, Figure 7.7, show comparable cell counts (Image
A) and percentages (Image B) of cancerous and benign cells in the alginate cap and
bottom region of the fiber for both modified wicking bundles containing large or small
fibers. The top region of the bundles containing large wicking fibers showed significantly
more MCF-10A cells than the bundles containing small wicking fibers. The scatter and
fluorescent intensity plots from the flow cytometry analysis from each region presented
in Figure 7.8 show for both large and small modified wicking bundles significantly less
cells were removed from the top region of the fiber bundle and the alginate cap. The lack
of cells in these regions is due to the cell removal processing methods. Further work
needs to investigate alternate methods to improve the removal of cells.

Figure 7.7 (A) Cell count in each region of the modified small and large wicking bundles.
The alginate cap and bottom region of the wicking fiber bundle show similar cell counts
of both cell types. The top region of the smaller fiber depicted significantly less MCF-10A
and MCF-7 cells than the top region of the modified large fiber construct. (B) Percentage
of each cell type in each region of the modified small and large wicking fiber constructs.
The alginate cap and bottom fiber region show similar percentages of benign and cancer
cells for both large and small fiber bundles. The percentage of MCF-10A cells in the top
region of the large fiber bundle is significantly greater than the small fiber bundle.
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Figure 7.8: Scatter and fluorescent intensity plots of benign and cancer cells in each
region of the alginate modified construct. (A) Bottom region of modified small bundles
(left) shows comparable amounts of benign and cancer cells as the modified large
bundles (right). (B) Top region of modified small bundles (Left) show less cell
penetration and less green labeled benign cells than the modified large bundle construct
(Right). (C) Alginate cap from modified small bundle construct shows comparable
amounts of cancer and benign cell in large bundle construct.

Investigating Cytoskeletal Arrangement and Protein Expression along the Modified
Wicking Bundles
Materials and Methods
Cell Culture
The cytoskeleton arrangement was investigated for various cancer types as well
as mouse progenitor and pre-osteoblast cells. Benign epithelial cells, MCF-10A
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(ATCC), and human breast cancer cells, MCF-7 (ATCC), were cultured in DMEM
(Invitrogen) supplemented with 10% FBS (Gibco), 1% Fungizone, and MEGM single
quots (Lonza) and DMEM (Invitrogen) supplemented with 0.01 mg/mL human
recombinant insulin (Gibco), 10% FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and
10 mg streptomycin/mL (Sigma-Aldrich), respectively. Metastatic breast epithelial cells,
MDA-MB-231 (ATCC) were cultured in DMEM (Invitrogen) supplemented with 10%
FBS, 1% Fungizone (Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (SigmaAldrich). Mouse mesenchymal stem cells, D1 (ATCC), and mouse pre-osteoblast cells,
MC3T3E1 (ATCC) were cultured in growth media consisting of Dulbecco’s Modified
Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS,
Gibco), 10,000 U penicillin, and 10 mg streptomycin/mL (Sigma-Aldrich), and Minimal
Essential Medium α without ascorbic acid (Gibco) supplemented with 10% fetal bovine
serum (Gibco), 10,000 U penicillin, and 10mg streptomycin/mL (Sigma), respectively.
Immunofluorescence Staining for Actin Cytoskeleton and Vinculin
Staining for vinculin and actin cytoskeleton was performed on both the modified
wicking bundles after conducting the vertical test with cell solutions, as well as cells
seeded directly on a glass coverslip. Prior to staining along the wicking fiber bundles, 1
mL containing 500,000 cells from each cell line being investigated was seeded in a lowattachment 12-well plate. The modified wicking bundle was used to conduct the vertical
test method as previously described. After two hours of incubation the modified wicking
bundles were removed and prepared for staining. Cells were also seeded at a density of
100,000 cells per mL on a glass cover slip in a 24-well plate. The cytoskeleton
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organization was evaluated for MCF-10A and MCF-7 cells along the modified wicking
bundle after performing the vertical test with both cell lines mixed in each well.
Fluorescent images of the actin and vinculin were captured in the bottom, middle, and top
regions of the bundle. This procedure was also performed to investigate cell mechanics of
MCF10A and MDA-MB-231 along the fiber. D1 progenitor cells and the MC3T3E1 preosteoblast cells were analyzed, however, these cell lines were not mixed and each cell
line was analyzed separately along the construct. The table below presents the different
cell line groups that were used to investigate cell cytoskeletal arrangement. All cell lines
investigated along the modified wicking bundle were also analyzed on a glass slide.
Table 7.1: Cell lines investigated
Cell lines assessed along the modified
wicking bundle
MCF-10A and MCF-7
MCF-10A and MDAMB-231
D1
MC3T3E1

Cell lines analyzed on glass slides
MCF-10A
MCF-7
MDA-MB-231
D1
MC3T3E1

Prior to the actin and vinculin staining, the samples were washed with PBS and
fixed in 10% formalin for 20 minutes. Formalin was removed and samples were further
rinsed in PBS. To stain for actin and vinculin, samples were blocked for 1 hour using
blocking solution containing 2% BSA (Sigma; St. Louis, MO, USA), 5% goat serum
(Sigma), and 0.1% triton X (ThermoScientific; Rockford, IL). The blocking solution was
removed and the samples were washed with PBS. To prevent auto-fluorescence from the
polylactide fibers, the samples were blocked in 1% (w/v) sodium borohydride (Sigma; St.
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Louis, MO) in PBS and incubated at room temperature for 30 minutes. The sodium
borohydride was removed and the samples were washed extensively with PBS for 30
minutes. Following the blocking step, the samples were incubated overnight at 4°C with
the vinculin primary antibody (mouse anti-rabbit; Abcam; Cambridge, MA, USA) using a
1:200 dilution. After the overnight incubation, the primary was removed and stored for
later use. The samples were gently washed with PBS and incubated in 500 μL of solution
containing Alexa Fluor 488 phalloidin (Invitrogen; Grand Island, NY) using a 1:20
dilution, and Alexa Fluor 568 goat anti-rabbit antibody (Molecular Probes; Grand Island,
NY, USA) using a 1:500 dilution for two hours at room temperature. Following the two
hour incubation the phalloidin and secondary antibody solution was removed and 1 mL
of a 2 mg/mL Hoechst 33342 solution (Thermo Scientific; Rockford, IL) was added to
the samples and incubated for 5 minutes at room temperature. Samples were rinsed with
PBS and stored at 4°C. To analyze cell cytoskeletal arrangement, images were obtained
from each region of the fiber bundle using fluorescent microscopy (EVOS; Floid Cell
Imaging Station, Life Technologies); Image J imaging software was used to overlay
images.
Immunofluorescence Analysis of EpCAM and CD44
EpCAM expression of the MCF-10A, MDA-MB-231, and MCF-7 cells was
investigated along the modified wicking bundles. MCF-7, MCF-10A, and MDA-MB-231
cells were cultured and plated in low-attachment 12-well plate. Six wells were plated
with MCF-7 and MCF-10A cells at a cell density of 500,000 cells per mL. The remaining
six wells were seeded with MD-AMB-231 and MCF-10A cells at the same cell density.
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The vertical test using the modified wicking bundles was performed. After 2 hours, the
samples were removed and prepared for immunofluorescence staining. To investigate the
amount of EpCAM and CD44 expressed by each cell type the cells were also individually
plated at 20,000 cells per well on glass slides in a 24-well plate.
Immunofluorescence staining for EpCAM was performed on the modified
wicking bundles. Both EpCAM and CD44 expression was investigated on the cancer
cells plated on the glass slides. To stain for EpCAM and CD44 samples were blocked for
1 hour using blocking solution containing 2% BSA (Sigma; St. Louis, MO, USA), 5%
goat serum (Sigma), and 0.1% triton X (ThermoScientific; Rockford, IL). The blocking
solution was removed and the samples were washed with PBS. To prevent autofluorescence from the polylactide fibers, the samples were blocked in 1% (w/v) sodium
borohydride (Sigma; St. Louis, MO) in PBS and incubated at room temperature for 30
minutes. The sodium borohydride was removed and the samples were washed extensively
with PBS for 30 minutes. Following the blocking step, the samples were incubated
overnight at 4°C with the primary antibody EpCAM (mouse anti-rabbit; Abcam;
Cambridge, MA USA) using a 1:200 dilution or with the primary antibody CD44 (rabbit
anti-human; Life Technologies; Grand Island, NY USA). After the overnight incubation,
the primary was removed and stored for later use. The samples were gently washed with
PBS and incubated in 500 μL of solution containing the secondary antibody Alexa Fluor
488 goat anti-rabbit antibody (Invitrogen; Grand Island, NY) using a 1:500 dilution, or
Alexa Fluor 568 goat anti-rabbit antibody (Molecular Probes; Grand Island, NY, USA)
using a 1:500 dilution for two hours at room temperature. Following the two hour
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incubation, the secondary antibody solution was removed and 1 mL of a 2 mg/mL
Hoechst 33342 solution (Thermo Scientific; Rockford, IL) was added to the samples at a
and incubated for 5 minutes at room temperature. Samples were rinsed with PBS and
stored at 4°C. Fluorescent images of EpCAM expression along the fibers were obtained
from each region of the fiber bundle using fluorescent microscopy (EVOS; Floid Cell
Imaging Station, Life Technologies). Both EpCAM and CD44 expression was imaged for
each cell line that was cultured on a glass cover slide. Image J imaging software was used
to overlay images.
Flow Cytometry Analysis of EpCAM Expression along Fibers
Prior to EpCAM expression analysis by flow cytometry, the vertical test was
conducted along the modified wicking bundles using a cellular mixture of MCF-10A and
MDA-MB-231, or a mixture of MCF-10A and MCF-7 cells with all cell types seeded at
500,000 cells. Immediately after the vertical test, the samples were removed, transferred
to a 6-well plate, and washed with PBS. The cells were stained for EpCAM prior to the
removal from the modified wicking bundle. To stain for EpCAM, samples were
incubated for 30 minutes at 4°C in 1 mL of primary antibody solution containing 5% goat
serum (Sigma) and the primary antibody EpCAM (mouse anti-rabbit; Abcam;
Cambridge, MA USA) using a 1:200 dilution. Following incubation, the samples were
gently washed with PBS and incubated in 1 mL of solution containing the secondary
antibody Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen; Grand Island, NY) using
a 1:500 dilution for 30 minutes at room temperature. Samples were rinsed in PBS and
cells were removed from each region of the construct following previous procedures and
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resuspended in 500 μL of PBS for flow cytometry analysis. Positive and negative
controls for each cell line were prepared by seeding 100,000 cells in microcentrifuge
tubes. The positive controls from each cell line were rinsed with PBS and stained for
EpCAM using the procedure described above. The negative controls were left unstained.
The amount of EpCAM expression in each region of the modified wicking bundle
was analyzed using a Guava easyCyteTM flow cytometer (Guava Technologies) and by
following the manufacturer’s instructions for InCyte software (Guava Technologies). The
green intensity plots were used to determine the amount of cells expressing EpCAM in
each of the regions.
Results
Exploring Cell Mechanics of Cancer Cell Lines along Fibers
The actin and vinculin arrangement of each cancer line was investigate both on a
2-dimensional glass cover slide, as well as, along the modified wicking bundle. Figure
7.9 depicts the actin and vinculin arrangement of the cell lines tested along the wicking
fibers. The MCF-7 cell lines (Image A) portray a rounded morphology with actin fibers
primarily unorganized and circumferentially localized. MCF-10A show more aligned
actin stress fibers along the periphery of the cell (Image B). MDA-MB-231 cells (image
C) depict the fibril actin abundantly distributed around the cells with a more overall
organized fiber arrangement. Both MCF-10A and MDA-MB-231 cells show less rounded
morphology with more a more spindle shape appearance.
The morphology and cytoskeletal arrangement of benign, MCF-10A, and
cancerous cells, MCF-7 was explored along the bottom, middle, and top regions of the
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modified wicking bundles. Figure 7.10 depicts the cytoskeletal architecture of the cells
after wicking through the bundle. The cancer cells present a rounded morphology with
actin concentrated along the periphery in all regions of the bundle. This morphology
suggests the cancer cells are tethered to the surface and are not spreading out on the
fibers. The cell morphology of metastatic cancer, MDA-MB-231, and benign, MCF-10A,
cells was also investigated along the wicking fibers after the cell mixture was wicked
through the modified wicking bundle, Figure 7.11. The outcomes show similar rounded
morphology in all regions of the fiber bundle. However, in comparison to the MCF-7 and
MCF-10A separation, the MDA-MB-231 cell displacement through the fibers shows less
cell-cell contact with more individual cell movement through the conduits.
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Figure 7.9: Actin cytoskeletal and vinculin arrangement of the various cancer types (A)
MCF-7 non-metastatic cancer cells show weak actin cytoskeleton lacking fiber
arrangement (B) MCF-10A benign cells show actin fibril arrangement with alignment
along the periphery of the cell. Benign cells depict vinculin expression concentrated in
central region of cells. (C) MDA-MB-231 cells depict more actin fiber arrangement
compared to the other cell lines. Images show distinct actin fibers along the periphery
and central regions of the cell.
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Figure 7.10: The actin and vinculin arrangement of MCF-7 and MCF-10A cells along
the modified wicking fiber construct (A) Bottom region of the wicking fiber bundle shows
the actin fibers are arranged along the periphery forming an outer shell. (B) Middle
region of the wicking fiber bundle shows clumps of cells with round morphology (C) Top
region of wicking fiber bundle depicts the same rounded morphology of the cells

336

Figure 7.11: Cytoskeletal architecture of MDA-MB-231 cells along the modified wicking
fiber construct. (A) Cells in bottom region of construct depict rounded morphology with
actin concentrated along the periphery. The middle region (B) and top region (C) of the
modified construct shows the same rounded morphology.
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Exploring Cell Mechanics of Mesenchymal Stem Cells and Pre-Osteoblasts along the
Fibers
The cell cytoskeletal architecture of mouse mesenchymal stem cells and mouse
pre-osteoblasts was analyzed after attachment to a glass slide and wicking through the
modified wicking bundle. Figure 7.12 depicts the fluorescent images of the actin
cytoskeleton arrangement for D1 (Image A) and MC3T3E1 cells (Image B). The D1
cells depict a fibroblast-like morphology with a more spindle-like shape. In
comparison, the MC3T3E1 cells also depict a more fibroblast morphology with greater
actin fiber alignment, suggesting the pre-osteoblasts have a stronger cytoskeleton.
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Figure 7.12: (A) Actin arrangement of D1 mouse mesenchymal stem cells show
fibroblast-like morphology with actin fiber formation predominantly on the periphery of
the cell. (B) MC3T3E1 pre-osteoblast cells depicts a less spindle shaped morphology
with more actin fiber formation within the cell

The D1 and MC3T3E1 cell movement along the fibers after the vertical wicking
test is depicted in Figure 7.13. The MC3T3E1 cells show greater cell attachment to the
fibers with a more spread-out actin cytoskeleton along the bottom and middle regions
of the fiber bundles. The D1 cells show a more rounded morphology along each of the
regions with less cell attachment.
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Figure 7.13: (A) Pre-osteoblast cells and (B) D1 cells along the top region of the wicking
fiber bundle show the pre-osteoblasts have a less rounded morphology and more spreadout along the fiber. (C) Pre-osteoblast and (D) D1 cells in the middle region depict the
pre-osteoblast have adhered more to the fiber compared to the rounded shape of the D1
cells. The pre-osteoblasts (E) and D1 cells (F) both show more rounded morphology in
the top regions of the fiber
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EpCAM Expression of Cancer Cell Lines along the Fibers
Each cancer cell line was cultured on a glass plate and analyzed for EpCAM
expression using immunofluorescence. Figure 7.14 illustrates the levels of EpCAM
expression for each cell line. MCF-7 cells showed high levels of EpCAM expression
(Image A). Both MCF-10A (Image B) and MDA-MB-231 cells (Image C) demonstrated
low levels of EpCAM.
A mixture of MCF-10A and MCF-7 were used to conduct the vertical wicking
test. After the cells wicked into the modified wicking bundle, the EpCAM expression was
investigated along each region of the fiber bundles using both immunofluorescence and
flow cytometry. The immunofluorescence results show some expression of EpCAM in
the bottom region of the fiber bundle, Figure 7.15. The middle (and top regions of the
fiber bundles depict higher percentages of EpCAM expression. This is due to the greater
penetration of MCF-7 cells to these regions. The flow cytometry results showed similar
results, Figure 7.18. Higher percentages of cells expressing EpCAM were found in the
top region of the wicking fiber bundle and alginate cap (Image A). The scatter and
intensity plots depict EpCAM expression in each region of the construct (Image B). The
higher percentage of EpCAM expression in the top region and alginate cap correlates to
the greater number of MCF-7 cells that wick to these regions.
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Figure 7.14: EpCAM expression (Green fluorescence) of each cancer cell line (A) MCF7 cells show high expression of EpCAM (B) MCF-10A cells and (C) MDA-MB-231 show
low expression of EpCAM
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Figure 7.15: EpCAM expression (Tagged with red-fluorescent secondary antibody) of
MCF-7 and MCF-10A cells in the bottom region of the wicking fiber bundle
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Figure 7.16: EpCAM expression of MCF-7 and MCF-10A cells along central region of
wicking fiber bundle
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Figure 7.17: Depicts high percentage of EpCAM expression in top region of the wicking
fiber bundle
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Figure 7.18: Flow cytometry analysis (A) Percentage of cells expressing EpCAM (B)
Scatter and intensity plots of EpCAM expression from each region
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The EpCAM expression was also investigated along modified wicking bundles
after MCF-10A and MDA-MB-231 cells were processed through the vertical test. The
fluorescent images of the modified wicking bundle (Figure 7.19) depict low EpCAM
expression in all regions. As indicated previously both MCF-10A and MDA-MB-231 cell
lines show minimal EpCAM expression. The EpCAM expression from the top and
bottom regions of the modified wicking bundle was quantified using flow cytometry. The
scatter and intensity plots of the control groups showed low EpCAM expression for both
MCF-10A and MDA-MB-231 cells. Cell isolated from the top and bottom regions of the
bundle showed low expression of EpCAM, approximately 10%. The EpCAM expression
of MDA-MB-231 cells mixed with benign cells along the fiber bundles was significantly
lower than MCF-7 mixed with benign. The results suggest the modified wicking bundle
can separate cancer cells that expressing EpCAM, such as MCF-7 cells, into the top
region of the wicking fiber bundle and alginate cap. Conversely, metastatic cancer cells
often lack EpCAM expression and are still captured in the top region of the fiber bundle
and the alginate cap. The outcomes imply EpCAM expression may play a role in cancer
cell type separation along the fibers, but further investigation is needed. Preliminary
works has also investigated expression of other proteins along the modified wicking
bundle to determine if this separation device can be used to isolate subpopulations of
cancer cells within cell lines. CD44 expression was assessed between each of the cell
lines. High expression of this marker has been used to define metastatic cancer cells, as
well as, breast cancer stem cells that are tumorigenic and can differentiate, propagating a
heterogeneous tumor. Figure 7.21 depicts CD44 expression from benign, cancerous, and
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metastatic cancer cell lines. The MDA-MB-231 and MCF-10A cells show high
expression of CD44, and the MCF-7 cells show low expression. Future work involves
investigating expression of CD44 and other tumorigenic protein markers along the fibers
to optimize the system to distinguish cancer cells of varying phenotypic expression.
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Figure 7.19: Depicts low EpCAM expression (tagged with green fluorescent secondary
antibody) of MCF-10A and MDA-MB-231 cells in bottom (A), middle (B), and top
regions (C) of the wicking fiber bundle.
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Figure 7.20: Flow cytometry analysis of EpCAM expression along top and bottom
regions of wicking fiber bundle (A) Percentage of cells expressing EpCAM in top and
bottom regions of wicking fiber (B) MCF10A control group shows low expression of
EpCAM (C) MDA-MB-231 group depicts almost no EpCAM expression
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Figure 7.21: Levels of CD44 expression of the various cancer cell lines (A) MCF-7 show
low CD44 expression (B) MCF10A and (C) MDA-MB-231 cells show high levels of
CD44 expression
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Discussion
The first part of this chapter explored the role of cell size as a major factor in cell
separation between different cell types. The outcomes showed that there are differences
in cell size of the various cell types that were separated along the modified wicking fiber
construct. Interestingly, the MCF-7 cancer cells and D1 cells were both similar in cell
size, and significantly smaller than the benign MCF-10A and MC3T3E1 pre-osteoblast
cells. The increased travel of the smaller cell types, D1 and MCF-7 cells suggest cell size
may play a major role in separation along the fiber construct. Beads of 6 and 20 μm were
used to mimic cells of different sizes in modified wicking fiber constructs containing
small or large wicking fiber bundles. The outcomes showed approximately 90% of the
bead populations in each region were the 6 μm sized beads for both types of modified
wicking fiber constructs.
The results confirm the size of the cell will play a role in the modified wicking
fiber construct. It also reveals using bundles with individual wicking fibers of larger
cross-section does not increase the amount of large beads into the system. The larger
cross-sectional fibers consist of larger individual grooves along the fiber, providing
conduits with larger diameters. Laplace equation, shown below, describes the capillary
pressure generated in a capillary with a defined radius. According to Laplace equation the
larger the diameter of the capillary the less capillary pressure is generated16.

352

Equation 7.1: 𝐿𝑎𝑝𝑙𝑎𝑐𝑒 𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛
𝑃𝐶𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 =

𝛾𝐿𝑉 𝑐𝑜𝑠𝜃
𝑅𝑐

𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦
𝛾𝐿𝑉 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛 𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑙𝑖𝑞𝑢𝑑 𝑎𝑛𝑑 𝑎𝑖𝑟

The maximum liquid height reached is also inversely proportional to the radius of the
conduits. Jurin’s law describes the maximum height reach along a capillary when the
pressure reaches equilibrium17.
Equation 7.2: Jurin’s Law
𝐻𝑀𝑎𝑥𝑖𝑚𝑢𝑚 =

2𝛾𝐿𝑉 𝑐𝑜𝑠𝜃
𝜌𝑔𝑅𝑐

𝜃 = 𝑐𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑

The larger wicking fiber bundles consist of larger grooves or conduits with lower
capillary pressure that will influence the vertical wicking behavior. The outcomes showed
the modified wicking bundle containing the small groove sizes contained significantly
more 6 μm beads than the bundles with larger groove sizes. The bundled fibers of smaller
groove sizes create smaller capillaries that produce greater capillary pressure to transport
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the bead solution vertically through the bundle. Although the modified wicking bundles
contained different sized fibers, the amount of tension used to twist the fibers remained
the same. The twist of the fibers will create pores or inter-fiber spaces between the fibers.
The tension of the twist will result in different pore sizes. High tension can affect the
continuity and reduce the radius of the capillaries between the fibers. Hajian and
coworkers demonstrated twisted fibers of the same diameter with different twist rates
exhibit different wicking behaviors. This group showed increased twisting results in
smaller inter-fiber spaces reducing the effective radius as well as the continuity causing a
reduction in the rate of capillary rise17. The twisting of the larger fibers in our system
may have caused discontinuities along the fiber inhibiting the wicking action in some of
the conduits. Although the larger conduits will decrease capillary pressure and the
maximum height reached, increased pore size generated from the inter-fiber spaces will
actually increase the rate of capillary action. This is described by the Lucas Washburn
equation, which is determined by integrating the Hagen-Poiseuille equation that describes
liquid capillary rise, shown below16–18.
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Equation 7.3: Hagen-Poiseuille Equation
𝒅𝒉
𝒓𝟐
𝒓𝟐 𝟐𝜸𝒄𝒐𝒔𝜽
=
𝚫𝐏 =
(
− 𝝆𝒈𝒉)
𝒅𝒕 𝟖𝜼𝒉
𝟖𝜼𝒉
𝒓
𝜃 = 𝐶𝑜𝑛𝑡𝑎𝑐𝑡 𝑎𝑛𝑔𝑙𝑒
𝑅𝑐 = 𝑅𝑎𝑑𝑖𝑢𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦
𝛾 = 𝑆𝑢𝑟𝑓𝑎𝑐𝑒 𝑡𝑒𝑛𝑠𝑖𝑜𝑛
𝜌 = 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑
𝜂 = 𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑣𝑖𝑠𝑐𝑜𝑠𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑙𝑞𝑖𝑢𝑖𝑑
ℎ = 𝐻𝑒𝑖𝑔ℎ𝑡 𝑟𝑒𝑎𝑐ℎ𝑒𝑑 𝑏𝑦 𝑙𝑖𝑞𝑢𝑖𝑑 𝑏𝑦 𝑡𝑖𝑚𝑒 𝑡
Δ𝑃 = 𝑃𝑟𝑒𝑠𝑠𝑢𝑟𝑒 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒

Equation 7.4: Lucas – Washburn Equation
𝒉𝟐 =

𝒓𝜸𝒄𝒐𝒔𝜽
𝒕 = 𝒌𝒕
𝟐𝜼

𝑘 = 𝑐𝑎𝑝𝑖𝑙𝑙𝑎𝑟𝑦 𝑟𝑖𝑠𝑒 𝑟𝑎𝑡𝑒 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡

The Lucas-Washburn equation demonstrates the larger pore sizes between the
fibers, the less resistance due to fiber and liquid interfaces increasing the liquid rate17,19.
The twisting of the bundles can control the pore size. The larger the pore size the faster
the fluid can fill and the more fluid can be absorbed by the construct16,17. The small and
large modified wicking bundles were used to compare the wicking separation of MCF10A and MCF-7 cells. The bundles showed similar cell counts and percentage of cell
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types in each region. The larger fiber, however, showed increased MCF-10A cells in the
top region. The increased number of cells in this region can be a result of the larger pore
sizes. The benign cells were shown to be larger than the MCF-7 cells in a suspended
solution. The larger pore sizes along the modified large fiber bundle has less liquid-fiber
action allowing larger cells to fit through and travel with the liquid through the pores.
Future work will investigate the various bundling configurations and tension rates to
increase the wicking rate, as well as, the amount of capillary pressure generated to
increase the amount of cells in the top regions of the fiber and with alginate cap. The
system can be optimized to determine an effective cross-sectional size and twist rate to
enhance the rate of separation and improve the separation and isolation of non-metastatic
and metastatic cancer cell types.
This chapter also investigated the role of cell morphology and cytoskeletal
arrangement of various cell types on their wicking behavior along the modified wicking
bundles. The immunofluorescence staining of the cytoskeletal components on a 2dimensional surface showed the cancer cell types had different morphology and actin
arrangement. The non-metastatic cancer cells showed the least disorganized actin
arrangement with a round morphology. Both the benign cells and metastatic cancer cells
showed a more spindle shaped phenotype with more actin fiber arrangement. The
difference in cell morphology is a factor of cell origin. MCF-10A and MDA-MB-231
cells are both basal epithelial cells and MCF-7 cells are luminal. Generally, basal type
cells show a more spindle mesenchyme-like morphology and luminal cells show a more
cobblestone appearance20. Although the MCF-10A and MDA-MB-231 cells illustrated a
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more spindle-like morphology the cytoskeletal arrange will greatly impact the cell
mechanics of the cell. The fibrous actin organization, as well as, microtubule structure
will affect the cell stiffness or deformability of the cells. The metastatic cancer cells are
shown to be more deformable than both cancerous and benign cells. Guck and coworkers
measured optical deformability of MCF-7, MCF-10A, and MDA-MB-231 cells. The
metastatic cancer cells deformed more than both non-metastatic cancer cells MCF-7 and
benign MCF-10A cells21. The increased deformation and reduction of cytoskeletal
strength of the metastatic cancer cells correlates to their ability to squeeze through tissue
to reach the blood stream and penetrate other tissue21,22. The cancerous cells, however,
showed significantly more deformation than the MCF-10A cells. The degree of
deformability of the cell has been correlated with metastatic potential. Other groups have
developed microfluidic systems to isolate circulating tumor cells using the ability of
cancer cells to deform. These systems include arrays, posts, or channels in combination
with a hydrodynamic force to deform the cells through the size-limited barriers to isolate
the more flexible cancer cells, which are also considered to have more metastatic
potential12. Biomechanical measurements from atomic force microscopy (AFM) and
optical tweezer measurements confirm the cell stiffness of cancer cells are significantly
softer than normal cells, relating to the cancer cell’s increased deformability and
metastatic potential 11,12. The ability of MCF-7 and MDA-MB-231 cells to deform may
play a significant role in their ability to wick along the wicking fiber bundles. The
cytoskeletal arrangement of the cancer cells along the wicking fiber bundles showed
mostly round morphology. The images showed cancer cells tethered along the fibers with
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very minimal cell spreading. This suggests cell morphology may play less of a role in cell
separation in our system. The staining along the fibers containing MCF-7 and MCF-10A
cells showed clusters of cells within the bundles of the fiber. The staining of MDA-MB231 and MCF10A cells showed more individual cell movement with significantly less
clusters. The clumping and moving of cells as clumps is characteristic migratory behavior
of both MCF-10A and MCF-7 cells. Metastatic cancer cells, MDA-MB-231, migrate
individually, which is characteristic for a mesenchyme-like cell. Regardless of the
clusters shown, each of the cancer cell lines investigated showed a round phenotype
along the fiber. In addition to cell morphology, cell adhesion can play a role. Chen and
coworkers investigated cancer cell separation based on the cell adhesion to a substrate
and found cancer cell types will adhere preferentially23,24. Further work can investigate
the cell adhesion strength along the wicking fibers of the various cell types and the
effects of modifying surface topography on cell wicking behavior. The outcomes of this
work show cell size and cell deformability may play greater roles in the mechanism for
cell wicking than cell morphology.
The mouse mesenchymal stem cells and pre-osteoblast cells depicted
morphological differences. The D1 stem cells showed weaker actin alignment and fiber
formation compared to the more differentiated MC3T3E1 cells. Titushki and coworkers
investigated cellular mechanic changes during cell differentiation. This group found
changes in the cell mechanics of progenitor cells as they differentiate into bone cells25.
Furthermore, stem cells have been shown to be highly deformable12. The thick bundle
actin shown in the fluorescent image of the MC3T3E1 cells suggests the cells are less
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deformable with higher cells stiffness. Further work will need to investigate the
deformability of D1 cells and MC3T3E1 cells, but the outcomes suggest the D1 cells are
more deformable and this characteristic may explain the high cell densities of D1 cells in
the top region and alginate cap of the modified bundle. The D1 cells showed a similar
round morphology as the cancer cells along the wicking fiber bundles. Interestingly, the
MC3T3E1 cells depicted a more fibroblast morphology along the bottom and middle
regions of the fibers. The pre-osteoblasts showed cell attachment and spreading along the
grooves. The high actin fiber arrangement of the MC3T3E1 cells may limit deformability
of the cell causing minimal penetration into the bundle. The pre-osteoblasts also show
higher adhesion preference to the wicking fibers. The topography of the wicking fibers
was shown to have a rough surface. The pre-osteoblasts may have a greater affinity to
adhere to the rough surface than the D1 progenitor cells. This is reflected by the low
amount of cells in the top regions of the fibers and the increased adherence and cell
spreading of the pre-osteoblasts along the bottom regions of the fibers.
The standard for isolating CTCs involves isolating cells based on the expression
of EpCAM and/or cytokeratin and the negative expression of CD45. The only FDA
approved technology to isolate CTCs from blood biopsy samples is the CellSearch
system (Verdex, USA). This system isolates cells expressing EpCAM using an
immunomagnetic approach26. The major limitation of these EpCAM based systems is the
specificity for one type of cancer cell. Cancer cells of high metastatic potential have been
defined with negative EpCAM expression and high expression of mesenchymal markers.
Circulating tumor cells are transient and may transition into mesenchymal phenotypes by
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a process called epithelial-mesenchymal transition (EMT)27. In this conversion, cells lose
epithelial markers, such as EpCAM, and express mesenchymal markers, resulting in a
more aggressive, motile cell type. Aggressive CTC populations with mesenchymal
phenotype in the bloodstream are missed by these conventional technologies 4–8. Tumorinitiating cells with high metastatic potential are a small subpopulation of cancer cells
that have been defined by CD44+ and CD24-. In this work we investigated EpCAM
expression along the modified wicking bundle. EpCAM expression was analyzed in each
region after separation of MCF-10A and MCF-7 cells. The results for this study showed
higher percentages of EpCAM expression in the top region and alginate cap, because of
high percentages of MCF-7 cells wicking to these regions. This suggests the construct
can separate cancer cells expressing EpCAM. However, low expression of EpCAM was
observed along the construct for cell separation of MCF-10A and MDA-MB-231. Since
both cancer cell lines MCF-7 and MDA-MB-231 were observed in the top region of the
fiber bundle and the alginate cap, EpCAM expression may not play a role in the
mechanism for separation. However, the outcomes show cells expressing EpCAM are
captured in the top region and alginate cap of modified fiber construct. Preliminary work
investigated CD44 expression of each cancer cell line used. The results showed the
different cancer types contain varying expression of CD44. Further work will investigate
the expression of CD44 and CD24, markers of highly metastatic cancer cells along the
fibers. The goal of the system is to isolate and distinguish between cancerous and
metastatic cancer cells. We have shown the modified wicking bundle will separate both
non-metastatic and cancerous cell types from benign cells. However, further work is
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needed to enhance separation of cancer cells of varying metastatic potential. Due to the
heterogeneity of tumors and CTC, there is a need for a CTC isolation technology that can
capture and distinguish the heterogeneous phenotype.
This heterogeneity has also been translated to cell lines. Fillmore and coworkers
has shown phenotypic and functional differences within cell lines and found that
established breast cell lines contain a small subpopulation of tumorigenic self-renewing
cells that can differentiate into various phenotypic cells28. The results of this chapter
show the mechanism of separation along the modified wicking fiber construct is due to
functional and physical properties of the cancer cells, including cell size, deformability,
and cell adhesion potential. Further work will optimize the system to separate
subpopulations of highly metastatic cancer cells between cell lines.

Conclusions
This chapter investigated various factors that may contribute to the separation of
various cell types along the modified wicking fiber bundles. The outcomes showed cell
size, deformability, and ability to adhere to substrates play a major role in the cell
wicking behavior. By understanding the mechanism of separation we can optimize the
wicking fiber construct to not only separate cancer from benign cells but also cells of
varying metastatic potential. Further work will optimize the tension and cross-sectional
sizes of the wicking fiber bundles to increase efficiency of separation. Alterations to the
topography of the grooves and the alginate cap will be explored to improve the separation
of metastatic and non-metastatic cancer cells.
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CHAPTER EIGHT
DEVELOPMENT OF A BONE TISSUE ENGINEERING LEARNING MODULE FOR
MIDDLE SCHOOL STUDENTS
Introduction
The National Academy of Sciences has reported that the United States
educational system is lagging in the production of students in STEM (Science
Technology Engineering Mathematics) fields compared to other countries1. Due to the
lack of interest in STEM careers there is a shortage of professionals to fill STEM
positions1,2. To encourage STEM participation there is a major push for STEM education,
especially for elementary school students, who during this time develop perceptions and
interests in STEM related fields. STEM education also strives to increase the lack of
diversity, as well as, the low interest of women involvement. The American Society for
Engineering Education has reported the percentage of women earning a bachelor’s degree
in engineering was 18.4% in 20113. Lower female participation in STEM fields reflects a
need to increase awareness and involvement of female students at an earlier age. Howard
and coworkers describe middle school as critical years where students begin to consider
careers and develop personal career goals, which is reflected in their class choices and
activities in high school4. Educational researchers have shown introducing and
emphasizing STEM activities to middle school students, especially women, can impact
student interest in STEM fields4.
The purpose of STEM education is to not only increase numbers and awareness of
the field, but to provide students a foundation for life problem-solving skills and critical
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thinking2. This chapter focuses on the development and testing of a biomedical
engineering learning module to effectively teach concepts focused on bone tissue
engineering to young female students in middle school. The activities introduced the
engineering design process involving systematic critical thinking. The student’s
knowledge of engineering and tissue engineering concepts were assessed before and after
the learning module. Additionally, interest in student educational and career path towards
engineering was evaluated.
The educational program was conducted in coordination with ProjectWise
summer camp for young girls in middle school. This camp provides experiences and
hands-on learning activities in the field of science and engineering. During the camp the
girls participated in six different mini courses of different engineering and science
disciplines. The developed bioengineering mini course was held on two different days for
an hour and fifteen minutes long each day. Each day consisted of an interactive lecture
introducing bone tissue engineering concepts followed by a hands-on activity to reinforce
the concepts of the lecture and further introduce the engineering design process. The bone
tissue engineering concepts presented to the students focused primarily on transport
phenomena in tissues of the human body and how this applies to tissue engineering
applications. The module on the first day specifically focused on diffusion concepts and
the second day presented another transport phenomena in the body, capillary action. Preand post- quizzes were implemented before and after the teaching module to investigate
the effectiveness of the module. Pre- and post- surveys were also implemented to assess
if the students interest in engineering was affected by the teaching module. Fifty middle
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school girls participated in the bioengineering teaching modules. An Institutional Review
Board (IRB) was approved prior to implementation of the module to collect and publish
the survey and quiz data from the students. The Clemson University Office of Research
Compliance (ORC) reviewed and approved the IRB exempt protocol submitted,
IRB2013-202: IBIOE-Project WISE Perception by Female Students. Parental permission
and child agreement forms were implemented as part of the IRB for consent from both
parents and students to participate in study.

Teaching Modules
Day 1 – Diffusion Concepts Related to the Human Body
Interactive Teaching Module
The first day provided an interactive presentation that introduced the students to
bioengineering and how the field impacts them and the field of medicine. The
presentation showed the young girls how bioengineering can be both a rewarding and an
exciting career. The presentation further introduced the tissue engineering segment of
bioengineering and demonstrated the impact and significance of this field in their lives.
This segment of the presentation described design criteria for tissue engineered scaffolds
and how different tissues require different design specs. The second part of the
presentation specifically focused on transport concepts in the body including diffusion
and osmosis and how these concepts relate to designing tissue engineered constructs.
Demos, shown Figure 8.1, were conducted during the presentation to show diffusion in
various applications and what parameters affect the rate of diffusion.
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Figure 8.1: Demos presented to students to illustrate diffusion and osmosis (A) Diffusion
of smell (B) Osmosis in an egg in a hypertonic or hypotonic solution after the shell is
removed with vinegar (C) Osmosis in gummy bears in hypertonic or hypotonic solutions

The remaining half of the teaching module, the students participated in a hands-on
group activity, adapted by Hove and coworkers, investigating diffusion in materials
representing tissues of different stiffness5. The students were first given three different
materials that simulated three different tissues of varying stiffness, depicted in image A
of Figure 8.2. The students worked in groups to determine which material best
represented the mechanical properties of fat, bone, or muscle5.
To further demonstrate diffusivity of tissues the students worked in groups to
hypothesize how stiffness might affect diffusion. The group activity involved exploring
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diffusion of a dye solution on hydrogels of varying stiffness. The hydrogels were premade using varying concentrations of agarose (0.5%, 1%, and 2% agarose) to represent
the three different tissues consisting of different stiffness. Students first predicted how the
stiffness would affect the movement of a colored solution. Prior to conducting the
experiment, students were given worksheets to record their predictions, as well as track
their measurements and results. To begin the study, students used transfer pipettes to
pipette one drop of dye solution on each of the agarose gels, Image B of Figure 8.2. The
students measured the diameter of spread on each agarose gel every 3 minutes for a 15
minutes.
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Figure 8.2: (A) Different materials with varying stiffness to represent muscle, fat, and
bone tissues (B) The group activity where students determine the rate of movement of the
dye solution in various agarose stiff gels

Following the recording of measurements the students made a plot of diameter of
the colored solution over time. The worksheets used for this group activity are shown in
Appendix B. The students explored any differences in diffusion rates between samples
and determined if stiffness of tissue would influence the rate of diffusion. As a group, the
outcomes of the study were discussed and the students learned that diffusivity changes
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with different tissue types causing the colored solution to move faster in less stiff tissues
such as fat.
Day 2 – Transport Phenomena in Tissue Engineered Scaffolds
Interactive Teaching Module
The second day provided another interactive presentation focusing on the lack of
vascularity in tissue-engineered scaffolds and the need for vascularity. The presentation
introduced capillary action and provided a demonstration using celery stalks with food
coloring.

Figure 8.3: Demonstration of water moving through capillaries or xylem in the celery
stalks by capillary action

A group activity was develop to show the students the various factors that
influence capillary action. The students were shown how to conduct a vertical test with
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fabric and assess the movement of the colored solution over time. Students were provided
yarns of various sizes and materials. The students were allowed to bundle the yarns and
use various blends to increase capillary action. The students worked together in groups to
follow the engineering design process to optimize the capillary action in a yarn system.
The students followed the engineering design process by first brainstorming, developing
ideas, choosing a solution, testing the solution, communicating the problems with that
particular solution, and as a group going back and redesigning. Worksheets were
developed to help students work through the engineering design process and record
measurements of the testing (Appendix B).
The final demo evaluate vertical test of dye-solution with various types of paper
towel brands. The students predicted which paper towel brand would perform the best
based on the porosity, strength, weaves, and patterns. These activities illustrated how the
architecture of a tissue-engineered scaffold can affect the diffusion and transport, which
can affect cell survival.
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Figure 8.4: (A) Designing and testing capillary action in various yarn materials (B)
Architecture of the paper towel will affect capillary action

Assessment of Modules
Pre- and post- surveys (Appendix B) were conducted using a likert ranked system,
open-ended questions, and a drawing question to assess any change in interest in the field
of science and engineering after the modules. The first part of the survey investigated
interest and attitude of the students towards STEM (Science, Technology, Engineering,
and Mathematics) fields. This part of the survey included 21 questions with Likert scale
responses. The questions were adapted from existing established STEM interest surveys
developed by Lyons and colleagues, and previous work conducted by IBIOE lab
members6,7. To further investigate the student’s attitude and perception of engineering
two open-ended questions and a “Draw an Engineer test” (DAET) were also included in
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the assessment. The open-ended questions asked the students to describe engineering and
what engineers do. To analyze the responses for the open-ended questions, categories
were established to code the responses and the frequency of each category was analyzed.
The DAET was adapted from Knight and colleagues8. This test was developed to
investigate student’s perceptions of engineering. To assess the drawings various
categories were created and the pictures were coded for each category. The frequency of
activities drawn, common objects, and images were assessed.
Pre- and post- quizzes (Appendix B) were used to evaluate the effectiveness of
the modules to evaluate if the students have an improved understanding of bioengineering
and related transport phenomena. The quizzes consisted of four open-ended questions
each worth 3 points. A grading scale was developed for each question based on the
student responses. The table below describes the grading scale used to determine the
percentage grade of the pre- and post- quizzes.
Statistical Analysis
Statistical analysis was conducted in JMP 10 using Wilcoxin Signed-Rank Test to
determine significant change of the student responses to the likert scale survey questions.
The data distribution was assumed non-parametric and tested with a significance level of
0.05. The Wilcoxin Signed-Rank Test was also used to investigate changes in grade
percentages for each question as well as the total score because data distribution was
assumed without a normal distribution. The purpose of the quizzes was to investigate if
the module positively affected the students understanding of bioengineering, tissue
engineering scaffolds, as well as transport phenomena that occurs in scaffolds,
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specifically diffusion and capillary action. The table below describes the questions and
the grading scale used to determine the percentage scores for each student. The total
number of students who participated in the WISE module was n=50. Due to lost surveys
and lack of interest to participate in the study, the number of students who participated in
the sample size for the surveys and quizzes was n=44.
Table 8.1: Grading Scale
Score 0

Score 1

Score 2
Understands
bioengineering can
improve medicine
and the well-being
of people

Score 3
Understands
bioengineering is
a broad field with
the goal to
improve the field
of medicine
Describes the
movement of
particles from
high
concentrations to
lower
concentration

What does a
bioengineer do?

No Response
“I don’t know”
“I forgot”

Connects biology
and life with
engineering

What is
diffusion?

No Response
“I don’t know”
“I forgot”

Describes some
relation to
spreading or
moving

Describes change
in concentrations
and balancing of
substances

What is the
length of your
thumb in cm?

No Response
“I don’t know”
“I forgot”

>15 cm or use of
different units

10-14 cm
1-2 cm

3-9 cm

Describes
movement

Understands the
vertical movement
of water in a tube
is caused by
capillary action

Understands
capillary action
occurs in pores or
tubes based on
adhesion and
cohesion of water
molecules

What is
capillary
action?

No Response
“I don’t know”
“I forgot”

Results
Both pre- and post- survey questions assessing student interest in STEM using
Likert scale questions showed high percentages of students interested in STEM fields.
Table 8.2 shows the frequency of student responses as percentages for each question.
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Table 8.2: Pre Survey responses. Table depicts the percentage of students who agree or
disagree for each survey question

Survey Questions

Strongly
Disagree
(%)

Somewhat
Disagree
(%)

Somewhat
Agree
(%)

Not sure
(%)

Strongly
Agree
(%)

I like engineering

2.3

4.5

13.6

54.5

27.3

I like math

4.5

6.8

6.8

40.9

40.9

I like science
Boys are better at being
engineers than girls
Engineering has nothing to
do with our lives
Engineering and science
help make people's lives
better
I find it boring to hear new
ideas
I would like to join a
science club

2.3

4.5

6.8

29.5

36.4

84.1

11.4

4.5

0.0

0.0

81.8

11.4

6.8

0.0

0.0

0.0

0.0

4.5

20.5

75.0

65.9

15.9

11.4

6.8

0.0

6.8

13.6

34.1

20.5

25.0

38.6

29.5

18.2

6.8

6.8

29.5

25.0

18.2

25.0

2.3

0.0

0.0

18.2

63.6

18.2

25.0

31.8

36.4

6.8

0.0

2.3

4.5

52.3

20.5

20.5

79.5

9.1

9.1

2.3

0.0

I like doing experiments
I like reading and thinking
about science

0.0

4.5

4.5

15.9

75.0

2.3

13.6

20.5

43.2

22.7

I find engineering boring
I am smart enough to be an
engineer
Being an engineer is more
fun than other jobs

34.1

31.8

18.2

11.4

4.5

6.8

2.3

15.9

25.0

50.0

4.5

22.7

40.9

22.7

9.1

I dislike science lessons
I get bored watching science
programs on TV
I am good at solving
problems
I am nervous to take an
engineering class
I would like to join an
engineering club
Boys know more about
engineering and technology
than girls
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Table 8.3: Post survey questions depicts similar responses to pre survey questions

I like engineering

Strongly
Disagree
2.3

Somewhat
Disagree
6.8

I like math

0.0

I like science
Boys are better at being
engineers than girls
Engineering has nothing
to do with our lives
Engineering and science
help make people's lives
better
I find it boring to hear
new ideas
I would like to join a
science club
I dislike science lessons
I get bored watching
science programs on TV
I am good at solving
problems
I am nervous to take an
engineering class
I would like to join an
engineering club
Boys know more about
engineering and
technology than girls
I like doing experiments
I like reading and thinking
about science
I find engineering boring
I am smart enough to be
an engineer
Being an engineer is more
fun than other jobs

Survey Questions

4.5

Somewhat
Agree
50.0

Strongly
Agree
36.4

9.1

6.8

34.1

50.0

2.3

2.3

6.8

20.5

68.2

84.1

11.4

4.5

0.0

0.0

81.8

4.5

9.1

2.3

2.3

4.5

2.3

2.3

9.1

81.8

68.2

20.5

6.8

4.5

0.0

6.8

13.6

29.5

25.0

25.0

47.7

31.8

18.2

2.3

0.0

27.3

27.3

15.9

22.7

6.8

0.0

0.0

15.9

50.0

34.1

43.2

25.0

11.4

15.9

4.5

11.4

9.1

22.7

22.7

34.1

88.6

4.5

6.8

0.0

0.0

0.0

0.0

9.1

15.9

75.0

4.5

13.6

20.5

31.8

29.5

59.1

15.9

9.1

9.1

6.8

2.3

0.0

15.9

22.7

59.1

9.1

6.8

38.6

31.8

13.6
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Not sure

Table 8.4: Significant positive change between pre and post survey responses, no
negative changes were seen
Survey Questions
I like engineering
I like math
I like science
Boys are better at being engineers than girls
Engineering has nothing to do with our lives
Engineering and science help make people's lives better
I find it boring to hear new ideas
I would like to join a science club
I dislike science lessons
I get bored watching science programs on TV
I am good at solving problems
I am nervous to take an engineering class
I would like to join an engineering club
Boys know more about engineering and technology than
girls
I like doing experiments
I like reading and thinking about science
I find engineering boring
I am smart enough to be an engineer
Being an engineer is more fun than other jobs

Significant Positive
Change
p=0.0366

p=0.0217

p=0.0388

Most of the questions showed no significant difference between the pre- and postsurveys responses, shown in tables below. The results showed significantly more students
liked math and science lessons; as well as did not find engineering boring.
The first open-ended question on the pre- and post- surveys asked the students to
describe engineering. The students’ responses to this question were similar for the pre
and post surveys, as illustrated in the frequency chart below. No significant difference
was observed in the responses to this question. The most common engineering themes
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described to this question were helping people, as well as, solving, improving, and
building.

Figure 8.5: Student responses to the open-ended question "What is engineering?"

The second open-ended question asked the students to describe what engineers
do. The post survey responses to this question were similar to the pre survey responses,
as shown in the figure below. The most common engineering activities described were
similar to those mention in question one. The common responses include helping people,
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building, creating, and solving problems. The most common engineering theme described
was medical related for both pre and post surveys.

Figure 8.6: Student responses to second open-ended question: "What does an engineer
do?"

The final assessment analyzed the student’s perception of an engineer before and
after the module. The students drew a picture of an engineer at work. The drawings were
characterized based on common themes found in the drawings. The chart below
summarizes the frequency of each of the categories. The frequency plot shows under the
people category more male engineers were drawn than females on both pre and post
surveys. Most of the drawings from the pre surveys showed actions of building and
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fixing. Interestingly, the post survey drawings showed an increase in pictures related to
lab and research and less related to fixing. The related themes described by the pre and
post surveys were also different. Drawings of robots and computers were higher for the
pre survey than the post survey. The post survey showed a significant increase in the
amount of tissue engineering related pictures compared to the pre survey. These
outcomes show drawing pictures as an assessment may provide educators and researchers
a tool to determine perception and attitude of students.

Figure 8.7: Categorizes the drawings of pre and post surveys. The categories include
people, actions, and themes
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The pre and post quizzes were implemented to determine the effectiveness of the
teaching module. The outcomes of the post quiz showed improvement in the students
understanding of bioengineering, measurements, and transport phenomena including
diffusion and capillary action. The figure below shows there was a significant increase in
grade percentage for the post quiz for all post quiz questions, p<0.05. Question 1
responses showed improved understanding of bioengineering (p=0.0001). Question 2, 3,
and 4 responses reflected a better understanding of diffusion, measurements, and
capillary action (p=0.0001, p=0.0254, p=0.0001 respectively). The overall average test
score for the post quizzes was significantly higher than the average pre quiz scores
(p=0.0001). The post quiz scores showed a 30 % increase in grade percentage. The
outcomes suggest the module was effective in teaching students tissue engineering
related concepts.
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Figure 8.8: The post quiz grade percentages were significantly greater than the pre quiz
grade percentages, (*) signifies p<0.05.

Discussion
The outcomes revealed this module did not influence the student’s interest in
STEM fields. The post survey responses of the Likert style questions showed no
significant difference compared to the pre survey responses. The results from the
questionnaire showed high interest in STEM prior to the module. This may be a factor of
the ProjectWise summer camp. Most of the students participating in this camp express
interests in STEM fields prior to attending. The post survey of the open-ended question
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responses also showed no difference. Interestingly, the DAET of the post survey depicted
different trends in responses than the pre survey. The pre survey showed a majority of the
students drew pictures related to building and robots or computes. The post survey
showed a number of students drew pictures related to tissue engineering and research.
This variety of pictures can also be influenced by the other engineering related activities
the students are participating in. Prior to attending this module students participated in
electrical computer science engineering activities related to robots and computers. The
additional activities of the camp may influence the student’s perceptions and attitudes of
engineering. However, the DAET analysis suggests students may have a greater
understanding of what an engineers can do. The outcomes also indicate the DAET can
capture more information about student’s perceptions and attitudes through the drawings
than open-ended questions or the Likert-scale questions
The interactive modules improved their understanding of tissue engineering and
how the field impacts them as well as the medical field. The responses on the post-quiz
reflected greater understanding of what bioengineering is and the concepts involve in
developing a tissue-engineered scaffold. The post-quiz showed the module was effective
in providing the students a better understanding of transport phenomena that occurs in the
body and tissue engineered scaffolds. This module was developed for students in grades
6-8th. Future work will tailor the activities and presentation for students in high school or
in lower grades.

384

Conclusion
The assessment showed the module had no effect on the interest of the students in
STEM fields. However, the outcomes from the pre and post quizzes demonstrate the
module was effective in teaching the students tissue engineering concepts. The post quiz
results showed a significant increase in grade percentages than the results of the quiz prior
to student participation in the module. This module can be an effective tool for teachers in
the classroom to introduce students to bioengineering.
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CHAPTER NINE
CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE WORK
Conclusions
This work developed and tested the ability of a wicking bundle system to (1)
improve mass transport and cellular distribution in large bone tissue engineered scaffolds
and (2) separate cell types based on their wicking behavior. A major limitation of large
bone defects is the vascularity to support all regions of the defect site to provide
homogeneous bone regeneration. Conventional approaches to improving transport of
tissue engineered grafts involving incorporated angiogenic factors or vascular-promoting
cells have shown very limited success. The survival and success of large tissue
engineered constructs are dependent on the vascularity of surrounding tissue and
sufficient mass transport. We developed and tested a new approach to provide a synthetic
vascular like system within a large bone graft to improve mass transport and cell
infiltration.
The second application of the wicking fiber system involved cell separation and
isolation based on signature cell wicking characteristics for both cancer and progenitor cell
identification applications. A major challenge of cancer diagnostics is the heterogeneity
and transient properties of the tumor, and subsequently cancer cells that have detached
from the tumor (CTCs). Tumors and CTCs have been reported to have different
subpopulations of cancer cells with varying phenotypes and degrees of tumor-initiating
capabilities. The inherent dynamic heterogeneity of cancer cells limits the ability molecular
biomarker detection, typically gene and protein expression. Molecular biomarker detection
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can be unreliable, lack specificity, and provide limited information regarding cancer cell
stage. We developed a cell identification based on the signature wicking profiles of various
cell types. This work showed a proof-of-concept identification system using cancer cell
types with varying metastatic potential and progenitor cells of varying differentiation
potential. This work further explored the mechanisms of cell separation along the wicking
fiber system. The following conclusions were drawn from each of the aims investigated:
Characterization of Fluid, Biomolecule, and Cellular Transport by Wicking Fibers
1. The fluid transport tests showed the wicking fibers significantly enhanced the
wicking rate and maximum height reach of fluid compared to round fibers. The
twisted configuration of the wicking fibers showed superior wicking behavior
compare to the braided configuration.
2. The wicking fibers enhanced the transport rate of FITC conjugated albumin into a
collagen-agarose hydrogel compared to round fibers, suggesting the fibers provide
conduits that can enhance and facilitate biomolecule movement.
3. The wicking fibers can recruit and distribute cells by wicking and providing conduits
for cell travel. Progenitor cell vertical displacement along wicking fibers was
significantly greater than round fibers. The wicking fibers showed enhanced
distribution of progenitor cells in collagen gel compared to round fibers.
Assessment of Wicking Fibers in ChronOS Strip Bone Scaffolds
1. The wicking fiber bundles enhanced the fluid retention and distribution in the
chronOS strip scaffolds.
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2. The wicking fiber bundles improved cell viability, proliferation, and distribution by
increasing the porosity of the scaffold and providing conduits to facilitate diffusion
and enhanced capillary action.
3. The osteogenic differentiation of pre-osteoblast cells in modified chronOS strip
scaffolds showed earlier and increased bone forming related protein expression
compared to the unmodified scaffolds. Higher gene expression and ALP was
observed earlier in the differentiation study compared to unmodified scaffolds
suggesting the wicking fiber may augment osteogenic differentiation.
4. The major limitation of the differentiation study was the scaffold size used. Due to
the small geometry of the scaffolds used and the in vitro set-up, mass transport may
not have been limited in the scaffolds.
Characterizing Modified Wicking Bundles and Their Effect on Cell Seeding

1. The wicking fiber bundles were successfully modified with an absorbent cap. The
wicking rate and fluid absorbed were significantly increased by the modification of
the wicking bundle. The enhanced wicking rate was a result of the greater change in
pressure generated by the transpiration of fluid from the alginate cap. The
transpiration pressure primes the system leading to an increased wicking rate and
fluid height.
2. The modified wicking bundles increased the recruitment of progenitor cells and the
rate of FITC conjugated albumin into a hydrogel compared to the unmodified
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bundles. In a submerged system the alginate enhanced the transport of cells and
biomolecules until the hydrogel reached swollen capacity.
3. The modified wicking bundles significantly improved the cell viability, proliferation,
and distribution of the chronOS strip scaffolds following cell seeding with a perfusion
pack system. The modified wicking bundles provide an intrinsic cell seeding
approach for scaffolds to initially improve the recruitment and distribution of cells
that could be easily implemented for clinical use.
Investigation of Modified Wicking Bundles as an Antibiotic Release System
1. Three loading mechanisms of gentamicin antibiotic into polylactide fibers were
developed and tested. The third mechanism, mixing the gentamicin with the
polylactide pellets prior to extrusion, showed elution levels above the minimal
inhibitory concentration for the duration of the study. The first mechanism, wicking
the antibiotic solution into the bundles, and second mechanism, incorporating the
antibiotic in the water bath, were not loaded initially with enough antibiotic solution
to sustain release.
2. The cross-section of the polylactide fiber affects the amount of antibiotic loaded and
the release profile. The wicking fibers loaded by mechanism 2, incorporated a higher
concentration of antibiotic, and showed increased elution compared to the round
fibers. The single large fiber loaded by mechanism 3 showed significantly faster
release of the antibiotic compared to the small fiber bundle. The bundle incorporated
more antibiotic and showed a slower constant release profile.
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3. The release from the alginate cap showed sustained release of gentamicin above the
MIC for 7 days. The results suggest higher initial loading concentration may improve
the duration of release.
4. The DSC results suggest the incorporation of gentamicin may affect the crystallinity
of the polylactide and alter the degradation of the polymer.
Cell Separation and Isolation using Modified Wicking Bundles
1. Cell separation of cancer and normal cells was observed along unmodified wicking
bundles. A mixture of mesenchymal stem cells and monocytes was also separated
using the unmodified wicking fibers.
2. The modified wicking bundles increased the amount of cells separated along the
system and provided a mechanism for isolating cancer cells by the absorbent cap.
3. The modified wicking bundles showed separation of non-metastatic cancerous and
benign breast epithelial cells. The cancer cells were observed and isolated from the
top region of the fiber bundles and alginate cap.
4. Metastatic cancer cells were also separated and isolated from benign cells using the
modified wicking bundle.
5. The modified wicking bundle showed greater densities of metastatic cancer cells than
non-metastatic cancer cells, however, more work is needed to more efficiently
separate metastatic for non-metastatic cancer cells.
6. Mesenchymal stem cells were separated and isolated from a more differentiated preosteoblast cells using the modified bundles.
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7. Stem cells and cancer cells showed similar wicking behaviors along the modified
fiber bundles
Investigation of Cell Separation Factors of the Wicking Fibers
1. The cell types (D1, mouse mesenchymal stem cells, and MCF-7, human epithelial
cancer cells) that displace to the top regions of the bundle and alginate cap showed
smaller size cell diameters than the cells that remain in the bottom region of the
bundle (MC3T3E1, mouse pre-osteoblast cells, and MCF-10A, human benign
epithelial cells). Cell size may play a role in cell separation along fibers.
2. The beads used to mimic cell size in the modified wicking fibers showed very limited
penetration of the larger beads into the system. The smaller beads were isolated from
the top region of the fiber and alginate cap.
3. The modified wicking bundles containing smaller fibers increased the number of
beads isolated in the alginate cap and the fiber bundles. The smaller conduits of the
fiber bundle generated greater capillary pressure increasing the fluid height and
subsequently the amount of beads in the system.
4. The inter-fiber spaces created by the tension of fiber bundle influence the wicking
rate of the fluid and affect the cell wicking behavior.
5. The cancer cell types differed in cell morphology and cytoskeletal arrangement,
which influenced the deformability of the cell. Cell deformation also plays a role in
the ability of different cell types to move through the system. Cancer cells of high
metastatic potential are more deformable than non-metastatic cancer and benign cells.
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Additionally, the mesenchymal stem cells have less actin stress fibers than the preosteoblast, which may contribute to the increased deformability of stem cells.
6. The cytoskeletal arrangement of cancer cell types along the fibers showed a rounded
morphology with limited cell spreading. Uniquely, the pre-osteoblasts adhered to the
fibers and illustrated spread morphology along the grooves. This suggests the surface
topography and cell adherence properties may also contribute to varying levels of cell
separation.
7. The modified bundle fibers separated and isolated both non-metastatic cancer cells
expressing EpCAM and metastatic cancer cells that show very limited expression of
EpCAM. This suggests the system can isolate cancer cells of varying phenotypic
expression but further work investigate optimizing the separation of the various
phenotypes.
Bone Tissue Engineering Teaching Module for Middle School Students
1. The outcomes of the pre and post surveys showed the module had no effect on the
students interest in engineering. This is a factor of the type of students surveyed. Most
of the students who participated were already interested in engineering and chose to
participate in the Women in Science and Engineering (WISE) summer camp.
2. The drawings reflecting the student’s perception of engineering showed a difference
between the pre and post quizzes. The outcomes of this assessment were influenced
by the other engineering related activities the students participated in during the
camp.
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3. The post quizzes showed a significant increase in grading percentages compared to
the pre quiz results. This indicates the module was effective in improving the students
understanding of tissue engineering and related transport phenomena.

Future Work
1. Further work can investigate the effects of bundle tension and architecture on the
wicking behavior of the bundle. A twisting apparatus should be developed that can
incrementally adjust the tension and provide a bundle with homogenous tension
across it. Other bundling configurations can also be explored, such as various braided
and weaved configurations.
2. Further work can investigate the transpiration pressure generated from the alginate
cap. Hydrogels of varying stiffness and swelling potential can also be investigated to
experimentally determine the effect of different hydrogels on the wicking behavior of
the fluid.
3. To further our understanding of the fluid transport phenomena in the system
permeability measurements can be performed. A micro CT scanner could also be
used to better quantify the biomolecule and cellular movement.
4. A COMSOL model can also be developed to investigate transport of fluid,
biomolecules, and cells within the modified wicking fiber system to optimize the
system for the different applications. The model can investigate the effects of
changing the hydrophobicity of the polymer, as well as the effects of bundles of
various tensions and fiber sizes.
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5. The oxygen levels of the unmodified and modified chronOS strip samples in the
central and peripheral regions of the scaffold can be quantified using fiber-optic
oxygen microsensors. A model can be developed using this data to determine the
oxygen gradients in modified and unmodified chronOS strip scaffolds. This data can
provide information to help determine ideal fiber arrangement and placement in the
scaffolds.
6. Test the mechanical properties of the chronOS strips with and without modified
wicking bundles.
7. The differentiation of pre-osteoblast cells on the alginate modified polylactide fiber
bundles should also be investigated to assess if the alginate caps should be removed
prior to implantation.
8. Further work can test the modified chronOS strip scaffolds in an in vitro test system
to better simulate the vascular limitations of the specific implant site for the bone
graft.
9. A rabbit posterolateral fusion animal model can be used to compare the modified and
unmodified chronOS strip samples in vivo.
10. Future work can also consider functional modifications to the fiber and coatings to
the alginate to direct and sustain transport
11. Future work will investigate long-term release of antibiotic from the wicking bundles.
The initial loading concentration and fiber size and bundle should be optimized to
provide antibiotic release ideally for six weeks to a year based on application.
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12. Bacterial studies should also be performed to verify the gentamicin was not altered
from the processing of the fibers and the concentration is high enough to prevent
bacterial growth. Other studies need to determine the toxicity of the gentamicin and
any effect on bone differentiation.
13. The DSC results indicated the gentamicin may alter the crystallinity of the
polylactide. Further work should investigate changes in degradation and mechanical
properties of the polylactide.
14. Future work should improve the efficiency of the modified wicking bundles to
separate and isolate cancer cells. Modifications to the fibers, such as tapering the top
region of the bundles and altering the fiber tension may improve the separation of
non-metastatic and metastatic cancer cells.
15. More physiologically relevant cell densities should be tested to determine the
efficiency of the system. Circulating tumor cells (CTCs) are found in the blood
typically at a density of 10-100 cells per mL. Future work would determine if the
modified wicking bundle can recover cancer cells seeded at this density.
16. To further prove the efficacy of the modified bundle system metastatic and nonmetastatic cancer cells, spiked volunteer blood at the physiologically relevant
concentration of 10 cells per mL should be evaluated. Determine if erythrocytes
and/or leukocytes will effect cell movement along fibers.
17. Future work should also investigate the mesenchymal and epithelial phenotypes of
the cells recovered by the system.
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18. A statistical model could be developed to further investigate interactions of different
fiber configurations as well as variations of cell lines.
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APPENDICES
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Appendix A
Educational Surveys and Activities

Figure A-1: Survey questions evaluating perception of engineering.
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Figure A-2: Survey questions evaluating interests in engineering.
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Figure A-3: Activity worksheet for exploring diffusion.
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Figure A-4: Activity worksheet for exploring capillary action.
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